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ABSTRACT OF THE DISSERTATION
Cholera Toxin B Subunit-Diabetes Autoantigen Fusion Proteins Modulate Dendritic Cell
Maturation and T Cell Morphogenesis
by
Oludare Jeremiah Odumosu
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2011
Dr. William H. R. Langridge, Chairperson
Type 1 diabetes mellitus is a chronic inflammatory disease in which the insulin
and glutamic acid decarboxylase producing β-cells of the pancreatic islets are killed by
autoreactive cells of the immune system in response to a loss of tolerance. Early
experiments showed that self-tolerance could be partially restored by oral inoculation
with small amounts of insulin. Later experiments showed that insulin autoantigen induced
immune tolerance could be greatly enhanced by linkage of β-cell autoantigens (Auto Ag)
to adjuvant molecules such as the non-toxic cholera enterotoxin B subunit (CTB).
To identify mechanisms responsible for CTB-autoantigen fusion protein
suppression of diabetes autoimmunity, dendritic cells (DCs), a major class of antigen
presenting cells (APC) involved in restoration of immunological tolerance, were
differentiated from umbilical cord blood monocytes and incubated with recombinant
CTB- pro-insulin and CTB-glutamic acid decarboxylase adjuvant-autoantigen fusion
proteins. The fusion proteins were shown to dramatically suppress DC biosynthesis of
costimulatory factors and proinflammatory cytokines IL-12 and IL-6 required for
autoreactive T cell development. In addition, a substantial increase in DC secretion of the
anti-inflammatory cytokine IL-10 was also detected further confirming the previous

xxi

observation. Naïve T cells incubated with CTB-autoantigen inoculated DCs developed
into mature T cells that synthesized IL-10 and TGF-β cytokines indicative of Th2, Tr1
and Th3 regulatory T cell populations involved in suppression of CD4+ and CD8+ T
lymphocytes responsible for the initiation of diabetes autoimmunity. Further, vaccine
inoculated DCs suppressed T cell pro-inflammatory cytokines IFN-γ, IL-17 and IL-2
guiding T cell morphogenesis in the direction of tolerance rather than toward
inflammation responsible for diabetes onset. In summary: the experimental results
presented in this Dissertation indicate that ex vivo vaccination of human DCs favors
immunological suppression of diabetes development and suggests that mechanisms of
immunological tolerance responsible for multicomponent vaccine suppression of diabetes
onset and possibly progression are comparable in humans and in animals.

xxii

CHAPTER ONE
INTRODUCTION
Type 1 Diabetes
Diabetes Etiology
Juvenile onset autoimmune diabetes also known as type 1 diabetes (T1D) or
insulin-dependent diabetes mellitus (IDDM) is considered to be the most serious
metabolic disease of children and adolescents. High blood sugar (hyperglycemia) and
inflammation of the pancreatic islets (insulitis) result from a breakdown in
immunological homeostasis leading to loss of immunological tolerance. Consequently,
the pancreatic islets of Langerhans insulin-producing β-cells are destroyed by the body’s
immune system gone rogue. Chronic insulitis and progressive β-cell death are initiated by
islet autoantigen stimulated maturation of antigen-presenting cells, largely dendritic cells
(DC) part of the host innate arm of the immune system. Autoantigen activated DCs
migrate to pancreatic and other peripheral lymph nodes where they induce naïve T
lymphocyte (Th0) development into autoreactive CD4+ T helper cell and CD8+ cytotoxic
T lymphocytes, as well as B cells that synthesize autoreactive antibodies (Atkinson,
Bowman et al. 1994; Atkinson and Maclaren 1994; Tisch and McDevitt 1996; Han, Serra
et al. 2005). The progressive loss of β-cell function causes increased insulin deficiency
eventually resulting in the onset and progression of hyperglycemia, (frank diabetes) (Fig
1.1).
Young and older T1D patients alike must monitor their blood sugar levels and

1

inject insulin several times a day for the remainder of their lives or risk diabetic shock,
coma and death. While daily multiple insulin injections suppress diabetes symptoms, this
therapy does not provide consistent physiological levels of insulin. Without insulin, there
is a problem of chronic glucose dysregulation resulting in unacceptable levels of
disability and mortality. Symptoms of hyperglycemia include, but are not limited to,
frequent thirst and urination as the kidneys attempt to cope with efforts at eliminating
excess sugar from the bloodstream. In addition, extreme hunger, weight loss, fatigue, and
blurred vision may occur due to cellular glucose deprivation. Long-term complications
include a progressive risk for neural and circulatory failure resulting in amputation of the
extremities, blindness, kidney failure, heart attack and stroke reducing average life
expectancy by an average of 15 - 20 years (Libby, Nathan et al. 2005). See Table 1.1.
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Table 1.1. Secondary Effects of Diabetes Onset from Diabetes Health Statistics (U.S.A.)
•

Heart disease
and stroke
High Blood
Pressure

Blindness

•

•

About 75 percent of adults with diabetes have blood pressure greater
than or equal to 130/80 mm Hg or use prescription medications for
suppressing hypertension.

•

Diabetes is the leading cause of new cases of blindness among
adults aged 20 to 74 years.
Diabetic retinopathy causes 12,000 to 24,000 new cases of blindness
each year.

•

•

Kidney
Disease

•

•

Nervous
System
Disease

•

•

•

Amputations

•

•

Dental
Disease

Heart disease and stroke account for about 65 percent of deaths in
people with diabetes.
Adults with diabetes have heart disease and stroke death rates about
2 to 4 times higher than adults without diabetes.

•

•

Diabetes is the leading cause of kidney failure, accounting for 44
percent of new cases in 2005.
In 2005, 46,739 people with diabetes began treatment for end-stage
kidney disease in the United States and Puerto Rico while 178,689
people had end-stage kidney disease that required chronic dialysis or
kidney transplantation.
About 60 to 70 percent of people with diabetes have mild to severe
forms of nervous system damage. The results of such damage
include impaired sensation or pain in the feet or hands, slowed
digestion of food in the stomach, carpal tunnel syndrome, erectile
dysfunction, or other neuropathological problems.
Almost 30 percent of people with diabetes ages 40 years or older
have impaired sensation in the feet—for example, at least one area
that lacks feeling.
Severe forms of diabetic nerve disease are a major contributing
cause of lower-extremity amputations.
More than 60 percent of non-traumatic lower-limb amputations
occur among people with diabetes.
In 2004, about 71,000 non-traumatic lower-limb amputations were
performed in people with diabetes.
Periodontal or degenerative gum, disease is more common in people
with diabetes. Among young adults, those with diabetes have about
twice the risk as those without diabetes.
People with poorly controlled diabetes—A1C greater than 9
percent—were nearly three times more likely to have severe
periodontitis than those without diabetes.
Almost one-third of people with diabetes have severe periodontal
disease with loss of attachment of the gums to the teeth measuring 5
millimeters or more.
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Table 1.1. Continued.
•

Complications
of Pregnancy

•

•

•

Other
Complications
•

•

Health
Disparities

Poorly controlled diabetes before conception and during the first
trimester of pregnancy among women with T1D can cause major
birth defects in 5 to 10 percent of pregnancies and spontaneous
abortions in 15 to 20 percent of pregnancies.
Poorly controlled diabetes during the second and third trimesters of
pregnancy can result in excessively large babies, posing a risk to
both mother and child during delivery.
Uncontrolled diabetes often leads to biochemical imbalances that
can cause acute life-threatening events, such as diabetic ketoacidosis
and hyperosmolar, or nonketotic, coma.
People with diabetes are more susceptible to many other illnesses
and, once they acquire these illnesses, often have worse prognoses.
For example, they are more likely to die with pneumonia or
influenza than people who do not have diabetes.
People with diabetes ages 60 years or older are two to three times
more likely to report an inability to walk a quarter of a mile, climb
stairs, do housework, or use a mobility aid compared with people
without diabetes in the same age group.
Non-Hispanic white youth had the highest rate of new cases of type
1 diabetes—24.8 per 100,000 per year among those younger than 10
years and 22.6 per 100,000 per year among those ages 10–19 years
(Source: SEARCH for Diabetes in Youth Study 2002-2005)

Source: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/
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Figure 1.1. Basic Mechanism of Type 1 Diabetes Inflammation and Vaccine Action
Antigen presenting cells, more specifically dendritic cells, process endogenous pancreatic
beta cell autoantigens (Insulin, GAD…) in lysosomal vesicles and transfer peptide
fragments of the autoantigen to MHCII molecules that migrate to the plasma membrane
and present the autoantigen fragments to cognate T cell receptors on naïve T helper cells
(Th0), left portion of Figure 1.1. Dendritic cell processing of the autoantigen stimulates
biosynthesis and secretion of the inflammatory cytokine interleukin 12 (IL-12) which
stimulates naive Th0 lymphocytes to undergo morphogenesis into autoreactive effector T
helper cells (Th1). The autoreactiveTh1 cells secrete inflammatory cytokines such as
IFN-gamma and IL-2 that stimulate cytotoxic lymphocytes (CTL) to secrete nitric acid,
peroxide and several additional inflammatory cytokines such as TNF-α and IL-1 β that
stimulate pancreatic islet inflammation (insulitis). Chronic insulitis results in progressive
pancreatic beta cell death resulting in an increasing insulin deficiency and a progressive
increase in blood sugar (hyperglycemia). Oral delivery of small amounts of islet
autoantigens (right portion of panel); exert a specific protective antigen therapeutic effect
by stimulating dendritic cell secretion of the anti-inflammatory cytokine IL-10. Secretion
of IL-10 stimulates naïve cognate naïve Th0 lymphocytes to undergo morphogenesis into
anti-inflammatory CD4+ Th2 helper cells that in turn secrete IL-10, which suppresses
autoreactive Th1 cell development and decreases the potential for insulitis onset.
Alternatively, naive Th0 cells may develop into one of several subclasses of regulatory T
cells (Treg), which can block dendritic cell activation, Th2, Th1 and CTL development
leading to prevention of insulitis, continued insulin secretion and maintenance of
immunological homeostasis (Ploix, Bergerot et al. 1999; Liu, Iyoda et al. 2002).

6

Epidemiology of Type 1 Diabetes
According to the National Institutes of Diabetes and Digestive and Kidney
Diseases-NIDDK, the current incidence rate of TID in the U.S is approximately 19.7 per
100,000 annually. Among youth ages 10 years or older, the incidence rate is 18.6 per
100,000 children (National Diabetes Statistics Fact Sheet, 2010). Stratified by race and
ethnicity, non-Hispanic white youth had the highest rate of new cases of TID with 24.8
cases per 100,000 per year among those younger than 10 years and 22.6 cases per
100,000 per year among those of ages 10–19 years (National Diabetes Statistics Fact
Sheet, 2010). Worldwide, it is estimated that there are 65,000 newly diagnosed cases of
T1D per year for children less than 15 years of age (source: International Diabetes
Federation, 2009). Over the past 50 years, T1D prevalence has experienced an
exponential rise, which seemingly has more to do with environmental factors than genetic
causation (Gillespie, Bain et al. 2004). Worldwide, the incidence of T1D in children
under 14 yr has increased on all continents except Central America and the West Indies
from 1990 – 1999 (2006). In this study of 43,013 cases of T1D out of a population size
of 84 million (representing 114 populations in 57 countries), the average rise in incidence
of T1D from 1990 to 1994 was 2.4%. From 1995 to 1999 the worldwide incidence rose
to 3.4%. Figure 1.2 shows the worldwide incidence of Type 1 diabetes in children ≤14
years of age.
In a large longitudinal study conducted in 17 European countries and based on
current T1D statistics, it is predicted that between the years 2005 and 2020, new cases of
T1D in European children younger than five years of age will double, while the
prevalence of T1D is expected to rise by 70% to 160,000 cases in children under fifteen
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Type 1 diabetes incidence per 100,000/year
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Figure 1.2: Worldwide incidence of Type 1 diabetes in children ≤14 years of age.
Values presented are age-adjusted and listed in descending order of incidence (per
100,000 people per year). Note that many of the countries with the highest incidence of
diabetes are located north or south of the equatorial belt, where sunshine is less intense
annually and therefore dermal vitamin D synthesis is lower, on average, suggesting a role
for vitamin D in diabetes onset. Other countries with a high incidence of people with
T1D are industrialized nations, where children and adults spend more time indoors and
out of the sun. Despite being in a sunny location, apparent anomalies like Kuwait—the
country with the 4th highest incidence of T1D—might have increased numbers of people
with autoimmune diabetes due to their darker skin color and a tendency to clad
themselves extensively in clothes that may block vitamin D synthesis.
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years (Patterson, Dahlquist et al. 2009). The disparity between T1D prevalence and
incidence across the globe may be explained by a multi-factorial and complex
combination of factors involving population genetics, socioeconomic status, exposure to
pathogens, geographic location, skin color (melanin density), diet (e.g. vitamin D
supplementation, consumption of cow’s milk, nitrates, etc.) and genetics.
The first sign of disease onset in patients with T1D is the presence of autoantibodies
produced by self-reactive B-cells. Serological analyses showed that some children
develop autoantibodies as early as three months of age (Kukko, Kimpimaki et al. 2005).
In T1D patients, the number of autoantibodies to insulin (INS), glutamic acid
decarboxylase (GAD), or islet cell autoantigen-512 (ICA512) is indicative of the relative
risk for development of diabetes among first-degree relatives (Verge, Gianani et al. 1996;
Verge, Gianani et al. 1996). The five-year risk of a diabetes outcome was as follows:
No positive islet autoantibodies = 0%;
Presence of autoantibodies to one islet autoantigen = 15%;
Presence of autoantibodies to two islet autoantigens = 44%;
Presence of autoantibodies to three islet autoantigens = 100% risk.
Anti-INS antibodies can be found in 50-70% of T1D children (Greenbaum, Palmer et
al. 1992) and anti-IA-2 antibodies are seen in 70-80% of cases (Gorus, Goubert et al.
1997). Anti-GAD antibodies occur in 70-75% of T1D patients. However, it was found
that 1-2% of the general population generates anti-GAD antibodies yet still retains
normal pancreatic function (Sanjeevi, Falorni et al. 1996). This observation suggests that
autoreactive lymphocytes may be present in healthy individuals, but may be down
regulated by tolerogenic mechanisms after they escape thymic selection early in life.
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Disease onset due to hyperglycemia (>250 mg/dl blood glucose), can take years to
develop following initial detection of autoantibodies (Eisenbarth 1986). While
autoantibodies produced by B-cells are indicative of disease onset, they are not thought to
serve a pathogenic role (Yoon and Jun 2005). The main role of B-cells in pancreatic islet
beta cell destruction may be related to their ability to present β-cell antigens to
autoreactive T-cells, which in turn activates cytotoxic lymphocyte destruction of the βcells. Hyperglycemia, the major clinical symptom of overt diabetes, occurs only after
>80-90% of the insulin-producing β-cells have been destroyed by cytotoxic Tlymphocytes and macrophages (Knip and Siljander 2008). Although β-cell destruction
continues throughout the lifetime of the T1D patient, it appears that insulin-producing
cells continue to be differentiated to a small degree within the pancreas and can still be
detected in >88% of patients with frank diabetes (Meier, Bhushan et al. 2005). This
condition suggests that if a targeted immune suppression therapy such as that proposed in
this dissertation was to be applied, newly formed β-cells could be protected from
autoimmune destruction, resulting in improved possibility for restoration of
normoglycemia. Islet transplant or stem cell therapy may supplement and even
accelerate the regeneration of islet beta cells, but only if autoreactive lymphocyte activity
can be persistently blocked to prevent their destruction of nascent β-cells.

Factors Affecting the Etiology of Type 1 Diabetes
Genetics
Haplotype differences in the major histocompatibility complex (MHC) genes
responsible for self-antigen presentation to the immune system may account for many
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individuals with increased susceptibility to autoimmunity. Specifically as it applies to
TID, disease susceptibility is determined by variations in the HLA-DQ (an
αβ heterodimer of the MHC class II cell surface receptor found on antigen presenting
cells) on chromosome 6 beta genes, while additional alleles provide significant resistance
to T1D development (Todd, Bell et al. 1987). More recently, a genome-wide search
identified alleles at 41 loci that increase the risk of T1D development, including
variations in several important interleukin (IL) genes and surface markers involved in
immune activity or β-cell function such as IL10, IL19, IL20, GLIS3, CD69 and IL27
(Barrett, Clayton et al. 2009).
In some cases, random genetic recombination of T-cell receptor (TCR) genes for Tcell specific antigenic epitope recognition can result in TCRs that bind self-peptides.
Normally, autoreactive T-cells are selected and eliminated in the thymus (thymic
selection). However, it is possible that some of these autoimmunity-stimulating T-cells
may escape this process and become suppressed by regulatory immune cells located in
the periphery of healthy individuals. In autoimmune disease victims, the regulatory
capacity of the immune system is no longer able to downregulate autoreactive T-cell
development. The majority of epitopes responsible for induction of TID autoimmunity
are fragments of proinsulin —INS (Palmer, Asplin et al. 1983), glutamic acid
decarboxylase—GAD (Baekkeskov, Aanstoot et al. 1990), insulinoma associated
autoantigen-2 (IA-2 and IA-2β/phogrin) (Bonifacio, Lampasona et al. 1995; Lu, Li et al.
1996), carboxypeptidase-H (Castano, Russo et al. 1991), islet cell autoantigen-69—
ICA69 (Pietropaolo, Castano et al. 1993), GM gangliosides (Nayak, Omar et al. 1985),
imogen-38 (Arden, Roep et al. 1996), sex-determining region Y-related protein-13—
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SOX13 (Kasimiotis, Myers et al. 2000). A compilation of the predominant epitopes
recognized by CD4 and CD8 T-cells from humans and mice with TID has been published
by Di Lorenzo, T.P. et al. (2007). Recently, autoantibodies to zinc transporter protein—
ZnT8 were found in 60 – 80% of patients with new onset T1D, including 26% that
uniquely had ZnT8 antibodies in the absence of antibodies that recognize the usual
markers of β-cell autoimmunity—INS, GAD, IA-2, and ICA (Wenzlau, Juhl et al. 2007).
Detection of T1D at disease onset was achieved in 98% of individuals when antibodies
were screened against a combination of INS, GAD, IA-1, and ZnT8 proteins.

Molecular Mimicry
Since genetics alone only accounts for approximately 50% of diagnosed T1D
cases, environmental influences on disease initiation cannot be ignored (Drescher and
Tracy 2008). Although poorly developed, there is increasing evidence that exposure to
certain pathogens may increase susceptibility to TID. Particularly, molecular mimicry,
epitope spreading, or direct bystander activation by pathogen epitopes with similar
structure or binding capacity to human proteins may lead to cross-reactive antibody or Tcell receptor formation that can trigger an immune attack against self-tissues (Olson,
Croxford et al. 2001). To date, 14 different viruses have been reported that may be
strongly associated with T1D in humans and various animal models (Jun and Yoon
2003). The Coxsackie B enterovirus (a member of the picornaviridae) is one of the
viruses most suspected of eliciting a cross-reactive immune response (Drescher and
Tracy 2008).
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Immune Suppression of Diabetes Autoimmunity
Dendritic Cells are Sensors of Infection and Activate T cells in
Peripheral Lymphoid Organs
Dendritic cells (antigen presenting cells that bridge the innate and adaptive arms
of the immune system); continuously patrol the microenvironment for invading
pathogens. DCs are not a single cell type, but a heterogeneous collection of cells that
arise from distinct, bone marrow-derived or hematopoietic lineages (Caux, Massacrier et
al. 1997; Reid 1997). That is, subsets from different tissues have been shown to possess a
differential morphology, phenotype and function (Appendix 5). Three-color flow
cytometry revealed two subpopulations of HLA-DR+ DCs, characterized primarily by the
phenotypes CD11c- HLA-DR+ (lymphoid appearance) and CD11c+ HLA-DR+
(monocytoid morphology) respectively (Thomas and Lipsky 1994; Robinson, Patterson et
al. 1999). Further, both subsets lack expression of the LC marker CD1a and express only
low levels of adhesion and co-stimulation molecules CD80, CD86 and CD40, suggesting
that these cells are relatively immature (Carnevali, Bonati et al. 1980; O'Doherty, Peng et
al. 1994; Robinson, Patterson et al. 1999). However, when cultured, both populations
develop into cells with typical DC morphology that express high levels of adhesion and
co-stimulatory molecules and possess potent allostimulatory function (O'Doherty, Peng et
al. 1994). It has been suggested that the so-called myeloid and lymphoid-derived subsets
of DCs perform specific stimulatory or tolerogenic function, respectively. Regardless of
their subset, the ability to stimulate naïve T cell proliferation appears to be shared
between these various DC subsets (Hart 1997; Shortman and Caux 1997). DCs become
activated by inflammatory or pathogenic products derived from microbes, toxins or from
damaged tissues (Viney 2001). The acquired stimulus induces DC mobilization from
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non-lymphoid tissues to draining lymphoid organs via afferent lymphatic vessels. DCs
are thought to exist either in an immature or mature state. The capacity of DCs to induce
immunity depends on their state of development frequently referred to as “maturation”
(Figure 1.3). During maturation, the DCs convert antigens to immunogens, which they
transfer via MHC molecules from intracellular vesicles to the cell surface. In addition
during activation, DCs express adhesion and co-stimulatory molecules (e.g. CD86,
CD80, CD83 and CD40), for establishment of cell-to-cell interactions and the release of
soluble cytokines, chemokines and enzymes responsible for regulating cellular
communication and mobilization (Banchereau and Steinman 1998; de Saint-Vis, FugierVivier et al. 1998; Guermonprez, Valladeau et al. 2002; Jiao, Lo-Man et al. 2002).
Immature DCs are characterized by very low levels of synthesis and membrane
presentation of surface co-stimulatory molecules and by low levels of IL-6, IL-1β, TNF-α
and IL-12 inflammatory cytokine biosynthesis (Hackstein and Thomson 2004). In
contrast, DC maturation triggers an increase in the expression of inflammatory cytokines.
DCs become terminally matured when they finally make contact with cognate T
lymphocytes in the specialized microenvironment of lymph node tissues, which permits
intimate physical interaction among DCs and naïve T lymphocytes referred to as the
immunologic synapse (Merwe 2002; Gogolak, Rethi et al. 2003). Primarily, DCs function
as specialized cellular sensors of pathogenic changes that occur within a tissue. In
addition to detection of pathogenic changes, a second major DC function is transmission
of this information to cognate T lymphocytes for further processing leading to an
amplified immune response (Reis e Sousa 2001). The immunological synapse formed
between the DC and the T cell is stabilized by multiple co-stimulatory and adhesive
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Figure 1.3. The antigen presentation and T cell activation functions of mature dendritic
cells.
Differentiated (mature) dendritic cells are professional antigen presenting cells located in
tissues throughout the body and especially adjacent to the epidermal mucosae. Mature
DCs are able to activate both CD4+ helper and CD8+ cytotoxic T lymphocytes based on
the nature of the pathogen proteins taken up and processed by the antigen-presenting
cell. Helper T lymphocytes can also support B cell differentiation and antibody
production (Gogolak, Rethi et al. 2003)

17

molecules, while the immunological specificity of the signaling complex is maintained
by interactions between the MHC-Peptide –TCR complex (Figure 1.3). The expression
of co-stimulatory molecules and cytokine receptors on DCs in combination with the
pattern of DC released cytokines are responsible for differentiation of the naïve CD4+
helper T lymphocyte component into either a Th1 or Th2 effector cell (Itano and Jenkins
2003). Naïve T cells are known to differentiate into immunostimulatory Th1 cells in the
presence of the DC secreted pro-inflammatory cytokine IL-12. Alternatively Th0 cells
develop into immunosuppressive Th2 cells in the presence of DC secreted
immunotolerizing cytokines IL-4 and IL-10. The Th1 lymphocyte subtype secretes
inflammatory cytokines such as IL-2 and IFN-γ. These Th1 cells can also support the
priming of CD8+ cytotoxic T lymphocytes (CTL), (De Smedt, Butz et al. 2001;
Maldonado-Lopez, Maliszewski et al. 2001; Maldonado-Lopez and Moser 2001).
Alternatively, Th2 lymphocytes secrete IL-4, IL-10 and TGF-β (Lutz and Schuler 2002).
DCs can also determine the differentiation of naïve T cells into regulatory T cells (Tregs),
(Levings, Sangregorio et al. 2001; Roncarolo, Bacchetta et al. 2001; Roncarolo, Levings
et al. 2001). Research has shown that Treg cells can suppress DC maturation resulting in
maintenance of the immunosuppressive, less mature DC phenotype (Mahnke, Johnson et
al. 2007).

The Role of Toll like Receptors in Immune Suppression
To maintain immunological homeostasis, DCs, macrophages and B cells
recognize pathogen antigens and autoantigens in the periphery by binding conserved
pathogen associated molecular patterns (PAMPS), to trans-membrane Toll-like receptor
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(TLR) domains (Takeda and Akira 2001; Takeda and Akira 2003; Wen, Peng et al.
2004). Different PAMPS stimulate specific TLRs activating DC signal transduction
pathways through adaptor proteins (e.g., MyD88), leading to synthesis or stimulation of
transcriptional activators e.g., nuclear factor kB (NFkB), mitogen activated protein
kinases (MAPKs), c-Jun N-terminal kinase (JNK) and interferon regulatory factor 3
(IRF3). These transcriptional activators initiate expression of genes encoding specific
cytokines (IL-12, IL-10), costimulatory molecules and chemokines that enable antigen
activated DCs to guide the development of naïve Th0 cell into immunoreactive Th1 cells,
Th2 immunosuppressive effector cells or regulatory T cell subsets (Kaisho and Akira
2001; Kaisho and Akira 2002). Further, TLR agonists can break immunological tolerance
and induce autoimmune diseases such as arthritis (Deng, Nilsson et al. 1999),
experimental autoimmune encephalomyelitis (EAE) (Segal, Chang et al. 2000) and
diabetes (Lang, Recher et al. 2005). While most TLR agonists are potent adjuvants that
promote the development of inflammatory Th1 effector cells, a number of reports show
that TLR stimulation may also suppress autoimmune pathogenesis, suggesting a dual role
for TLRs in autoimmune diseases (see review by Ehlers and Ravetch, 2007). On
occasion, the dual role of TLRs can be demonstrated in the same model, but using
different routes of ligand administration. For example, intravenous injection of the TLR9
ligand CpG together with ovalbumin resulted in the induction of tolerance in vivo.
However, following subcutaneous injection, the same ligands induced inflammation
(Wingender, Garbi et al. 2006). Further, it was demonstrated that TLR2 ligands drive
induction of Th2 lymphocyte populations that stimulate immunosuppression, (Hemmi,
Takeuchi et al. 2000; Bauer, Kirschning et al. 2001; Kapsenberg 2003; Dillon, Agrawal
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et al. 2004; Jarnicki, Conroy et al. 2008; Agrawal S 2003) and modulate the functions of
CD4+CD25+ regulatory T cells (Liu, Liao et al. 2006). Recently, examination of TLR2
and TLR4 expression in monocytes from T1D patients showed that TLR2 and TLR4
surface expression and mRNAs were significantly increased in T1D monocytes in
comparison with the controls (Devaraj, Dasu et al. 2008). Downstream transcriptional
activator and adaptor proteins NF-κB, MyD88, Trif and pIRAK, were also significantly
upregulated suggesting DC activation is involved in immune suppression of T1D.
Agonists of TLR-4 or TLR-9 can also inhibit autoimmune diseases, such as EAE,
arthritis, diabetes, ulcerative colitis and systemic lupus erythematosus (SLE) in mice
(Gilkeson, Ruiz et al. 1996; Rachmilewitz, Karmeli et al. 2002; Alyanakian, Grela et al.
2006; Buenafe and Bourdette 2007). Autoreactive T cells involved in EAE and other
chronic inflammatory autoimmune diseases are considered to follow defined TLR
pathways of DC processing and autoantigen presentation triggered by environment
signals (Haverkos, Battula et al. 2003; Ylipaasto, Klingel et al. 2004; Bach 2005).
Signaling through TLRs 3 and 7 exacerbates autoimmune diabetes in a mouse model, and
the effect is mediated by IFN-α (Lang, Recher et al. 2005).

Dendritic Cell Costimulatory Molecules CD86 (B7-2) and CD83 are
Essential for Efficient CD4+ T helper Lymphocyte Activation
Unlike other antigen presenting cells, DCs have a unique capacity to present
peptides via MHC class II molecules during maturation, pointing to complex multilevel
regulation of antigen presentation by mature DC (Gogolak, Rethi et al. 2003). Activation
of naïve Th0 lymphocytes requires engagement of the TCR with the MHC class II antigen peptide complex presented on the DC plasma membrane surface (Bromley,
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Iaboni et al. 2001). DCs can acquire external antigens from the environment; process
them within specialized MHC class II rich compartments within the DC as a result of
activation and maturation. This initial DC processing induces the transport of antigen
peptide loaded MHC class II molecules to the plasma membrane. The capacity of the DC
to transport the MHC class II –antigen peptide complex to the cell membrane is
dependent upon co-transport of the antigen along with the CD86 co-stimulatory factor
protein which together provides efficient activation of CD4+ helper T cells (Inaba, Turley
et al. 1998; Inaba, Turley et al. 2000; Turley, Inaba et al. 2000). In addition to antigen
specific interactions mediated by the MHC II peptide complex, a second protein
interaction involving CD28 originating on T cells and its respective DC ligand CD86
(B7-2), which exists as a monomer on the APC, is required for optimal T cell activation
(Carreno and Collins 2002; Collins, Ling et al. 2005).
The cluster of differentiation molecule CD83 is a type-1 membrane glycoprotein
of the Ig superfamily expressed by most DCs, including thymic DCs, skin Langerhan’s
cells, circulating DCs, interdigitating reticulum cells present in the T cell zones of
lymphoid organs and monocyte derived DCs (Zhou, Schwarting et al. 1992; Weissman,
Li et al. 1995; Zhou and Tedder 1995; Zhou and Tedder 1995; Zhou and Tedder 1996).
The CD83 protein is considered to be a marker of DC maturation. The fact that CD83
biosynthesis is strongly upregulated together with co-stimulatory molecules CD80 and
CD86 during DC maturation suggests CD83 plays an important role in the induction of
immune responses. Infection studies with herpes simplex virus type 1 (HSV-1) and the
inhibition of CD83 mRNA specific transport from the nucleus to the cytoplasm suggests
a possible functional role for CD83 (Lechmann, Zinser et al. 2002). The first clear proof
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that CD83 is indeed important for DC biology came from recently performed studies
employing a soluble form of the extracellular CD83 domain to inhibit DC-mediated T
cell proliferation (Lechmann, Kremmer et al. 2002). Additional studies elucidated
immunostimulatory as well as regulatory effects of the CD83 molecule (Lechmann,
Berchtold et al. 2002; Lechmann, Zinser et al. 2002; Kuwano, Prazma et al. 2007). These
studies revealed that CD4+ T cell generation was blocked in CD83-/- knockout mice.

The Role of CD4 and CD8 T Lymphocytes in Type 1 Diabetes
Pathogenesis
T cells specifically provide immune protection by activating macrophages and
stimulating neutrophil migration to sites of infection, in addition to inducing B cell antibody
production (Zhu and Paul 2008).
T lymphocytes exist as a heterogeneous population of CD4+ helper or CD8+
CTLs. However, each T lymphocyte cell type is subdivided into distinct subpopulations.
The CD4 lymphocytes are considered to be largely the sole player in the induction of
autoimmune annihilation of islet beta cells for the following reasons: 1) in animal models
of T1D, CD4 cells were abundantly identified in islet cell infiltrates. 2) Lymphocyte
transfer studies suggested that isolation of CD4 T cells from diabetic NOD mice could
transfer diabetes into disease free animals (Haskins, Portas et al. 1988). 3) Defective
genes involved T1D were mapped within the same region of the MHC for expression of
class II polypeptides that specifically interact with CD4. Together, these findings
suggested that the autoimmune pathology was caused by rogue T cells escaping into the
circulation as a result of faulty positive T cell selection following presentation with
diabetogenic peptides (Faustman and Davis 2009). Alternatively, CD8 cells were not
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actively considered to play a significant role in T1D because their functions were thought
to be limited to fighting foreign antigens such as viruses. However, there is an increasing
body of evidence arising from monozygotic twin and NOD mouse studies of T cell
education that implicate CD8+ T cells in the pathogenesis of T1D (Faustman, Li et al.
1991; Li, Guo et al. 1994; Faustman and Davis 2009). Other murine and human studies
have expanded the role of class I polypeptide presentation of antigens, from providing
protection against viral antigens, to protecting against both viral and self antigens. These
results directly implicate poorly educated CD8 T cells in the destruction of beta cells
expressing self peptides in the class I MHC polypeptide groves (Faustman, Li et al. 1991;
Yan, Shi et al. 1997; Faustman and Davis 2009).

Lymphocyte Subsets Th17 and Tc17 Produce the Inflammatory
Cytokine IL-17
Both CD4+ Th17 cells and CD8+ Tc17 cells are two recently described T lymphocyte
subsets that are mainly characterized based on their ability to produce the
proinflammatory cytokine IL-17. The Th17 lymphocyte subset constitutes a third group
of effector T lymphocytes (in addition to Th1 and Th2 cells), found to be associated with
autoimmunity (Harrington, Hatton et al. 2005). In addition to the production of IL-17,
IL-21, and IL-22 (Bettelli, Oukka et al. 2007), Th17 cells are also distinguished by their
expression of the transcription factor retinoic acid, orphan receptor gamma—ROR-γt
(Ivanov, McKenzie et al. 2006). The Th17 lymphocyte subset is generated when naïve
CD4+ T cells are exposed to TGF-β and IL-21, or when central memory CD4+ T cells
encounter inflammatory cytokines IL-1β and IL-6 (Acosta-Rodriguez, Napolitani et al.
2007; Manel, Unutmaz et al. 2008; Volpe, Servant et al. 2008; Yang, Anderson et al.
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2008). The Th17 lymphocyte subset normally functions to control extracellular
pathogens, but Th17 cells can also play an important role in human and animal
experimental autoimmunity (Bettelli, Oukka et al. 2007). Transfer of islet-specific Th17
cells to NOD mice resulted in diabetes induction, but only after the cells had converted to
largely IFN-γ-producing cells (Bending, De La Pena et al. 2009; Martin-Orozco, Chung
et al. 2009). The inhibition of Th17 cells, either with neutralizing anti–IL-17 antibodies
or with recombinant IL-25, was shown to influence the course of diabetes development in
NOD mice (Emamaullee, Davis et al. 2009). Monocytes isolated from the blood of T1D
patients were found to spontaneously secrete the proinflammatory cytokines IL-1β and
IL-6, which are now known to induce and expand Th17 cell populations (Bradshaw,
Raddassi et al. 2009). However, Th17 cells do not in general seem to be independently
responsible for the development of autoimmunity. The Th1 cell subset can induce
diabetes in the absence of Th17 cells. However, Th17 cells are not sufficient to induce
disease in the absence of Th1 cells (Chitnis, Najafian et al. 2001; Bettelli, Sullivan et al.
2004). Recently, it was discovered that Th17 cells also generate large amounts of IL-9, a
cytokine normally associated with immuno-suppressive functions produced by Th2 cells
(Elyaman, Bradshaw et al. 2009). To further add to the confusion, IL-17 was shown to
have a protective effect in T-cell mediated intestinal inflammation (O'Connor, Kamanaka
et al. 2009).
The Tc17 lymphocyte subset can also produce IL-17 and usually releases IFN-γ as
well (Kondo, Takata et al. 2009). The Tc17 cell phenotype normally functions in the
clearance of viral infection (Hamada, Garcia-Hernandez Mde et al. 2009). However Tc17
cells can become diabetogenic if exposed to the inflammatory cytokine IL-23 (Ciric, El-
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behi et al. 2009). Little else is known at present about this recently described
inflammatory T lymphocyte subset.

Interleukin-10
Interleukin-10, (IL-10) is an anti-inflammatory cytokine with a homodimeric
subunit length of 160 amino acids and described immunosuppressive properties (Moore,
Vieira et al. 1990; Yoon, Logsdon et al. 2006). IL-10 was identified in APCs including
dendritic cell subsets (de Waal Malefyt, Abrams et al. 1991; Sica, Saccani et al. 2000).
Mouse knockout studies showed that IL-10 can down-regulate autoimmunity in the
intestine and is active in suppression of Crohn’s disease (Grimbaldeston, Nakae et al.
2007; Minderhoud, Samsom et al. 2007). Autocrine production of IL-10 by immature
DCs (iDCs), was shown to inhibit synthesis and release of pro-inflammatory cytokines
and other molecules (IL-12, TNF-α, IL-6, LTB4, NO, PGE2), and to suppress Th1
lymphocyte activity by down-regulating costimulatory molecule expression on the APC
surface (Grutz 2005; Harizi and Gualde 2006). Through inhibition of these endogenous
pro-inflammatory mediators, IL-10 is central to maintenance of DCs in an immature state
and in the down-regulation of DC mediated inflammatory responses (Harizi and Gualde
2006). In paracrine fashion, IL-10 synthesized by DCs regulates immunity by altering the
function of different adjacent cell types. In two studies, IL-10 secreted by iDCs
stimulated the development of cognate naïve Th0 cells into Th2 lymphocytes, or
suppressor regulatory CD4+ T cells (Romagnani 1998; Romagnani, Kapsenberg et al.
1998; Stassen, Fondel et al. 2004; Stassen, Schmitt et al. 2004). Since IL-10 can partially
suppress T1D (Slavin, Maron et al. 2001) in combination with adjuvanted autoantigens
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IL-10 may function in an additive or synergistic fashion to enhance multi-subunit
vaccines for more effective immune suppression of T1D.

Diabetes - autoantigen Therapy
Immunologic tolerance induced by islet β-cell autoantigens was shown to
partially suppress diabetes autoimmunity (Zhang, Davidson et al. 1991) and has been
used since then in the treatment of the pathological inflammation associated with organspecific autoimmune diseases, particularly T1D. This application was developed because
the mechanisms of action of the autoantigen may be similar to those operating in the
maintenance of immunological homeostasis (Vigouroux, Yvon et al. 2004). Prevention of
autoimmune T1D onset or retardation of its progression by repeated oral inoculation with
small amounts of pancreatic islet autoantigens has been demonstrated in animal models
of autoimmune diabetes (Czerkinsky, Anjuere et al. 1999). Immunotherapy using major
β-cell antigens such as insulin, GAD, or heat shock protein (hsp60), was shown in a
variety of studies to delay or prevent T1D onset (Elliott, Qin et al. 1994; Tisch and
McDevitt 1996; Atkinson and Leiter 1999). Oral inoculation with small amounts of islet
autoantigens was shown to induce self-tolerance through IL-4 and Stat 6 activation of
CD4+ Th2 and Th3 regulatory T cells that down-modulate autoreactive effector T cell
inflammation at close proximity e.g., “bystander suppression”, (Hommann, Schotte et al.
2001; Weiner 2001). Protection against T1D was shown to be associated with Th3
regulatory lymphocyte secretion of TGF-β in prediabetic NOD mice gavaged with
insulin, (Zhang, Davidson et al. 1991). Further, oral autoantigen inoculation generated
partial diabetes suppression in patients (Chaillous, Lefevre et al. 2000; Millington,
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Mowat et al. 2004). In several related Th1 cell mediated autoimmune diseases, collageninduced arthritis (Thompson and Staines 1986) and encephalomyelitis (Higgins and
Weiner 1988), disease suppression was observed following prolonged feeding of small
amounts of specific autoantigens. The induction of multiple sclerosis in animals was not
only halted but reversed by feeding small amounts of myelin basic protein (MBP)
suggesting that this type of oral autoantigen therapy can suppress and even aid in
recovery from autoimmunity (Bitar and Whitacre 1988).
Incidentally, most individual autoimmune diabetes vaccination strategies were
developed in two mammalian (rodent) models that spontaneously develop T1D, the NOD
mouse and the BioBreeding (BB) rat. These animal models have allowed detailed
exploration of the altered communication between DCs of the innate arm of the immune
system that underlies development of pancreatic β-cell-reactive effector T cells of the
adaptive portion of the immune system. However, the animal model that has emerged as
the most frequently employed for pre-clinical evaluation of prophylactic and therapeutic
strategies for treatment of T1D has been the NOD mouse, which has an etiology of
autoimmune diabetes similar to that of humans such as the influence of sex on disease
incidence (Anderson and Bluestone 2005).
Preference for the NOD mouse model is based on a better defined genome, more
monoclonal reagents for the analysis of immune system components and lower animal
maintenance costs. So much preference has been placed on the NOD mouse for diabetes
studies that other animal models frequently remain untested and potential differences in
the NOD model as compared with humans are often neglected prior to extrapolations
made to patients. More than 125 individual therapeutic strategies have been reported to
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have a therapeutic effect on diabetes prevention in the NOD mouse (Atkinson and Leiter
1999). However, most of these therapies have shown only partial suppression of the
disease.
In contrast to diabetes prevention, amelioration of diabetes hyperglycemia
following disease onset is even more difficult to achieve. Less than a dozen
immunomodulatory protocols have been reported to have a detectable therapeutic effect
(Anderson and Bluestone 2005). Importantly, several of these therapies subsequently
showed partial efficacy in clinical trials (Raz, Elias et al. 2001; Herold, Hagopian et al.
2002; Keymeulen, Vandemeulebroucke et al. 2005). Based on the partial success in
prevention of T1D onset in NOD mice, this mammalian model has often been considered
to be an indicator of the potential for individual therapies in humans.

Cholera Toxin B Subunit (CTB) Enhances Autoantigen-Mediated
Immune Tolerance
Cholera enterotoxin (CT) is an oligomeric protein produced in nature by the Gramnegative bacterium Vibrio cholerae. The toxin causes excretion of a high volume of
dilute (“rice water”) diarrhea initiated in the upper part of the small intestine. SDS-PAGE
analysis showed that CT consists of a single large A subunit (CTA) of approximately 27
kDa and a pentameric B subunit (CTB) with an approximate monomer molecular weight
(MW) of 10.6 kDa (Lonnroth and Holmgren 1973). The CTA subunit can be subdivided
into CTA1 and CTA2 subunits linked by a disulfide bond. The CTA1 subunit was found to
be responsible for CT toxicity (Sattler and Wiegandt 1975). The assembly of CT structures
revealed that the toxic CTA1 subunit contained ADP-ribosylating activity, while the
helical CTA2 fragment was found to be responsible for embedding the CTA1 subunit
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into the center of the doughnut shaped CTB pentameric oligomer (Sixma, Kalk et al.
1993). In addition, the CTB subunit, held together by hydrogen bonds and salt bridges
was shown to bind to ganglioside GM1[Gal(β1-3)galNac(β1-4)(NeuA-c(α23)Gal(β14)Glc]ceramide (Merritt, Sarfaty et al. 1995) an anchor molecule embedded in
the mammalian epidermal cell membrane (Holmgren, Lonnroth et al. 1973; Holmgren,
Lonnroth et al. 1975) (Fig. 1.4). Cholera toxin was shown to bind and infect a variety of
somatic cells in vivo, especially intestinal epithelial cells, through high affinity binding of
the toxin to its cell surface receptor GM1 ganglioside (Holmgren, Lindholm et al. 1974;
Holmgren, Lonnroth et al. 1975; van Heyningen 1976; van Heyningen and King 1976).
However, only epidermal cells in the Go/G1 phase of the cell cycle were shown to both
bind and internalize CT.
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Figure 1.4. Crystal structure of cholera toxin.
The heterodimeric CTA protein subunit (blue) is composed of two polypeptide chains,
CTA1 (22 kDa) and CTA2 (5 kDa), linked by a single disulfide bond. The enzymatically
active CTA1 peptide is the (toxic) mono-ADP-ribosyltransferase subunit while the CTA2
helical peptide links the CTA1 subunit to the pentameric CTB subunits. The cholera toxin
B subunit (10.6 kDa) is composed of five identical polypeptide subunit chains (yellow,
purple, red, orange and turquoise), each with membrane receptor GM1ganglioside
binding capacity.
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CT binds preferentially and almost exclusively to GM1 ganglioside (Sixma,
Kalk et al. 1993; Sanchez and Holmgren 2008). Cholera toxin secretion in bacteria
involves transport across the outer membrane through a CT secretion system known
as the extracellular protein secretion system (Eps) (Camberg, Johnson et al. 2007).
The energy for secretion is provided by EpsE, a cytoplasmic ATPase, that forms a
complex with other secretory proteins to transfer CT across the periplasmic
compartment (Camberg and Sandkvist 2005). This transfer is believed to be
facilitated by the outer membrane component of the Eps, EpsD, which induces
opening of the channel and subsequent secretion (Davis, Lawson et al. 2000). This
protein transfer system moves CT from the periplasm where its subunits are
assembled, across the membrane and into the extracellular environment (Hirst,
Sanchez et al. 1984; Hardy, Holmgren et al. 1988). In order to mediate its toxic
activity, CT binds with high affinity to GM1 ganglioside in lipid rafts on the
epidermal cell surface of the lumen of the small intestine. The high binding affinity
of CTB to ganglioside GM1 is due to the contribution of a single amino acid
(Gly33) on the neighboring CTB monomer to the GM1 binding site on an adjacent
CTB monomer (Merritt, Sarfaty et al. 1994). Subsequently, the crystal structure of
CT revealed that Tyr12 on the CTB monomer along with Gly33 and Trp88 on the
adjacent monomer are critical for CT-GM1 interaction (Jobling and Holmes 2002).
The binding of CT via its CTB subunits to GM1 permits toxin endocytosis
through caveolin-coated and clathrin-coated vesicles (Chinnapen, Chinnapen et al. 2007).
In addition, CT was shown to enter cells through both Arf6 dependent and non-Arf6
dependent pathways, which still remain unidentified (Chinnapen, Chinnapen et al. 2007).
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Interestingly, blocking all known endocytic pathways does not appear to alter the
toxicity of CT within the cell (Massol, Larsen et al. 2004). The toxin is transported not
only to endosomes but also to the endoplasmic reticulum (ER) via Golgi retrograde
transport mechanisms (Sandvig and van Deurs 2002). An endoplasmic reticulum
retention motif (KDEL) is located near the C terminus of the CTA chain. This motif
allows the toxin to interact with the KDEL receptor which permits recycling of ER
components from the trans-Golgi network (TGN), back to the ER (Spooner, Smith et al.
2006). Endocytosis of the toxin results in CTA1 subunit induction of adenylate cyclase.
The up-regulation of adenylate cyclase activity occurs through CTA stimulation of ADP
ribosylation of the adenylate cyclase Gsα subunit (O'Neal, Jobling et al. 2005). Increased
intracellular cAMP concentrations result in an imbalance in electrolyte influx into the cell
due to decreased sodium uptake by enterocytes and an increase in anion efflux from the
cells. The decrease in sodium intake in addition to the extrusion of anions and
bicarbonates causes water to be excreted from the cell into the lumen of the intestine.
Ultimately, large amounts of water and electrolytes are lost from the intestinal epithelium
resulting in severe bouts of “rice water” diarrhea. In addition, there is fluid loss from the
intestine of up to 2 liters per hour leading to dehydration and death, usually by stroke in
patients in which rehydration therapy is unavailable.

The Cholera Toxin B subunit (CTB) Functions as a Carrier and
Vaccine Adjuvant
Enhanced immunogenic and adjuvant properties of microbial holotoxin B
subunits such as CTB and heat-labile enterotoxin (LTB) from E. coli have been widely
reported upon in a number of recent studies (Sun, Holmgren et al. 1994; Czerkinsky, Sun
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et al. 1996; Guidry, Cardenas et al. 1997; Porgador, Staats et al. 1998; Sun, Xiao et al.
2000; Eriksson and Holmgren 2002). The intact CT holotoxin was also found to be a
potent mucosal immunogen. The presence of potent CT toxic effects, CT resistance to
proteases and bile salts, as well as the high affinity of CT binding to ganglioside GM1
and corresponding enzymatic ADP-ribosylating activity may contribute individually or
together to establish the powerful immunostimulatory activity of CT (Sanchez and
Holmgren 2008). Despite its strong immunogenic activity, and its wide use in animal
vaccination protocols, the ability of CT to induce persistent inflammation has delayed
application of the holotoxin as an adjuvant for stimulating immune responses in human
vaccines.
Despite this present drawback, oral CTB cholera vaccines have proved to be
effective against cholera toxin (Arakawa, Yu et al. 1998; Lucas, Deen et al. 2005).
Surprisingly, in addition to its known capacity to induce a pro-inflammatory response,
oral administration of CTB subunit coupled with an autoantigen was shown to induce a
state of immunological tolerance (George-Chandy, Eriksson et al. 2001; D'Ambrosio,
Colucci et al. 2008). In early studies, oral delivery of CTB conjugated to specific
autoantigens was shown to enhance autoantigen mediated protection of mice against
several autoimmune diseases including autoimmune encephalomyelitis (Sun, Xiao et al.
2000), autoimmune chondritis (Kim, Cheng et al. 2001), and uveitis (Phipps, Stanford et
al. 2003). Further, CTB-autoantigen conjugates were shown to substantially suppress
T1D in NOD mice (Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998). Results of
diabetes studies indicated that CTB-autoantigen conjugates reduced IFN-γ production
and the migration of Tr1 regulatory T cells into pancreatic islets (Roncarolo, Levings et
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al. 2001; Aspord and Thivolet 2002). Linkage of CTB to an autoantigen was shown to
provide up to a 10,000-fold reduction in the amount of autoantigen required for
generating immuno-tolerance (Arakawa, Chong et al. 1998; George-Chandy, Eriksson et
al. 2001).
Mechanisms underlying CTB-autoantigen modulated tolerance were shown to
include inhibition of DC maturation, autoreactive T cell development and/or stimulation
of Th2 and Foxp3 regulatory T cell proliferation and activation (Marinaro, Staats et al.
1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004). In other studies,
Incubation of immature DCs with CTB was shown to induce DC maturation in
experimental tumor models (George-Chandy, Eriksson et al. 2001; Isomura, Yasuda et al.
2005). Morphological changes in DCs incubated with CTB included cell enlargement,
elongation of DC dendrites and increased migration of DCs into draining lymph nodes as
well as increased expression of the B7-2/CD86 co-stimulatory molecule (Isomura,
Yasuda et al. 2005). Further, the mucosal administration of CTB conjugated to
autoantigens was shown to mediate synthesis of T cell cytokines in response to the
antigen or autoantigen complex. In experimental allergic encephalitis studies, the
secretion of proinflammatory cytokines IL-12, IFN-γ, and TNF-α were significantly
reduced while T cell expression of TGF-β was increased in animals treated with CTB
conjugated to MBP (Sun, Xiao et al. 2000). Similarly, immunosuppressive cytokine
secretion including increased IL-10 secretion was observed after oral administration of
CTB conjugated to insulin, resulting in suppression of diabetes onset in NOD mice
(Bergerot, Ploix et al. 1997; Ploix, Bergerot et al. 1999; Aspord and Thivolet 2002)
(Fig.1.5). Based on the recent findings that inflammatory Th17 lymphocytes were
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implicated in autoimmune disease pathogenesis, conjugation of CTB to myelin
oligodendrocyte glycoprotein (MOG) delivered together with Complete Freund’s
Adjuvant (CFA) resulted in suppression of lymphocyte IL-17 secretion (Sun and
Holmgren unpublished results).

CTB May Stimulate Tolerance through Binding DC Toll-like
Receptors
To maintain immunological homeostasis, DCs recognize pathogen antigens and
autoantigens in the periphery. Immunological recognition is achieved by binding
conserved PAMPS, to trans-membrane TLR domains (Takeda and Akira 2001; Takeda,
Kaisho et al. 2003; Wen, Peng et al. 2004). Different PAMPS stimulate specific TLRs
activating DC signal transduction pathways through adaptor proteins (e.g., MyD88),
which lead to synthesis or stimulation of transcriptional activators e.g., NFkB, MAPKs,
JNK and IRF3 as mentioned earlier. These transcriptional activators initiate expression of
genes encoding specific cytokines (IL-12, IL-10), costimulatory molecules and
chemokines that enable antigen activated DCs to guide the development of naïve Th0 cell
into immunoreactive Th1 cells, Th2 immunosuppressive effector cells or regulatory T
cell subsets (Kaisho and Akira 2001; Kaisho and Akira 2002).While most TLR agonists
are potent adjuvants that promote the development of inflammatory Th1 effector cells, a
number of reports show TLR2 ligands drive induction of Th2 lymphocyte populations
that stimulate immunosuppression (Hemmi, Takeuchi et al. 2000; Kapsenberg 2003;
Wen, Peng et al. 2004; Jarnicki, Conroy et al. 2008; Agrawal S 2003). Downstream
transcriptional activator and adaptor proteins NFκB, AP-1 MyD88, Trif and pIRAK,
were also significantly upregulated suggesting DC activation is involved in immune
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suppression of T1D. In parallel studies, the E. coli enterotoxin B subunit (LTB, which is
approximately 80% homologous in amino acid sequence to CTB), was shown to
stimulate TLR2, resulting in regulatory T cell proliferation, IL-10 secretion and induction
of Th2 anti-inflammatory lymphocyte development (Hajishengallis, Tapping et al. 2005;
Sutmuller, den Brok et al. 2006; Sutmuller, Morgan et al. 2006).The structural
homologies between CTB and LTB proteins and their amino acid sequences suggest
similarities in mechanisms underlying inhibition of DC maturation (Marinaro, Staats et
al. 1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004).

Conclusion
The cellular and molecular mechanisms responsible for adjuvant enhanced
autoantigen mediated suppression of autoimmune responses remain largely obscure. The
fusion of CTB subunits with autoantigens that in general stimulate immune tolerance
against the linked autoantigen was found to exert a particularly useful effect in the
prevention of organ-specific autoimmune disease onset (Arakawa, Yu et al. 1998;
Arakawa, Yu et al. 1999; Kobayashi, Abiru et al. 2007). However, in several studies,
fusion of the toxin B subunit to specific autoantigens such as carcinoembryonic antigen
(CEA) or prostate specific antigen (PSA) resulted in stimulation of an inflammatory
rather than an immunosuppressive response (Facciabene, Aurisicchio et al. 2007;
Fensterle, Bergmann et al. 2008).
To understand how multi-component vaccines can function to prevent diabetes
onset, it will be important to improve our understanding of mechanisms underlying T1D
onset. One of the first steps required to reach this goal, will involve identification of
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vaccine interactions with cells of the innate immune system involved in initial vaccine
processing i.e., DCs. It will be necessary to determine how DC processing of adjuvantautoantigen fusion proteins results in the initiation of immuno-reactive or immunosuppressive T cell populations capable of inhibiting the development of autoimmune T
cell responses.
The experimental studies presented in this dissertation emphasize the focus of our
laboratory in elucidation of early mechanisms underlying specific DC immune responses
to inoculation with CTB subunit-diabetes autoantigen fusion proteins. The experimental
results help to identify the role of protein adjuvants such as CTB linked to diabetes
autoantigens on DC maturation and how these immunomodulated DCs influence the
morphogenesis and proliferation of immunostimulatory Th1 and immunosuppressive Th2
and/or regulatory T cell subsets to enhance the immunological suppression of diabetes
onset ex vivo in humans. Mechanisms underlying multi-component vaccine stimulation of
immunological tolerance must be more completely elucidated in order to fully harness
this promising combinatorial vaccination strategy for transfer into safe and effective
clinical therapy in T1D patients.
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Figure 1.5. Adjuvant-autoantigen suppression of type 1 diabetes pathogenesis
In this cartoon model, immature dendritic cells (iDC) in the gut periphery take up CTBINS/GAD fusion proteins from the intestinal lumen. Alternatively, microfold (M)-cells
overlaying the Peyer’s patches take up the fusion proteins by endocytosis, where they are
then delivered to antigen presenting cells, particularly dendritic cells and macrophages
that reside in the lamina propria. Autoantigens, made more immunoreactive by linkage
to the CTB adjuvant, modulate iDC processing and maturation favoring DC secretion of
IL-10 and suppression of IL-12 secretion. The anti-inflammatory cytokine IL-10 directs
cognate Th0 cell development into immunosuppressive Th2 or iTreg (Th3 or Tr1) cell
phenotypes. CTB-INS/GAD may also activate CD4+CD25+ native regulatory T cell
(nTreg) synthesis of transcriptional activator protein FOXP3, leading to further immune
suppression activity.
Figure adapted from:
Afzali B. et al. (2007), Iwasaki A. and Kelsall, B.L. (2000), and a 2008 NIH R01
application submitted by W. Langridge and I. Fodor to the National Institute of Digestive
and Diseases of the Kidney (NIDDK) entitled, Immunostimulation of Autoantigen
Mediated Tolerance.

40

References
The DIAMOND Group: Incidence and trends of childhood Type 1 diabetes worldwide
1990-1999. Diabet Med. 23: 857-866.
Acosta-Rodriguez, E. V., G. Napolitani, et al. (2007). "Interleukins 1beta and 6 but not
transforming growth factor-beta are essential for the differentiation of interleukin
17-producing human T helper cells." Nat Immunol 8(9): 942-949.
Afzali, B., G. Lombardi, et al. (2007). "The role of T helper 17 (Th17) and regulatory T
cells (Treg) in human organ transplantation and autoimmune disease." Clin Exp
Immunol 148(1): 32-46.
Agrawal S, A. A., Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B ( 2003).
"Cutting edge: different Toll-like receptor agonists instruct dendritic cells to
induce distinct Th responses via differential modulation of extracellular signalregulated kinase-mitogen-activated protein kinase and c-Fos.J " Immunology
5(171(10)): 4984-4989.
Alyanakian, M. A., F. Grela, et al. (2006). "Transforming growth factor-beta and natural
killer T-cells are involved in the protective effect of a bacterial extract on type 1
diabetes." Diabetes 55(1): 179-185.
Anderson, M. S. and J. A. Bluestone (2005). "The NOD mouse: a model of immune
dysregulation." Annu Rev Immunol 23: 447-485.
Arakawa, T., D. K. Chong, et al. (1998). "Efficacy of a food plant-based oral cholera
toxin B subunit vaccine." Nat Biotechnol 16(3): 292-297.
Arakawa, T., J. Yu, et al. (1998). "A plant-based cholera toxin B subunit-insulin fusion
protein protects against the development of autoimmune diabetes." Nat
Biotechnol 16(10): 934-938.
Arakawa, T., J. Yu, et al. (1999). "Food plant-delivered cholera toxin B subunit for
vaccination and immunotolerization." Adv Exp Med Biol 464: 161-178.
Arden, S. D., B. O. Roep, et al. (1996). "Imogen 38: a novel 38-kD islet mitochondrial
autoantigen recognized by T cells from a newly diagnosed type 1 diabetic
patient." J Clin Invest 97(2): 551-561.
Aspord, C. and C. Thivolet (2002). "Nasal administration of CTB-insulin induces active
tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice." Clin
Exp Immunol 130(2): 204-211.

41

Atkinson, M. A., M. A. Bowman, et al. (1994). "Cellular immunity to a determinant
common to glutamate decarboxylase and coxsackie virus in insulin-dependent
diabetes." J Clin Invest 94(5): 2125-2129.
Atkinson, M. A. and E. H. Leiter (1999). "The NOD mouse model of type 1 diabetes: as
good as it gets?" Nat Med 5(6): 601-604.
Atkinson, M. A. and N. K. Maclaren (1994). "The pathogenesis of insulin-dependent
diabetes mellitus." N Engl J Med 331(21): 1428-1436.
Bach, J. F. (2005). "A Toll-like trigger for autoimmune disease." Nat Med 11(2): 120121.
Baekkeskov, S., H. J. Aanstoot, et al. (1990). "Identification of the 64K autoantigen in
insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid
decarboxylase." Nature 347(6289): 151-156.
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity."
Nature 392(6673): 245-252.
Barrett, J. C., D. G. Clayton, et al. (2009). "Genome-wide association study and metaanalysis find that over 40 loci affect risk of type 1 diabetes." Nat Genet.
Bauer, S., C. J. Kirschning, et al. (2001). "Human TLR9 confers responsiveness to
bacterial DNA via species-specific CpG motif recognition." Proc Natl Acad Sci U
S A 98(16): 9237-9242.
Bending, D., H. De La Pena, et al. (2009). "Highly purified Th17 cells from
BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice." J
Clin Invest.
Bergerot, I., C. Ploix, et al. (1997). "A cholera toxoid-insulin conjugate as an oral vaccine
against spontaneous autoimmune diabetes." Proc Natl Acad Sci U S A 94(9):
4610-4614.
Bettelli, E., M. Oukka, et al. (2007). "T(H)-17 cells in the circle of immunity and
autoimmunity." Nat Immunol 8(4): 345-350.
Bettelli, E., B. Sullivan, et al. (2004). "Loss of T-bet, but not STAT1, prevents the
development of experimental autoimmune encephalomyelitis." J Exp Med 200(1):
79-87.
Bitar, D. M. and C. C. Whitacre (1988). "Suppression of experimental autoimmune
encephalomyelitis by the oral administration of myelin basic protein." Cell
Immunol 112(2): 364-370.

42

Bonifacio, E., V. Lampasona, et al. (1995). "Identification of protein tyrosine
phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetesrelated 37/40K autoantigen and a target of islet-cell antibodies." J Immunol
155(11): 5419-5426.
Bradshaw, E. M., K. Raddassi, et al. (2009). "Monocytes from patients with type 1
diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells." J
Immunol 183(7): 4432-4439.
Bromley, S. K., A. Iaboni, et al. (2001). "The immunological synapse and CD28-CD80
interactions." Nat Immunol 2(12): 1159-1166.
Buenafe, A. C. and D. N. Bourdette (2007). "Lipopolysaccharide pretreatment modulates
the disease course in experimental autoimmune encephalomyelitis." J
Neuroimmunol 182(1-2): 32-40.
Camberg, J. L., T. L. Johnson, et al. (2007). "Synergistic stimulation of EpsE ATP
hydrolysis by EpsL and acidic phospholipids." EMBO J 26(1): 19-27.
Camberg, J. L. and M. Sandkvist (2005). "Molecular analysis of the Vibrio cholerae type
II secretion ATPase EpsE." J Bacteriol 187(1): 249-256.
Carreno, B. M. and M. Collins (2002). "The B7 family of ligands and its receptors: new
pathways for costimulation and inhibition of immune responses." Annu Rev
Immunol 20: 29-53.
Castano, L., E. Russo, et al. (1991). "Identification and cloning of a granule autoantigen
(carboxypeptidase-H) associated with type I diabetes." J Clin Endocrinol Metab
73(6): 1197-1201.
Chaillous, L., H. Lefevre, et al. (2000). "Oral insulin administration and residual beta-cell
function in recent-onset type 1 diabetes: a multicentre randomised controlled trial.
Diabete Insuline Orale group." Lancet 356(9229): 545-549.
Chinnapen, D. J., H. Chinnapen, et al. (2007). "Rafting with cholera toxin: endocytosis
and trafficking from plasma membrane to ER." FEMS Microbiol Lett 266(2):
129-137.
Chitnis, T., N. Najafian, et al. (2001). "Effect of targeted disruption of STAT4 and
STAT6 on the induction of experimental autoimmune encephalomyelitis." J Clin
Invest 108(5): 739-747.
Ciric, B., M. El-behi, et al. (2009). "IL-23 drives pathogenic IL-17-producing CD8+ T
cells." J Immunol 182(9): 5296-5305.

43

Collins, M., V. Ling, et al. (2005). "The B7 family of immune-regulatory ligands."
Genome Biol 6(6): 223.
Czerkinsky, C., F. Anjuere, et al. (1999). "Mucosal immunity and tolerance: relevance to
vaccine development." Immunol Rev 170: 197-222.
Czerkinsky, C., J. B. Sun, et al. (1996). "Cholera toxin B subunit as transmucosal carrierdelivery and immunomodulating system for induction of antiinfectious and
antipathological immunity." Ann N Y Acad Sci 778: 185-193.
D'Ambrosio, A., M. Colucci, et al. (2008). "Cholera toxin B subunit promotes the
induction of regulatory T cells by preventing human dendritic cell maturation." J
Leukoc Biol 84(3): 661-668.
Davis, B. M., E. H. Lawson, et al. (2000). "Convergence of the secretory pathways for
cholera toxin and the filamentous phage, CTXphi." Science 288(5464): 333-335.
de Saint-Vis, B., I. Fugier-Vivier, et al. (1998). "The cytokine profile expressed by
human dendritic cells is dependent on cell subtype and mode of activation." J
Immunol 160(4): 1666-1676.
De Smedt, T., E. Butz, et al. (2001). "CD8alpha(-) and CD8alpha(+) subclasses of
dendritic cells undergo phenotypic and functional maturation in vitro and in
vivo." J Leukoc Biol 69(6): 951-958.
de Waal Malefyt, R., J. Abrams, et al. (1991). "Interleukin 10(IL-10) inhibits cytokine
synthesis by human monocytes: an autoregulatory role of IL-10 produced by
monocytes." J Exp Med 174(5): 1209-1220.
Deng, G. M., I. M. Nilsson, et al. (1999). "Intra-articularly localized bacterial DNA
containing CpG motifs induces arthritis." Nat Med 5(6): 702-705.
Devaraj, S., M. R. Dasu, et al. (2008). "Increased toll-like receptor (TLR) 2 and TLR4
expression in monocytes from patients with type 1 diabetes: further evidence of a
proinflammatory state." J Clin Endocrinol Metab 93(2): 578-583.
Di Lorenzo, T. P., M. Peakman, et al. (2007). "Translational mini-review series on type 1
diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes." Clin
Exp Immunol 148(1): 1-16.
Dillon, S., A. Agrawal, et al. (2004). "A Toll-like receptor 2 ligand stimulates Th2
responses in vivo, via induction of extracellular signal-regulated kinase mitogenactivated protein kinase and c-Fos in dendritic cells." J Immunol 172(8): 47334743.

44

Drescher, K. M. and S. M. Tracy (2008). "The CVB and etiology of type 1 diabetes."
Curr Top Microbiol Immunol 323: 259-274.
Eisenbarth, G. S. (1986). "Type I diabetes mellitus. A chronic autoimmune disease." N
Engl J Med 314(21): 1360-1368.
Elliott, J. F., H. Y. Qin, et al. (1994). "Immunization with the larger isoform of mouse
glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD
mice." Diabetes 43(12): 1494-1499.
Elyaman, W., E. M. Bradshaw, et al. (2009). "IL-9 induces differentiation of TH17 cells
and enhances function of FoxP3+ natural regulatory T cells." Proc Natl Acad Sci
U S A 106(31): 12885-12890.
Emamaullee, J. A., J. Davis, et al. (2009). "Inhibition of Th17 cells regulates autoimmune
diabetes in NOD mice." Diabetes 58(6): 1302-1311.
Eriksson, K. and J. Holmgren (2002). "Recent advances in mucosal vaccines and
adjuvants." Curr Opin Immunol 14(5): 666-672.
Facciabene, A., L. Aurisicchio, et al. (2007). "Vectors encoding carcinoembryonic
antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific
immune responses and antitumor effects." Vaccine 26(1): 47-58.
Faustman, D., X. P. Li, et al. (1991). "Linkage of faulty major histocompatibility
complex class I to autoimmune diabetes." Science 254(5039): 1756-1761.
Faustman, D. L. and M. Davis (2009). "The primacy of CD8 T lymphocytes in type 1
diabetes and implications for therapies." J Mol Med 87(12): 1173-1178.
Fensterle, J., B. Bergmann, et al. (2008). "Cancer immunotherapy based on recombinant
Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific
antigen and cholera toxin subunit B." Cancer Gene Ther 15(2): 85-93.
George-Chandy, A., K. Eriksson, et al. (2001). "Cholera toxin B subunit as a carrier
molecule promotes antigen presentation and increases CD40 and CD86
expression on antigen-presenting cells." Infect Immun 69(9): 5716-5725.
Gilkeson, G. S., P. Ruiz, et al. (1996). "Modulation of renal disease in autoimmune
NZB/NZW mice by immunization with bacterial DNA." J Exp Med 183(4): 13891397.
Gillespie, K. M., S. C. Bain, et al. (2004). "The rising incidence of childhood type 1
diabetes and reduced contribution of high-risk HLA haplotypes." Lancet
364(9446): 1699-1700.

45

Gogolak, P., B. Rethi, et al. (2003). "Targeting dendritic cells for priming cellular
immune responses." J Mol Recognit 16(5): 299-317.
Gorus, F. K., P. Goubert, et al. (1997). "IA-2-autoantibodies complement GAD65autoantibodies in new-onset IDDM patients and help predict impending diabetes
in their siblings. The Belgian Diabetes Registry." Diabetologia 40(1): 95-99.
Greenbaum, C. J., J. P. Palmer, et al. (1992). "Insulin autoantibodies measured by
radioimmunoassay methodology are more related to insulin-dependent diabetes
mellitus than those measured by enzyme-linked immunosorbent assay: results of
the Fourth International Workshop on the Standardization of Insulin
Autoantibody Measurement." J Clin Endocrinol Metab 74(5): 1040-1044.
Grimbaldeston, M. A., S. Nakae, et al. (2007). "Mast cell-derived interleukin 10 limits
skin pathology in contact dermatitis and chronic irradiation with ultraviolet B."
Nat Immunol 8(10): 1095-1104.
Grutz, G. (2005). "New insights into the molecular mechanism of interleukin-10mediated immunosuppression." J Leukoc Biol 77(1): 3-15.
Guermonprez, P., J. Valladeau, et al. (2002). "Antigen presentation and T cell stimulation
by dendritic cells." Annu Rev Immunol 20: 621-667.
Guidry, J. J., L. Cardenas, et al. (1997). "Role of receptor binding in toxicity,
immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin."
Infect Immun 65(12): 4943-4950.
Hackstein, H. and A. W. Thomson (2004). "Dendritic cells: emerging pharmacological
targets of immunosuppressive drugs." Nat Rev Immunol 4(1): 24-34.
Hajishengallis, G., R. I. Tapping, et al. (2005). "Toll-like receptor 2 mediates cellular
activation by the B subunits of type II heat-labile enterotoxins." Infect Immun
73(3): 1343-1349.
Hamada, H., L. Garcia-Hernandez Mde, et al. (2009). "Tc17, a unique subset of CD8 T
cells that can protect against lethal influenza challenge." J Immunol 182(6): 34693481.
Han, B., P. Serra, et al. (2005). "Developmental control of CD8 T cell-avidity maturation
in autoimmune diabetes." J Clin Invest 115(7): 1879-1887.
Hardy, S. J., J. Holmgren, et al. (1988). "Coordinated assembly of multisubunit proteins:
oligomerization of bacterial enterotoxins in vivo and in vitro." Proc Natl Acad Sci
U S A 85(19): 7109-7113.

46

Harizi, H. and N. Gualde (2006). "Pivotal role of PGE2 and IL-10 in the cross-regulation
of dendritic cell-derived inflammatory mediators." Cell Mol Immunol 3(4): 271277.
Harrington, L. E., R. D. Hatton, et al. (2005). "Interleukin 17-producing CD4+ effector T
cells develop via a lineage distinct from the T helper type 1 and 2 lineages." Nat
Immunol 6(11): 1123-1132.
Haskins, K., M. Portas, et al. (1988). "T-lymphocyte clone specific for pancreatic islet
antigen." Diabetes 37(10): 1444-1448.
Haverkos, H. W., N. Battula, et al. (2003). "Enteroviruses and type 1 diabetes mellitus."
Biomed Pharmacother 57(9): 379-385.
Hemmi, H., O. Takeuchi, et al. (2000). "A Toll-like receptor recognizes bacterial DNA."
Nature 408(6813): 740-745.
Herold, K. C., W. Hagopian, et al. (2002). "Anti-CD3 monoclonal antibody in new-onset
type 1 diabetes mellitus." N Engl J Med 346(22): 1692-1698.
Higgins, P. J. and H. L. Weiner (1988). "Suppression of experimental autoimmune
encephalomyelitis by oral administration of myelin basic protein and its
fragments." J Immunol 140(2): 440-445.
Hirst, T. R., J. Sanchez, et al. (1984). "Mechanism of toxin secretion by Vibrio cholerae
investigated in strains harboring plasmids that encode heat-labile enterotoxins of
Escherichia coli." Proc Natl Acad Sci U S A 81(24): 7752-7756.
Holmgren, J., L. Lindholm, et al. (1974). "Interaction of cholera toxin and toxin
derivatives with lymphocytes. I. Binding properties and interference with lectininduced cellular stimulation." J Exp Med 139(4): 801-819.
Holmgren, J., I. Lonnroth, et al. (1975). "Interaction of cholera toxin and membrane GM1
ganglioside of small intestine." Proc Natl Acad Sci U S A 72(7): 2520-2524.
Holmgren, J., I. Lonnroth, et al. (1973). "Tissue receptor for cholera exotoxin: postulated
structure from studies with GM1 ganglioside and related glycolipids." Infect
Immun 8(2): 208-214.
Hommann, M., U. Schotte, et al. (2001). "[HELLP Syndrome as an indication for liver
transplantation]." Gynakol Geburtshilfliche Rundsch 41(1): 8-11.
Inaba, K., S. Turley, et al. (2000). "The formation of immunogenic major
histocompatibility complex class II-peptide ligands in lysosomal compartments of
dendritic cells is regulated by inflammatory stimuli." J Exp Med 191(6): 927-936.

47

Inaba, K., S. Turley, et al. (1998). "Efficient presentation of phagocytosed cellular
fragments on the major histocompatibility complex class II products of dendritic
cells." J Exp Med 188(11): 2163-2173.
Isomura, I., Y. Yasuda, et al. (2005). "Recombinant cholera toxin B subunit activates
dendritic cells and enhances antitumor immunity." Microbiol Immunol 49(1): 7987.
Itano, A. A. and M. K. Jenkins (2003). "Antigen presentation to naive CD4 T cells in the
lymph node." Nat Immunol 4(8): 733-739.
Ivanov, II, B. S. McKenzie, et al. (2006). "The orphan nuclear receptor RORgammat
directs the differentiation program of proinflammatory IL-17+ T helper cells."
Cell 126(6): 1121-1133.
Iwasaki, A. and B. L. Kelsall (2000). "Localization of distinct Peyer's patch dendritic cell
subsets and their recruitment by chemokines macrophage inflammatory protein
(MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine." J Exp Med
191(8): 1381-1394.
Jarnicki, A. G., H. Conroy, et al. (2008). "Attenuating regulatory T cell induction by TLR
agonists through inhibition of p38 MAPK signaling in dendritic cells enhances
their efficacy as vaccine adjuvants and cancer immunotherapeutics." J Immunol
180(6): 3797-3806.
Jiao, X., R. Lo-Man, et al. (2002). "Dendritic cells are host cells for mycobacteria in vivo
that trigger innate and acquired immunity." J Immunol 168(3): 1294-1301.
Jobling, M. G. and R. K. Holmes (2002). "Mutational analysis of ganglioside GM(1)binding ability, pentamer formation, and epitopes of cholera toxin B (CTB)
subunits and CTB/heat-labile enterotoxin B subunit chimeras." Infect Immun
70(3): 1260-1271.
Jun, H. S. and J. W. Yoon (2003). "A new look at viruses in type 1 diabetes." Diabetes
Metab Res Rev 19(1): 8-31.
Kaisho, T. and S. Akira (2001). "Dendritic-cell function in Toll-like receptor- and
MyD88-knockout mice." Trends Immunol 22(2): 78-83.
Kaisho, T. and S. Akira (2001). "Toll-like receptors and their signaling mechanism in
innate immunity." Acta Odontol Scand 59(3): 124-130.
Kaisho, T. and S. Akira (2002). "Toll-like receptors as adjuvant receptors." Biochim
Biophys Acta 1589(1): 1-13.

48

Kapsenberg, M. L. (2003). "Dendritic-cell control of pathogen-driven T-cell
polarization." Nat Rev Immunol 3(12): 984-993.
Kasimiotis, H., M. A. Myers, et al. (2000). "Sex-determining region Y-related protein
SOX13 is a diabetes autoantigen expressed in pancreatic islets." Diabetes 49(4):
555-561.
Keymeulen, B., E. Vandemeulebroucke, et al. (2005). "Insulin needs after CD3-antibody
therapy in new-onset type 1 diabetes." N Engl J Med 352(25): 2598-2608.
Kim, N., K. C. Cheng, et al. (2001). "Oral administration of collagen conjugated with
cholera toxin induces tolerance to type II collagen and suppresses chondritis in an
animal model of autoimmune ear disease." Ann Otol Rhinol Laryngol 110(7 Pt 1):
646-654.
Knip, M. and H. Siljander (2008). "Autoimmune mechanisms in type 1 diabetes."
Autoimmun Rev 7(7): 550-557.
Kobayashi, M., N. Abiru, et al. (2007). "Altered B:9-23 insulin, when administered
intranasally with cholera toxin adjuvant, suppresses the expression of insulin
autoantibodies and prevents diabetes." J Immunol 179(4): 2082-2088.
Kondo, T., H. Takata, et al. (2009). "Cutting edge: Phenotypic characterization and
differentiation of human CD8+ T cells producing IL-17." J Immunol 182(4):
1794-1798.
Kukko, M., T. Kimpimaki, et al. (2005). "Dynamics of diabetes-associated autoantibodies
in young children with human leukocyte antigen-conferred risk of type 1 diabetes
recruited from the general population." J Clin Endocrinol Metab 90(5): 27122717.
Kuwano, Y., C. M. Prazma, et al. (2007). "CD83 influences cell-surface MHC class II
expression on B cells and other antigen-presenting cells." Int Immunol 19(8):
977-992.
Lang, K. S., M. Recher, et al. (2005). "Toll-like receptor engagement converts T-cell
autoreactivity into overt autoimmune disease." Nat Med 11(2): 138-145.
Lavelle, E. C., A. Jarnicki, et al. (2004). "Effects of cholera toxin on innate and adaptive
immunity and its application as an immunomodulatory agent." J Leukoc Biol
75(5): 756-763.
Lavelle, E. C., E. McNeela, et al. (2003). "Cholera toxin promotes the induction of
regulatory T cells specific for bystander antigens by modulating dendritic cell
activation." J Immunol 171(5): 2384-2392.

49

Lechmann, M., S. Berchtold, et al. (2002). "CD83 on dendritic cells: more than just a
marker for maturation." Trends Immunol 23(6): 273-275.
Lechmann, M., E. Kremmer, et al. (2002). "Overexpression, purification, and
biochemical characterization of the extracellular human CD83 domain and
generation of monoclonal antibodies." Protein Expr Purif 24(3): 445-452.
Lechmann, M., E. Zinser, et al. (2002). "Role of CD83 in the immunomodulation of
dendritic cells." Int Arch Allergy Immunol 129(2): 113-118.
Levings, M. K., R. Sangregorio, et al. (2001). "IFN-alpha and IL-10 induce the
differentiation of human type 1 T regulatory cells." J Immunol 166(9): 55305539.
Li, F., J. Guo, et al. (1994). "Abnormal class I assembly and peptide presentation in the
nonobese diabetic mouse." Proc Natl Acad Sci U S A 91(23): 11128-11132.
Libby, P., D. M. Nathan, et al. (2005). "Report of the National Heart, Lung, and Blood
Institute-National Institute of Diabetes and Digestive and Kidney Diseases
Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus."
Circulation 111(25): 3489-3493.
Liu, J., H. Liao, et al. (2006). "[Regulation of the expression of interleukin-4 and
interleukin-5 by the signal pathway of PKC-NF-kappaB in T lymphocyte of
allergic rhinitis]." Lin Chuang Er Bi Yan Hou Ke Za Zhi 20(5): 197-200.
Lonnroth, I. and J. Holmgren (1973). "Subunit structure of cholera toxin." J Gen
Microbiol 76(2): 417-427.
Lu, J., Q. Li, et al. (1996). "Identification of a second transmembrane protein tyrosine
phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus:
precursor of the 37-kDa tryptic fragment." Proc Natl Acad Sci U S A 93(6): 23072311.
Lucas, M. E., J. L. Deen, et al. (2005). "Effectiveness of mass oral cholera vaccination in
Beira, Mozambique." N Engl J Med 352(8): 757-767.
Lutz, M. B. and G. Schuler (2002). "Immature, semi-mature and fully mature dendritic
cells: which signals induce tolerance or immunity?" Trends Immunol 23(9): 445449.
Mahnke, K., T. S. Johnson, et al. (2007). "Tolerogenic dendritic cells and regulatory T
cells: a two-way relationship." J Dermatol Sci 46(3): 159-167.

50

Maldonado-Lopez, R., C. Maliszewski, et al. (2001). "Cytokines regulate the capacity of
CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo." J
Immunol 167(8): 4345-4350.
Maldonado-Lopez, R. and M. Moser (2001). "Dendritic cell subsets and the regulation of
Th1/Th2 responses." Semin Immunol 13(5): 275-282.
Manel, N., D. Unutmaz, et al. (2008). "The differentiation of human T(H)-17 cells
requires transforming growth factor-beta and induction of the nuclear receptor
RORgammat." Nat Immunol 9(6): 641-649.
Marinaro, M., H. F. Staats, et al. (1995). "Mucosal adjuvant effect of cholera toxin in
mice results from induction of T helper 2 (Th2) cells and IL-4." J Immunol
155(10): 4621-4629.
Martin-Orozco, N., Y. Chung, et al. (2009). "Th17 cells promote pancreatic inflammation
but only induce diabetes efficiently in lymphopenic hosts after conversion into
Th1 cells." Eur J Immunol 39(1): 216-224.
Massol, R. H., J. E. Larsen, et al. (2004). "Cholera toxin toxicity does not require
functional Arf6- and dynamin-dependent endocytic pathways." Mol Biol Cell
15(8): 3631-3641.
Meier, J. J., A. Bhushan, et al. (2005). "Sustained beta cell apoptosis in patients with
long-standing type 1 diabetes: indirect evidence for islet regeneration?"
Diabetologia 48(11): 2221-2228.
Merritt, E. A., S. Sarfaty, et al. (1995). "Surprising leads for a cholera toxin receptorbinding antagonist: crystallographic studies of CTB mutants." Structure 3(6): 561570.
Merritt, E. A., S. Sarfaty, et al. (1994). "Crystal structure of cholera toxin B-pentamer
bound to receptor GM1 pentasaccharide." Protein Sci 3(2): 166-175.
Merwe, v. d. (2002). "Formation of functions of the immunological synapse." Current
Opinions in Immunology 14: 293-298.
Millington, O. R., A. M. Mowat, et al. (2004). "Induction of bystander suppression by
feeding antigen occurs despite normal clonal expansion of the bystander T cell
population." J Immunol 173(10): 6059-6064.
Minderhoud, I. M., M. Samsom, et al. (2007). "What predicts mucosal inflammation in
Crohn's disease patients?" Inflamm Bowel Dis 13(12): 1567-1572.
Moore, K. W., P. Vieira, et al. (1990). "Homology of cytokine synthesis inhibitory factor
(IL-10) to the Epstein-Barr virus gene BCRFI." Science 248(4960): 1230-1234.

51

Nayak, R. C., M. A. Omar, et al. (1985). ""Cytoplasmic" islet cell antibodies. Evidence
that the target antigen is a sialoglycoconjugate." Diabetes 34(6): 617-619.
O'Connor, W., Jr., M. Kamanaka, et al. (2009). "A protective function for interleukin
17A in T cell-mediated intestinal inflammation." Nat Immunol 10(6): 603-609.
O'Neal, C. J., M. G. Jobling, et al. (2005). "Structural basis for the activation of cholera
toxin by human ARF6-GTP." Science 309(5737): 1093-1096.
Olson, J. K., J. L. Croxford, et al. (2001). "Virus-induced autoimmunity: potential role of
viruses in initiation, perpetuation, and progression of T-cell-mediated
autoimmune disease." Viral Immunol 14(3): 227-250.
Palmer, J. P., C. M. Asplin, et al. (1983). "Insulin antibodies in insulin-dependent
diabetics before insulin treatment." Science 222(4630): 1337-1339.
Patterson, C. C., G. G. Dahlquist, et al. (2009). "Incidence trends for childhood type 1
diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a
multicentre prospective registration study." Lancet 373(9680): 2027-2033.
Phipps, P. A., M. R. Stanford, et al. (2003). "Prevention of mucosally induced uveitis
with a HSP60-derived peptide linked to cholera toxin B subunit." Eur J Immunol
33(1): 224-232.
Pietropaolo, M., L. Castano, et al. (1993). "Islet cell autoantigen 69 kD (ICA69).
Molecular cloning and characterization of a novel diabetes-associated
autoantigen." J Clin Invest 92(1): 359-371.
Ploix, C., I. Bergerot, et al. (1999). "Oral administration of cholera toxin B-insulin
conjugates protects NOD mice from autoimmune diabetes by inducing CD4+
regulatory T-cells." Diabetes 48(11): 2150-2156.
Porgador, A., H. F. Staats, et al. (1998). "Intranasal immunization with cytotoxic Tlymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective
augmentation of peptide-presenting dendritic cells in nasal mucosa-associated
lymphoid tissue." Infect Immun 66(12): 5876-5881.
Rachmilewitz, D., F. Karmeli, et al. (2002). "Immunostimulatory DNA ameliorates
experimental and spontaneous murine colitis." Gastroenterology 122(5): 14281441.
Raz, I., D. Elias, et al. (2001). "Beta-cell function in new-onset type 1 diabetes and
immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised,
double-blind, phase II trial." Lancet 358(9295): 1749-1753.

52

Reis e Sousa, C. (2001). "Dendritic cells as sensors of infection." Immunity 14(5): 495498.
Romagnani, S. (1998). "The Th1/Th2 paradigm and allergic disorders." Allergy 53(46
Suppl): 12-15.
Romagnani, S., M. Kapsenberg, et al. (1998). "Th1 and Th2 cells." Res Immunol 149(9):
871-873.
Roncarolo, M. G., R. Bacchetta, et al. (2001). "Type 1 T regulatory cells." Immunol Rev
182: 68-79.
Roncarolo, M. G., M. K. Levings, et al. (2001). "Differentiation of T regulatory cells by
immature dendritic cells." J Exp Med 193(2): F5-9.
Sanchez, J. and J. Holmgren (2008). "Cholera toxin structure, gene regulation and
pathophysiological and immunological aspects." Cell Mol Life Sci 65(9): 13471360.
Sandvig, K. and B. van Deurs (2002). "Transport of protein toxins into cells: pathways
used by ricin, cholera toxin and Shiga toxin." FEBS Lett 529(1): 49-53.
Sanjeevi, C. B., A. Falorni, et al. (1996). "Glutamic acid decarboxylase (GAD) in insulindependent diabetes mellitus." Diabetes Nutrition & Metabolism 9(4): 167-182.
Sattler, J. and H. Wiegandt (1975). "Studies of the subunit structure of choleragen." Eur J
Biochem 57(1): 309-316.
Segal, B. M., J. T. Chang, et al. (2000). "CpG oligonucleotides are potent adjuvants for
the activation of autoreactive encephalitogenic T cells in vivo." J Immunol
164(11): 5683-5688.
Sica, A., A. Saccani, et al. (2000). "Autocrine production of IL-10 mediates defective IL12 production and NF-kappa B activation in tumor-associated macrophages." J
Immunol 164(2): 762-767.
Sixma, T. K., K. H. Kalk, et al. (1993). "Refined structure of Escherichia coli heat-labile
enterotoxin, a close relative of cholera toxin." J Mol Biol 230(3): 890-918.
Slavin, A. J., R. Maron, et al. (2001). "Mucosal administration of IL-10 enhances oral
tolerance in autoimmune encephalomyelitis and diabetes." Int Immunol 13(6):
825-833.
Spooner, R. A., D. C. Smith, et al. (2006). "Retrograde transport pathways utilised by
viruses and protein toxins." Virol J 3: 26.

53

Stassen, M., S. Fondel, et al. (2004). "Human CD25+ regulatory T cells: two subsets
defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct
suppressive properties upon CD4+ T helper cells." Eur J Immunol 34(5): 13031311.
Stassen, M., E. Schmitt, et al. (2004). "Human CD(4+)CD(25+) regulatory T cells and
infectious tolerance." Transplantation 77(1 Suppl): S23-25.
Sun, J. B., J. Holmgren, et al. (1994). "Cholera toxin B subunit: an efficient transmucosal
carrier-delivery system for induction of peripheral immunological tolerance."
Proc Natl Acad Sci U S A 91(23): 10795-10799.
Sun, J. B., B. G. Xiao, et al. (2000). "Oral administration of cholera toxin B subunit
conjugated to myelin basic protein protects against experimental autoimmune
encephalomyelitis by inducing transforming growth factor-beta-secreting cells
and suppressing chemokine expression." Int Immunol 12(10): 1449-1457.
Sutmuller, R. P., M. H. den Brok, et al. (2006). "Toll-like receptor 2 controls expansion
and function of regulatory T cells." J Clin Invest 116(2): 485-494.
Sutmuller, R. P., M. E. Morgan, et al. (2006). "Toll-like receptors on regulatory T cells:
expanding immune regulation." Trends Immunol 27(8): 387-393.
Takeda, K. and S. Akira (2001). "Regulation of innate immune responses by Toll-like
receptors." Jpn J Infect Dis 54(6): 209-219.
Takeda, K. and S. Akira (2001). "Roles of Toll-like receptors in innate immune
responses." Genes Cells 6(9): 733-742.
Takeda, K. and S. Akira (2003). "Toll receptors and pathogen resistance." Cell Microbiol
5(3): 143-153.
Takeda, K., T. Kaisho, et al. (2003). "Toll-like receptors." Annu Rev Immunol 21: 335376.
Thompson, H. S. and N. A. Staines (1986). "Gastric administration of type II collagen
delays the onset and severity of collagen-induced arthritis in rats." Clin Exp
Immunol 64(3): 581-586.
Tisch, R. and H. McDevitt (1996). "Insulin-dependent diabetes mellitus." Cell 85(3):
291-297.
Todd, J. A., J. I. Bell, et al. (1987). "HLA-DQ beta gene contributes to susceptibility and
resistance to insulin-dependent diabetes mellitus." Nature 329(6140): 599-604.

54

Turley, S. J., K. Inaba, et al. (2000). "Transport of peptide-MHC class II complexes in
developing dendritic cells." Science 288(5465): 522-527.
van Heyningen, S. (1976). "The subunits of cholera toxin: structure, stoichiometry, and
function." J Infect Dis 133 Suppl: 5-13.
van Heyningen, W. E. and C. A. King (1976). "The role of gangliosides in the action of
cholera toxin." Adv Exp Med Biol 71: 205-214.
Verge, C. F., R. Gianani, et al. (1996). "Number of autoantibodies (against insulin, GAD
or ICA512/IA2) rather than particular autoantibody specificities determines risk
of type I diabetes." J Autoimmun 9(3): 379-383.
Verge, C. F., R. Gianani, et al. (1996). "Prediction of type I diabetes in first-degree
relatives using a combination of insulin, GAD, and ICA512bdc/IA-2
autoantibodies." Diabetes 45(7): 926-933.
Vigouroux, S., E. Yvon, et al. (2004). "Antigen-induced regulatory T cells." Blood
104(1): 26-33.
Viney, J. L. (2001). "Immune fate decided by dendritic cell provocateurs." Trends
Immunol 22(1): 8-10.
Volpe, E., N. Servant, et al. (2008). "A critical function for transforming growth factorbeta, interleukin 23 and proinflammatory cytokines in driving and modulating
human T(H)-17 responses." Nat Immunol 9(6): 650-657.
Weiner, H. L. (2001). "Induction and mechanism of action of transforming growth factorbeta-secreting Th3 regulatory cells." Immunol Rev 182: 207-214.
Weissman, D., Y. Li, et al. (1995). "Three populations of cells with dendritic morphology
exist in peripheral blood, only one of which is infectable with human
immunodeficiency virus type 1." Proc Natl Acad Sci U S A 92(3): 826-830.
Wen, L., J. Peng, et al. (2004). "The effect of innate immunity on autoimmune diabetes
and the expression of Toll-like receptors on pancreatic islets." J Immunol 172(5):
3173-3180.
Wenzlau, J. M., K. Juhl, et al. (2007). "The cation efflux transporter ZnT8 (Slc30A8) is a
major autoantigen in human type 1 diabetes." Proc Natl Acad Sci U S A 104(43):
17040-17045.
Wingender, G., N. Garbi, et al. (2006). "Systemic application of CpG-rich DNA
suppresses adaptive T cell immunity via induction of IDO." Eur J Immunol 36(1):
12-20.

55

Yan, G., L. Shi, et al. (1997). "Screening of the TAP1 gene by denaturing gradient gel
electrophoresis in insulin-dependent diabetes mellitus: detection and comparison
of new polymorphisms between patients and controls." Tissue Antigens 50(6):
576-585.
Yang, L., D. E. Anderson, et al. (2008). "IL-21 and TGF-beta are required for
differentiation of human T(H)17 cells." Nature 454(7202): 350-352.
Ylipaasto, P., K. Klingel, et al. (2004). "Enterovirus infection in human pancreatic islet
cells, islet tropism in vivo and receptor involvement in cultured islet beta cells."
Diabetologia 47(2): 225-239.
Yoon, J. W. and H. S. Jun (2005). "Autoimmune destruction of pancreatic beta cells."
Am J Ther 12(6): 580-591.
Yoon, S. I., N. J. Logsdon, et al. (2006). "Conformational changes mediate interleukin-10
receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex." J
Biol Chem 281(46): 35088-35096.
Zhang, Z. J., L. Davidson, et al. (1991). "Suppression of diabetes in nonobese diabetic
mice by oral administration of porcine insulin." Proc Natl Acad Sci U S A 88(22):
10252-10256.
Zhou, L. J., R. Schwarting, et al. (1992). "A novel cell-surface molecule expressed by
human interdigitating reticulum cells, Langerhans cells, and activated
lymphocytes is a new member of the Ig superfamily." J Immunol 149(2): 735742.
Zhou, L. J. and T. F. Tedder (1995). "A distinct pattern of cytokine gene expression by
human CD83+ blood dendritic cells." Blood 86(9): 3295-3301.
Zhou, L. J. and T. F. Tedder (1995). "Human blood dendritic cells selectively express
CD83, a member of the immunoglobulin superfamily." J Immunol 154(8): 38213835.
Zhou, L. J. and T. F. Tedder (1996). "CD14+ blood monocytes can differentiate into
functionally mature CD83+ dendritic cells." Proc Natl Acad Sci U S A 93(6):
2588-2592.
Zhu, J. and W. E. Paul (2008). "CD4 T cells: fates, functions, and faults." Blood 112(5):
1557-1569.

56

CHAPTER TWO
SUPPRESSION OF DENDRITIC CELL ACTIVATION BY DIABETES
AUTOANTIGENS LINKED TO THE CHOLERA TOXIN B SUBUNIT

Oludare Odumosu2, 1, Ineavely Baez3, 1, Jessica Jutzy2, 1, Nathan Wall2, 1, Kimberly
Payne3, 1, William Langridge 2, 1
Department of Biochemistry, Center for Health Disparities and Molecular Medicine and
Department of Physiology and Anatomy
Loma Linda University
Loma Linda, CA. 92354, USA
(1) Center for Health Disparities and Molecular Medicine, Loma Linda University,
School of Medicine, Loma Linda, CA 92354; (2) Department of Biochemistry, Loma
Linda University, School of Medicine, Loma Linda, CA, 92354; (3) Department of
Physiology, Loma Linda University, School of Medicine, Loma Linda, CA 92354.
Author to whom correspondence should be addressed:
William Langridge
Tel.: +1-909 558-1000 (81362); Fax: +1-909-558-0177
(Center for Health Disparities and Molecular Medicine
Loma Linda University
School of Medicine
Loma Linda, CA 92354)
Key words: adjuvant, autoimmunity, cholera toxin-B (CTB), dendritic cells, IDDM,
juvenile diabetes,
List of Abbreviations: DC: dendritic cell; TLR: Toll-like receptor; T1D: type 1 diabetes
PMA: Phorbol myristate acetate; LPS: lipopolysaccharide

57

Abstract
Antigen presenting cells (APC); specifically dendritic cells (DCs) are a focal
point in the delicate balance between T cell tolerance and immune responses contributing
to the onset of type I diabetes (T1D). Weak adjuvant proteins like the cholera toxin B
subunit when linked to autoantigens may sufficiently alter the balance of this initial
immune response to suppress the development of autoimmunity. To assess adjuvant
enhancement of autoantigen mediated immune suppression of T1D, we examined the
cholera toxin B subunit (CTB)-proinsulin fusion protein (CTB-INS) activation of
immature dendritic cells (iDC) at the earliest detectable stage of the human immune
response. In this study, incubation of human umbilical cord blood monocyte-derived
immature DCs with CTB-INS autoantigen fusion protein increased the surface membrane
expression of DC toll-like receptor (TLR-2) while no significant upregulation in TLR-4
expression was detected. Inoculation of iDCs with CTB stimulated the biosynthesis of
both CD86 and CD83 co-stimulatory factors demonstrating an immunostimulatory role
for CTB in both DC activation and maturation. In contrast, incubation of iDCs with
proinsulin partially suppressed CD86 co-stimulatory factor mediated DC activation,
while incubation of iDCs with CTB-INS fusion protein completely suppressed iDC
biosynthesis of both CD86 and CD83 costimulatory factors. The incubation of iDCs with
increasing amounts of insulin (INS) did not increase the level of immune suppression but
rather activated DC maturation by stimulating increased biosynthesis of both CD86 and
CD83 costimulatory factors. Inoculation of iDCs with CTB-INS fusion protein
dramatically increased secretion of the immunosuppressive cytokine IL-10 and
suppressed synthesis of the pro-inflammatory cytokine IL12/23 p40 subunit protein
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suggesting that linkage of CTB to INS may play an important role in mediating DC
guidance of cognate naïve Th0 cell development into immunosuppressive T lymphocytes.
Taken together, the experimental data suggests that TLR-2 plays a dominant role in CTB
mediated INS inhibition of DC induced T1D onset in humans. Further, fusion of CTB to
the autoantigen was found to be essential for enhancement of immune suppression as codelivery of CTB and INS did not significantly inhibit DC costimulatory factor
biosynthesis. The experimental data presented supports the hypotheses that adjuvant
enhancement of autoantigen mediated suppression of islet beta cell inflammation is
dependent on CTB stimulation of DC TLR-2 receptor activation and co-processing of
both CTB and the autoantigen in the same DC.

Introduction
Insulin dependent diabetes mellitus, or Type 1 diabetes (T1D), is the most
destructive metabolic disease of children. T1D is caused by autoreactive lymphocyte
destruction of insulin-producing islet β-cells of the pancreas (Eisenbarth 1986; Tisch and
McDevitt 1996). The progressive loss of islet β-cell function results in an increasing
deficiency of insulin production resulting in elevated blood sugar levels (hyperglycemia).
The inability to transfer glucose from the blood into the cells of the body results in
increased levels of cellular oxidative stress which leads to chronic inflammation
throughout the body resulting in an increased and premature risk for secondary neural
and circulatory health problems, including amputation of extremities, blindness, heart
attack and stroke (Libby, Nathan et al. 2005). Young T1D patients must inject insulin
several times a day for the rest of their lives or risk diabetic shock and death (Lodinova-
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Zadnikova, Prokesova et al. 2004).
The first step in diabetes-mediated breakdown of immunological homeostasis
leading to islet β-cell mortality is initiated by autoantigen-stimulated maturation of
antigen-presenting cells (APCs), largely dendritic cells (DC). Maturation of DCs induces
the development of autoreactive CD8+ cytotoxic T cells (CTL) and CD4+ T helper (Th1)
cells, as well as B cell production of autoantigen specific antibodies (Atkinson and
Maclaren 1994; Tisch and McDevitt 1996; Han, Serra et al. 2005; Tang, Adams et al.
2006). Following autoreactive CD4+ Th1 cell infiltration of pancreatic islets in nonobese diabetic (NOD) mice, autoreactive Th1 lymphocytes were shown to secrete the
inflammatory cytokines IFN-gamma and IL-2. These diabetes autoantibodies are known
to stimulate macrophage and CTL secretion of oxidative compounds (NO, O2, H202) in
addition to inflammatory cytokines (IL-1 beta, TNF-alpha, TNF-beta, IFN-gamma)
(Atkinson and Maclaren 1994; Han, Li et al. 2005; Tang, Adams et al. 2006). The
persistence of these immune responses induces chronic pancreatic inflammation
(insulitis), which results in the induction of apoptosis of approximately 90% of the islet
insulin-producing β-cells leading to insufficient levels of insulin production (Piccinni,
Beloni et al. 1998). A variety of immune cell types including B cells, dendritic cells
(DCs), macrophages and natural killer (NK) cells were shown to be involved in the onset
of diabetes pathogenesis (Kent, Chen et al. 2005; Wang, Zhang et al. 2005; Yoon and Jun
2005; Cardell 2006; Silveira and Grey 2006; Tian, Zekzer et al. 2006; Tian, Hao et al.
2009). Specifically, DCs were shown to play a primary role in antigen priming of naïve
Th cells (Th0) and in the modulation of their development into autoreactive Th1
lymphocytes or immunosuppressive Th2 cells critical for maintenance of immunological
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homeostasis (Pulendran, Smith et al. 1999; Pulendran, Kumar et al. 2001; Itano,
McSorley et al. 2003). Immuno-cytochemical analyses showed that oral inoculation
results in autoantigen uptake through M cells of the intestinal epithelium into peripheral
DCs via several routes that may aid in the establishment of immune suppression (Yoon
and Jun 2005). Autoantigens ( autoantigen (autoAg)) are taken up and processed by
immature DC subsets (Figdor, de Vries et al. 2004). Following DC activation by
autoantigens, the DCs migrate to adjacent lymph nodes, where they present antigen
peptides on major histocompatibility complex class II (MHCII) receptors, synthesize costimulatory molecules and secrete IL-12 which guides the development of naïve cognate
Th0 cells into Ag-specific inflammatory Th1 lymphocytes. In contrast, oral inoculation
with small amounts of autoantigen was shown to induce DC production of the antiinflammatory cytokine IL-10 which stimulates the development of naïve Th0
lymphocytes into anti-inflammatory Th2 lymphocytes, or alternatively into IL-10 or
TGF-beta producing CD4+CD25+ Tr1 or Th3 regulatory T cells (Kapsenberg 2003;
D'Ambrosio, Colucci et al. 2008). Thus, interactions between autoantigens, DCs and T
cells in the gut-associated lymphoid tissues, may dictate the onset of inflammatory or
tolerogenic outcomes following initial autoantigen (autoAg) presentation. In addition,
DCs residing in lymphoid follicles and the Peyer’s patches, shown to synthesize IL-10,
were found to down-regulate Th1 cell mediated autoimmunity (Steinbrink, Wolfl et al.
1997). Further, immature or peripheral DCs (iDCs), that displayed low levels of costimulatory molecule expression and that secreted cytokine IL-10, were shown to remain
in the periphery and were found to induce Th2 lymphocyte mediated immunological
tolerance (Rissoan, Soumelis et al. 1999; Liu, MacKenzie-Graham et al. 2001; Holmgren,
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Adamsson et al. 2005; Li, Zhong et al. 2006). In an alternative set of experiments, the
addition of IL-12 to iDCs induced autoreactive Th1 cell morphogenesis and accelerated
T1D in NOD mice (Trembleau, Germann et al. 1995). In composite, the available
experimental data suggests that initial stages of T1D progression may be largely under
DC control and may set the stage for anti-inflammatory or inflammatory disease
outcomes (Shinomiya, Fazle Akbar et al. 1999).
Oral administration of autoantigens has shown promise for prevention of
spontaneous autoimmune diabetes (Zhang, Davidson et al. 1991; Trentham, DynesiusTrentham et al. 1993). However, the need for repeated autoantigen administration over an
extended period of time poses a limitation to such therapy. Further, a low efficiency of
immune suppression was reported in previously sensitized hosts (Arakawa, Yu et al.
1998). These limitations were largely overcome through application of the nontoxic B
subunit of the cholera enterotoxin (CTB) from Vibrio cholerae. The CTB molecule was
shown to be a strong immunomodulator for induction of oral tolerance when used as a
carrier molecule for conjugated autoantigens (Sun, Holmgren et al. 1994; Sun, Rask et al.
1996; Sun, Li et al. 2000; Sun, Xiao et al. 2000). The bacterial AB enterotoxin from
Vibrio cholerae, cholera toxin (CTX) contains a toxic ADP-ribosyltransferase subunit A1
(CTA1), linked through a small helical (A2) peptide to a pentamer of non-toxic B carrier
subunits (CTB). The CTB subunits were shown to be required for binding the toxin to
monosialoganglioside receptor molecules embedded in gut epithelial cell membranes
facilitating entry of the holotoxin into the cell (Eriksson and Holmgren 2002). The CTB
subunit was shown to bind specifically to GM1-ganglioside, a receptor molecule found in
common on the membrane of most types of epidermal cells. Thus, CTB can provide an
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efficient trans-mucosal carrier molecule for autoantigen induction of peripheral tolerance
(Sun, Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003).
In previous studies, oral delivery of CTB conjugated to specific autoantigens was
shown to enhance autoantigen mediated protection of mice against several organ-specific
autoimmune diseases including autoimmune encephalomyelitis (Sun, Xiao et al. 2000)
autoimmune chondritis (Kim, Cheng et al. 2001) and uveitis (Phipps, Stanford et al.
2003). In addition, CTB-INS conjugates were shown to substantially suppress diabetes in
NOD mice (Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998). The observed
suppression of diabetes onset was associated with a reduction in Th1 cell IFN-γ
production and the migration of Tr1 regulatory T cells into pancreatic islets (Roncarolo,
Levings et al. 2001; Aspord and Thivolet 2002). Further, the fusion of CTB to insulin
was shown to provide up to a 10,000-fold reduction in autoantigen amounts required for
immuno-tolerization (Arakawa, Chong et al. 1998; George-Chandy, Eriksson et al. 2001).
Mechanisms underlying CTB modulated immune suppression of T1D may include the
inhibition of DC maturation, inhibition of autoreactive T cell development and/or
induction of Th2 and inducible T regulatory cell (iTreg) proliferation and activation
(Marinaro, Staats et al. 1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004).
Recent immunotherapy and vaccination strategies strongly target receptors that
mediate immune cell activation. Pathogen recognition receptors, especially TLRs
expressed by APCs, have received increasing attention because activation of innate
immunity through pathogen protein, nucleic acid and lipopolysaccharide (LPS) pattern
recognition has been increasingly identified as an essential first line of immunological
defense (Hemmi, Takeuchi et al. 2000; Schnare, Barton et al. 2001; Takeda, Kaisho et al.
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2003). In general, TLRs interact with a variety of microbial structures widely expressed
by fungi, bacteria, protozoa and viruses conferring a relatively high degree of specificity
to the immune response (Takeda, Kaisho et al. 2003). Recent developments support the
concept that activation of immunity by microbial molecules may involve cooperative
interaction with multiple host receptors within the membrane lipid raft (Triantafilou,
Miyake et al. 2002; Beutler, Jiang et al. 2006; Hoebe, Jiang et al. 2006). That is, TLRs
are usually present as preformed homodimers with the exception of TLR2, which
preferentially forms heterodimers with either TLR1 or TLR6 (Akira and Takeda 2004).
Toll like receptors TLR2/TLR1 and TLR2/TLR6 were shown to be activated in response
to agonists such as lipoteichoic acid and lipoproteins, while other APC surface and
internal TLRs respond to a variety of bacterial and virus DNA and LPS
immunostimulatory molecules (Akira and Hemmi 2003; Takeda, Kaisho et al. 2003;
Roger, Miconnet et al. 2005; Kanzler, Barrat et al. 2007). Recently, the type II heat-labile
enterotoxin from E. coli which has an AB5 subunit structure similar to cholera toxin was
found to stimulate cytokine release in mouse and human cells through interactions with
TLR2. However, up to the present, the mechanism of CTB mediated TLR activation is
only poorly understood. An increased understanding of the initial interactions between
CTB and its fusion proteins with TLRs is predicted to improve our understanding of
mechanisms by which these molecules exert their immunomodulatory activities.
The objectives of this study are to clarify mechanisms underlying early events in
CTB-INS vaccine induction of immunological tolerance leading to the suppression of
T1D through analysis of CTB-proinsulin autoantigen induced inhibition of human
immature DC activation and maturation leading to induction of Th0 lymphocyte
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development into inflammatory Th cells resulting in chronic pancreatic islet
inflammation and the death of insulin producing islet β-cells. Examination of CTB and
CTB-INS fusion protein interactions with DC membrane TLRs will provide information
on whether they or other membrane receptors may play a role in the initiation of
adjuvant-autoantigen mediated DC activation and maturation. Through analysis of CTBautoantigen fusion protein interactions with immature DCs we may be able to gain a
clearer understanding of how CTB-INS fusion proteins interact with DCs to suppress the
onset of T1D.

Materials and Methods
Construction of Bacterial Plasmids Containing CTB-INS
A gene encoding approximately 258bp of human proinsulin (INS) was physically
linked to the carboxyl-terminus (309bp) of CTB to generate the fusion gene CTB-INS.
The cholera toxin B subunit–autoantigen fusion gene CTB-INS was cloned into the (A)
configuration of the E. coli expression vector pRSET (Invitrogen™, Carlsbad, CA),
under control of the bacteriophage T7 promoter in order to achieve high levels of
transgene expression. The pRSET vector also contained an oligonucleotide encoding 6
histidines immediately upstream of the CTB permitting isolation of the transgene
product. The CTB-INS fusion gene (567bp) was cloned between the BamH1/Bgl1 and
EcoR1 sites flanked by a termination sequence and a poly (A) adenylation sequence in
the 3’ region of the transgene. Selective clones were assessed by DNA sequence analysis
to confirm the in-frame linkage of CTB and Insulin DNA fragments (Fig. 2.1A). The
expression vector pRSET-CTB-INS containing the gene encoding the CTB-INS fusion
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protein was introduced into E. coli producer strain BL21 (DE3)pLysS (Invitrogen,
Carlsbad, CA) for nickel affinity column isolation of the recombinant protein (Carter, Yu
et al. 2006).

Synthesis and Isolation of CTB-INS Fusion Proteins
The CTB-INS transformed E. coli strain BL-21, was grown in 250 ml Luria Broth
(LB) medium containing ampicillin (100mg/ml). While still in log phase of growth, CTBINS protein synthesis was stimulated by addition of 90 mg isopropyl β-D-1thiogalactopyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO), to the bacterial culture. After 6
hr continued growth at 370C, the bacterial culture was transferred into 50 ml polystyrene
Oakridge tubes and the cells harvested by centrifugation in a SA-600 rotor for 10 min, at
5,000 rpm and 40C, in a Sorvall RC5B centrifuge. The cell pellet was resuspended in 1.0
ml/tube of 10 mM HEPES buffer (pH 7.5), containing 100 mM imidazole. The cells were
disrupted by sonication at 3 x 10 sec bursts at 10 W, with a Sonic 60 Dismembrator,
(Fisher Scientific, and Sunnyvale, CA). The CTB-INS protein was isolated and purified
from the bacterial homogenate using a Maxwell Model 16 robotic protein purification
system (Promega Inc.TM), according to the protein isolation protocol provided by the
manufacturer (Promega Inc., Madison, WI). In order to obtain a pure protein product, the
robot employs electromagnetically charged Magne-His Nickel-Iron alloy particles with
an affinity for the 6-HIS tag linked to the N terminus of the recombinant CTB-INS fusion
protein. Imidazole was removed from the protein mixture by dialysis of the preparation
against 2 x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr at 40C. The purity of the
isolated CTB-INS protein (23.4kDa) was determined by electrophoretic mobility analysis
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in a 12% polyacrylamide gel in comparison with protein molecular weight standards
(Fig. 2.1B). The purified CTB-INS protein was stored at -200C until further use.
Isolation and Culture of Monocyte-Derived DC from Human Cord
Blood
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected
human umbilical cord blood (Appendix 1). The leukocyte fraction of approximately 50 ml
of cord blood obtained from normal healthy placenta donors (by LLU IRB approved
protocols), was separated from red blood cell and platelet fractions by Ficoll-paque density
gradient centrifugation for 30 min at 2,000 rpm @ 4oC, in a Beckman Coulter Allegra X15R centrifuge equipped with an SX4750 rotor (Appendix 2). The CD14+ monocytes were
obtained from the total lymphocyte fraction by incubation with anti-CD14 PE
(Phycoerythrin) for 10 min @ 4oC followed by incubation with anti-PE magnetic
microbeads for 15 min at 4oC. The cells were separated magnetically by passing them
through the MACS column as described by the manufacturer (Miltenyi Biotech, Auburn,
CA) (Devaraj, Glaser et al. 2006; Devaraj, Dasu et al. 2008). The purity of the monocyte
fraction was determined by flow cytometry in a BD FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA.
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA) in a humidified
atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ) (Appendix 4). The medium
was supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, 50 ng/ml human recombinant GMCSF, and 10 ng/ml
human recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel). The
monocyte cell culture was fed every 2 days by gentle replacement of 50% of the medium
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Figure 2.1 Construction of the CTB-INS Fusion Gene and Isolation of the Gene Product.
Panel A shows the plasmid map of the E. coli expression vector pRSET A (Invitrogen™,
Carlsbad, CA), carrying the CTB-INS fusion gene. The cholera toxin B subunit–
proinsulin autoantigen gene fusion, CTB-INS (567bp), was cloned into pRSET (A)
between the BamH1/Bgl 1 and EcoR1 sites. The expression vector pRSET-CTB-INS
with the CTB-INS coding sequence under control of the bacteriophage T7 promoter also
contains an oligonucleotide region encoding 6 histidine amino acid residues immediately
5’ upstream of the CTB DNA sequence. The recombinant plasmid was introduced into
the E. coli recipient strain BL21 (DE3) pLysS, for CTB-INS fusion protein expression
and for nickel binding isolation of the recombinant protein using a Maxwell 16 TM protein
isolation robot (Promega Inc, Madison, WI, USA). Panel B is an SDS polyacrylamide gel
stained with Commasie blue, Lane 1: Molecular Weight Marker Proteins (BIO-RAD,
Hercules, CA); Lane 2: pRSET-CTB protein (16.1kDa); Lane 3: the CTB-INS fusion
protein isolated and purified from BL21 E. coli cells containing pRSET-CTB-INS
(23.4kDa).
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with fresh medium. The cell cultures were kept in their original plates until harvested to
avoid induction of DC maturation caused by mechanical stress associated with replating the
cells. The percentage of monocyte-derived immature dendritic cells (M-iDC) was
determined directly by flow cytometry based on expression of DC specific cell surface
markers (CD14−HLA-DR+CD11c+) after 6 days further incubation.

DC Maturation Assay and Phenotyping
The iDCs were stimulated by the addition of CTB (10ug/ml), insulin (10ug/ml), CTBINS fusion protein (20ug/ml) and Phorbol myristate acetate (PMA) and Ionomycin at
10ng/ml (PMA+Ionomycin) for 48 hrs at 37oC in 5% CO2. After incubation, the
expression of DC surface markers indicating their state of activation and maturation
(CD14, CD11c, and HLA-DR) was determined by flow cytometry. Briefly, the gated
CD14- HLA-DR+ CD11c+ cell population was analyzed for the expression of CD86, and
CD83 activation markers (BD Pharmingen, San Jose, CA USA).

Flow Cytometry Analysis
For flow cytometry examination of DC surface markers, the DCs were surface stained
with antibodies conjugated to Phycoerythrin (PE), Fluorescein isothiocyanate (FITC),
Allophycocyanin (APC), and Peridinin Chlorophyll Protein Complex (PerCP) (Parrish,
Baez et al. 2009) and resuspended in 1.0% of freshly prepared formaldehyde for analysis
using the FACSCalibur flow cytometer. The following antibodies were used to identify
the different cell subsets: anti-CD86-FITC, anti-CD83-PE, anti- HLA-DR PerCP antiCD14-APC anti-mouse IgG1 FITC, anti-mouse IgG1 PE, anti-mouse IgG1 HLA-DR,
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anti-mouse IgG1 APC (BD Pharmingen); 7-Amino-actinomycin D (7-AAD) was used to
assess viability of the collected cells. Briefly, a pooled sample of harvested cells was
incubated with 7-Amino-actinomycin D (7-AAD) and prepared for flow cytometry
according to the manufacturer’s instructions (eBioscience, San Diego, CA, USA).
Fluorescence intensity on all flow histograms is shown on a log scale. Forward scatter
(FSC) and Side Scatter (SSC) and percentage of cell population on histograms are shown
in a linear scale.

Secreted Cytokine Analysis by Cytometric Bead Array
Immature DCs were stimulated with PMA+Ionomycin and proteins for 48 hrs as
described above. The supernatant was collected and stored at -20oC until analyzed for
concentrations of IL-10 and IL-12 using the cytometric Bead Array (CBA) kit (Becton
Dickinson Biosciences, San Jose, CA, USA). Briefly, 50 µl of premixed beads coated
with capture antibodies was incubated with 50µl of cytokine standards or test samples in
the dark at room temperature for 1 hr. Following the incubation, 50µl of a mixture of PEconjugated antibodies prepared against the specific cytokines was added to each
preparation, and the samples incubated for 2 hrs in the dark at room temperature. The
beads were washed once with the wash buffer supplied with the CBA kit and analyzed
immediately in a BD FACSCalibur flow cytometer (Becton, Dickinson Inc.). Data
analysis was performed using the FCAP Array software packages supplied by BD
Biosciences. Three thousand counting events were acquired from each sample. Cytokine
calibration curves were generated using cytokine standards supplied by BD Biosciences
(Potapova, Gaudette et al. 2007; LaFrance, Kehinde et al. 2008).
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Results
CTB-INS Mediated Suppression of DC Maturation involves
Upregulation of TLR2
To determine whether TLR2 or TLR4 was involved in CTB-INS mediated DC activation,
flow cytometric analysis of TLR2 and TLR4 markers was carried out on vaccine
inoculated activated DCs. The results of flow cytometry analysis indicated that CTB and
CTB-INS inoculated DCs significantly upregulated the presence of TLR2 proteins on the
surface of the vaccine inoculated DC membrane in comparison with unstimulated DCs,
insulin treated DCs and PMA+Ionomycin treated DCs (p<0.05) (Fig. 2.2). No significant
up-regulation of TLR4 receptor protein was detected on the surface of CTB, CTB-INS
and insulin treated DCs. However, TLR4 was significantly upregulated in
PMA+Ionomycin treated cells compared to CTB and CTB-INS treated cells (p<0.05), a
result consistent with those obtained earlier by Thierry et al. (2005) (Roger, Miconnet et
al. 2005). The finding that TLR2 is upregulated by CTB-INS treated cells and not on
insulin treated cells suggests that CTB-INS mediated suppression of DC maturation,
similar to that found for the E. coli heat sensitive enterotoxin B subunit is attributable to
CTB activation of iDCs through induction of TLR2 rather than TLR4.
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Figure 2.2: TLR2 upregulation by CTB-INS. The bar graph represents the percentages of
dendritic cells expressing Toll-like receptors 2 and 4 (TLR2 and TLR4). Umbilical cord
blood monocyte derived immature DC were stimulated for 48 hrs with CTB, CTB-INS,
Insulin and PMA+Ionomycin and the induction of TLR2(CD282) and TLR4(CD284) was
determined by flow cytometric TLR-specific antibody surface staining methods. The
mean and standard error of the mean (SE) were calculated for three separate experiments
(p<0.05).
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CTB-INS Treatment Suppresses Maturation of Dendritic Cells
The influence of CTB, Insulin, CTB-INS and PMA+Ionomycin on immature DC
iDC) activation and maturation was examined by measuring the expression of DC
synthesized co-stimulatory molecules CD86 and CD83. iDC were differentiated from
monocytes as described in methods and materials section and assessed for the expression
of CD14-HLA-DR+CD11C+ surface markers indicating DC differentiation from
monocytes (Fig. 2.3A). The iDC (CD14-HLA-DR+CD11C+) were inoculated with CTB,
INS and CTB-INS fusion proteins and assessed for stimulation of DC membrane surface
marker expression, indicating activation and maturation, i.e., CD86 and CD83,
respectively (Fig. 2.3B). Flow cytometric data obtained for CTB-INS treated cells
revealed that iDC exposure to CTB-INS resulted in a significant level of suppression of
CD86 and CD83 costimulatory factors as compared with CTB, INS, and
PMA+Ionomycin (p<0.05). These results suggest that the physical linkage of CTB to the
Insulin autoantigen is responsible for suppression of DC activation and maturation by
CTB-INS.
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Figure 2.3 Dendritic Cell Activation and Maturation is Suppressed by CTB-INS Fusion
Protein. Panel A: Flow cytometry dot plot showing dendritic cells differentiated from
monocytes isolated by ficoll gradient centrifugation from human umbilical cord blood.
The CD14+ monocytes were supplemented with granulocyte macrophage colony
stimulating factor (GM-CSF) and IL-4 and were cultured for 6 days to obtain CD14HLA-DR+CD11c+ immature human DCs. To determine the viability of DCs isolated
from the entire population of collected cells (Upper left panel), 7-AAD negative cells
were gated (Upper right panel) and analyzed for expression of the surface marker CD14
(Lower left panel). The CD14- cells were gated and analyzed for co-expression of HLADR and CD11c differentiation markers by flow cytometry (Lower right panel). Panel B:
The histograms depict the expression of CD83 and CD86 after stimulation of DCs for 48
hrs with CTB, CTB-INS, Insulin and PMA+Ionomycin. Maturation state of the DCs was
determined by flow cytometric analysis. The data are representative of three independent
experiments with comparable results.
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Linkage of CTB to Autoantigen is Necessary for Suppression of DC
Activation
Based on the results obtained from the insulin stimulation studies described
above, it was important to examine the role of CTB in the observed suppression of DC
activation. Therefore immature DCs were stimulated with 10ug insulin alone, codelivered with 10ug CTB and finally stimulated with equivalent amounts of CTB-INS
fusion protein. Co-delivery of insulin + CTB resulted in significant CD83 and CD86 costimulatory factor upregulation on DC compared to unstimulated DCs (p<0.05).
However, cells treated with CTB-INS fusion proteins showed almost no CD83 and CD86
upregulation as measured by mean fluorescent intensity analysis for each treatment group
(Fig. 2.4A). Samples treated with CTB, CTB-INS and PMA+Ionomycin showed a
significant increase in cell populations expressing CD86 and CD83 in comparison with
the control (unstimulated) DC sample (p<0.05). Interestingly, the population of cells
expressing CD83 was significantly reduced in comparison with the population of cells
expressing the CD86 costimulatory factor (p<0.05). However the ratios of costimulatory
expression for each treatment group remained unchanged (data not shown). Taken
together, the data indicate that the physical linkage of CTB to the autoantigen is essential
for achieving high levels of immunological suppression of DC activation.

78

A.

B.

79

Figure 2.4: Effects of CTB on Insulin Mediated DC Activation
Immature monocyte derived DCs were stimulated for 48 hrs with 10ug insulin + 10ug
CTB, 20ug CTB-INS and PMA+Ionomycin as a positive control for DC activation. The
activation and maturation of DCs measured by expression of CD86 and CD83 cell
surface markers was determined by flow cytometric methods. The mean fluorescence
intensity (MFI) and percentage population data is representative of four repeated
independent experiments with comparable results. Panel A: The overlapping histograms
depict the expression of CD83 and CD86 costimulatory factors in immature dendritic
cells after stimulation with PMA+Ionomycin, Insulin + CTB and CTB-INS. The
statistical significance for difference in MFI between treatment groups was calculated
based on p<0.05.
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Increased Amounts of Insulin Induce Dendritic Cell Activation
The effect of increasing concentrations of insulin protein on DC activation was
investigated by stimulating iDCs with increasing amounts of insulin from 10ug/ml up to
250ug/ml. There was no significant difference in the upregulation of CD86 costimulatory molecules on the DC cell surface for concentration 10ug/ml up to 50ug
insulin/ml. However, mean fluorescence intensity measurements suggest a progressive
increase in the expression of CD86, when the concentration of insulin was increased to
100ug/ml and 250ug/ml respectively (Fig. 2.5A). We also observed an increase in the
percentage of the DC cell population activated by increasing the amount of insulin
P<0.05 (Fig. 2.5B). Based on the increasing levels of CD86 fluorescence intensity
detected, increases in the percentage of activated DCs were shown to correlate with
increasing amounts of insulin. Our experimental data did not reveal a significantly
different level of CD83 protein synthesized in cells incubated with 100ug/ml and
250ug/ml insulin. Predictably, PMA+Ionomycin induced significantly increased levels
of DC synthesis of CD86 and CD83 costimulatory factors compared to other treatment
groups (p<0.05).
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Figure 2.5: Increasing Insulin Dosage Results in DC Activation. Immature monocyte
derived DCs were stimulated for 48 hours with different amounts of insulin and
PMA+Ionomycin. Activation of DCs was determined by flow cytometric methods. The
data presented are representative of more than three independent experiments with
comparable results. Panel A: Graph indicating increasing mean fluorescence intensity of
CD86 expression on DC cell surfaces with increasing amounts of insulin. Panel B:
Histogram showing the percentages of cells activated by different concentrations of
insulin as measured by CD86 costimulatory factor expression on the DC cell surface.
*p<0.05 for statistical differences between treatment groups.
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CTB-INS Stimulates Increased Synthesis of IL-10
To determine whether CTB-INS suppression of DC maturation (suppression of
co-stimulatory factor synthesis), resulted in increased secretion of immunosuppressive
cytokine IL-10 and decreased synthesis of IL-12, the supernatant medium was collected
from DCs exposed to 48 hrs incubation with CTB-INS fusion protein and analyzed by
cytometric bead assay (CBA) based flow cytometry for the presence of secreted
cytokines. The results of this experiment showed that there was a significant increase in
IL-10 production by DCs incubated with CTB-INS compared to DCs stimulated with the
autoantigen alone (p<0.05) with a concurrent decrease in proinflammatory cytokine IL12/23p40 oligomer compared to PMA+Ionomycin treated DCs (p<0.05). Incubation of
immature DCs with CTB-INS resulted in a 2.5-fold pg/ml increase in synthesis of IL-10
in comparison with DC incubation with CTB, insulin or PMA+Ionomycin treated cells.
Although CTB alone appeared to stimulate DC IL-10 synthesis, the cytokine levels were
significantly lower than CTB-INS induced DC IL-10 production (p<0.05) (Fig. 2.6). In
summary, CTB-INS induced suppression of DC activation and maturation appears to be
followed by an increased secretion of the anti-inflammatory cytokine IL-10 and a
decrease in secreted IL-12/23p40, suggesting the possibility of immune suppression of
inflammatory cytokine synthesis.
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Figure 2.6. CTB-INS Fusion Protein Stimulates IL-10 Synthesis
Panel A: The histograms show the mean fluorescence intensity of IL-10. Premixed plastic
beads coated with capture antibodies (BD Biosciences, San Jose, CA, USA) and a
mixture of Phycoerythrin-conjugated antibodies against IL-10 were incubated for 2 hrs
with the supernatant removed from different treatment conditions of proteins with DCs as
described in the Materials and Methods section. The beads were washed and analyzed by
flow cytometry for determination of the fluorescence intensity of bound IL-10. Panel B:
Cytometric Bead Array-defined concentrations of IL-10 and IL-12/23p40 subunit
measured from cell supernatants taken from DCs receiving different treatment conditions.
For each treatment the concentration of IL-10 and IL-12/23p40 subunit was normalized
to standard IL-10 and IL-12/23p40 cytokine curve and given in pg/ml. The data are the
Mean and SE (*P<0.05) showing statistically significant differences between CTB-INS
treated cells and PMA + Ionomycin treated cells for repeated independent experiments.
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Discussion
Our laboratory and others previously demonstrated the phenomenon of
suppression of insulitis and autoimmune diabetes in NOD mice inoculated with CTB-INS
(Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998; Sobel, Yankelevich et al. 1998).
However, the cellular and molecular mechanisms underlying CTB-proinsulin – immune
cell interactions involved in the suppression of disease pathology are incompletely
understood. Because DCs are the dominant population of APCs involved in the induction
of inflammatory and autoreactive T cell morphogenesis, we investigated early effects of
CTB-INS on human iDC activation and maturation in vitro and attempted to correlate
these results with findings from NOD mice diabetes onset studies.
Our experiments suggest that CTB when conjugated to pro-insulin (CTB-INS)
results in the suppression of DC activation and maturation as determined by a failure of
CTB-INS and to a limited extent proinsulin alone to stimulate the upregulation of CD86
and CD83 costimulatory factors on iDC. This observation was further confirmed when
CTB-INS stimulated DCs resulted in an increase in DC secretion of the antiinflammatory cytokine IL-10. Further, our experimental data appears to confirm
previous studies with the heat sensitive enterotoxin from E. coli (LTB), that CTB, a
molecule similar in structure to LTB like LTB selectively stimulates TLR2 activation in
response to DC incubation with CTB or CTB-INS proteins. Previous observations show
that CTB can greatly enhance the immunogenicity of linked antigens (George-Chandy,
Eriksson et al. 2001; D'Ambrosio, Colucci et al. 2008) by inducing DC upregulation of
CD86 and CD83 (George-Chandy, Eriksson et al. 2001; Isomura, Yasuda et al. 2005).
Morphological changes which included enlargement of iDC, elongation of DC dendrites

87

and increased migration of DCs into draining lymph nodes observed in those studies was
not monitored in the present study. D’Ambrosio et al. suggested that CTB could partially
prevent LPS-induced maturation of monocyte-derived DCs while Morita et al. reported
that CTB induced DC maturation. Careful consideration of these findings appears to
suggest that CTB may play a dual role as both an immunostimulatory and
immunosuppressive modulator molecule. We report that CTB activation of DCs appears
to be less than PMA+Ionomycin induced activation of DC maturation. However, when
compared to insulin and CTB-INS, CTB shows a significantly increased level of DC
activation. In essence, the question of the duality of CTB activity either as a proinflammatory or anti-inflammatory immune response modulator may be resolved by
understanding the activity of CTB in relation to another molecule (antigen or
autoantigen).
Earlier NOD mouse insulin inoculation experiments conducted by Bergerot et al.,
demonstrated sustained prevention of diabetes onset, even when oral insulin treatment
was initiated as late as 15 weeks after birth of the mice. In addition, the protective effect
against continued insulitis development was transferable to untreated NOD mice through
transfer of CD4+ T cells from CTB-INS inoculated animals (Bergerot, Ploix et al. 1997).
Our recent finding that CTB-INS is active in the suppression of DC maturation provides a
possible explanation for CTB enhanced insulin-mediated diabetes suppression observed
in NOD mice studies employing CTB-INS fusion protein produced in viruses, plants, and
silkworm larvae (Denes, Krausova et al. 2005; Gong, Jin et al. 2007; Gong, Long et al.
2009).
Previous studies demonstrated that insulin can function as a prime target for
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autoantigen directed T1D therapies (Palmer, Asplin et al. 1983; Jaeckel, Klein et al.
2003; Jaeckel, Lipes et al. 2004; Kent, Chen et al. 2005). These studies showed that
administration of insulin analogs, such as altered B: 9-23 insulin, induced T cell
mechanisms involved in the prevention of diabetes development in NOD mice (Weiner,
Zhang et al. 1991; Zhang, Davidson et al. 1991; Elliott, Qin et al. 1994; Atkinson and
Leiter 1999; Weiner 2001; Kobayashi, Abiru et al. 2007). However, a major concern is
that increasing amounts of insulin can act as a double edged sword with the potential to
protect against the development of autoimmunity at low insulin concentrations while
stimulating pathogenic immunity at higher insulin concentrations (Romagnani 1998;
Kobayashi, Abiru et al. 2007). Liu et al. (2009) recently demonstrated that increased
insulin concentration (2.5-25mg/L) significantly increased DC synthesis of costimulatory factors, increasing DC ability to activate autologous lymphocytes (Liu, Wang
et al. 2009). Our experimental data showed that exposure of iDCs to increasing amounts
of insulin resulted in an increase, rather than a further suppression, of DC activation. This
result provides a plausible answer to the earlier counter intuitive observation that
increased insulin levels might be expected to stimulate rather than suppresses diabetes
onset in NOD mice.
The observed increase in suppression of DC maturation by CTB-INS fusion
protein in comparison with insulin alone raises the question of whether CTB-INS
suppression of DC maturation is mediated through the activation of Toll-like receptor
signaling processes. The type II heat-labile enterotoxin (LT-IIB) of E. coli, which has an
AB5 type structure similar to CTB, was shown to induce DC activation through TLR2
resulting in downstream activation of NF-κB (Connell, Metzger et al. 1995; Lencer,

89

Constable et al. 1995; Merritt, Sarfaty et al. 1995; Hajishengallis, Tapping et al. 2005).
Examination of CTB-mediated suppression of DC activation and maturation similarly
suggests that TLR2 may be selectively upregulated as well in CTB stimulated DCs. The
CTB subunit may be selective for TLR2 since TLR2 depends specifically on hydrophobic
interactions for ligand binding (Okusawa, Fujita et al. 2004; Seong and Matzinger 2004)
as observed for LTBIIb. While the specific mechanism by which CTB may interact with
TLR2 is largely inferred from LTB studies, further insights may be provided from the
binding properties of CTB and other pentameric enterotoxin B subunits that have the
capacity to participate in both hydrophobic and hydrophilic interactions (van den Akker,
Sarfaty et al. 1996; Tinker, Erbe et al. 2003).
DC activation correlates with expression of the major immunosuppressive
cytokine, IL-10, identified in APCs including DC subsets (de Waal Malefyt, Abrams et
al. 1991; Sica, Saccani et al. 2000). Autocrine production of IL-10 by iDCs was shown to
inhibit synthesis and release of pro-inflammatory cytokines and other molecules (IL-12,
TNF-α, IL-6, LTB4, NO, PGE2). Further, IL-10 secretion by DCs was shown to suppress
Th1 lymphocyte activity by enhancing down-regulation of costimulatory molecule
expression on the DC surface (Grutz 2005; Harizi and Gualde 2006). In the case of
experimental encephalitis, oral administration of CTB linked to myelin basic protein
(MBP) increased suppression of encephalitis induced by TGF-β originating from CD4 T
cells in the animal spinal cord (Sun, Xiao et al. 2000). In the same way, immunological
analyses of patients with Behcet’s disease treated with CTB conjugated to HSP60 p336351 in a pilot clinical trial showed the presence of increased synthesis of IL-10 by CD4+
cells as well as a reduction in T cell synthesis of pro-inflammatory cytokines IL-2 and
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IFN-γ (Stanford, Whittall et al. 2004). Through inhibition of the above endogenous proinflammatory mediators, IL-10 was shown to be central to maintenance of DCs in an
immature state and in the down-regulation of DC-mediated inflammatory responses
(Harizi and Gualde 2006). In paracrine fashion, IL-10 synthesized by DCs can regulate
immunity by altering the function of different adjacent cell types. In several studies, IL10 secreted by iDCs stimulated the development of cognate naïve Th0 cells into either
Th2 lymphocytes, or suppressor regulatory T cells (Romagnani 1998; Romagnani,
Kapsenberg et al. 1998; Stassen, Fondel et al. 2004; Stassen, Schmitt et al. 2004). Studies
in knockout mice showed that IL-10 can down-regulate autoimmunity in the intestine and
can be active in the suppression of Crohn’s disease (Grimbaldeston, Nakae et al. 2007;
Minderhoud, Samsom et al. 2007).
In our experiments, CTB-INS stimulated iDCs produced significantly higher
levels of IL-10 than in CTB or proinsulin stimulated iDCs. However of interest, the
biosynthesis of IL-12/23p40 subunit was significantly inhibited. This result is critical
because induction of cognate naïve T helper cell (Th0) morphogenesis into Th1 effector
cells that secrete IFN-γ and IL-2 responsible for islet inflammation and β-cell death is
dependent on DC synthesis of IL-12 in addition to expression of surface costimulatory
molecules (Pulendran, Smith et al. 1999; Itano, McSorley et al. 2003; Kang and Kim
2006; Zorena, Mysliwska et al. 2008). Secretion of IL-10 was shown to be essential for
the inhibition of DC maturation through its effect of blocking IL-12 synthesis. As a result
of increased DC biosynthesis of IL-10, inflammatory autoreactive effector Th1 cell
proliferation and secretion of downstream inflammatory cytokines IFN-γ and IL-2 is
inhibited. This finding in combination with our experiments demonstrating CTB-INS
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inhibition of DC co-stimulatory factor upregulation and IL-12/23p40 synthesis may be
critical to determine the probable cellular mechanisms underlying CTB-INS mediated
immune suppression of T1D. Future experiments incubating CTB linked autoantigens
with naïve DCs will reveal the capacity of CTB-INS to arrest the progression of T1D
once hyperglycemia has become established. Establishment of CTB-INS mediated
immunological suppression of T1D progression will help to determine whether this form
of interventional therapy in combination with anti-inflammatory cytokines can prevent
both the onset and the progression of diabetes once hyperglycemia has developed. Once
durable immunological suppression of diabetes progression has been achieved,
interventional therapy with insulin producing mesenchymal stem cells may provide an
effective, safe and durable cure for the present ravages of autoimmune diabetes.
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Abstract
Dendritic cells (DC), the largest population of antigen presenting cells, regulate
the delicate balance between immune responses and tolerance involved in the onset of
type I diabetes (T1D). Cholera toxin B subunit (CTB) is a known mucosal adjuvant for
the generation of immune responses to linked antigens. However, CTB linked to
autoantigens may induce tolerance and therefore suppress the induction of autoimmunity.
In this present study, we examined the possibility that CTB linked to a 5 kDa C-terminal
protein fragment of the diabetes autoantigen glutamic acid decarboxylase (GAD), may
directly suppress the maturation of DCs assessed by CD86, CD83, CD80 and CD40
biosynthesis. Furthermore, we examined the possibility that CTB-GAD35 may suppress
human DC maturation and function in response to phorbol myristate acetate (PMA) and
Ionomycin stimulation. Incubation of human umbilical cord blood monocyte-derived
DCs (iDCs) with GAD induced low level surface expression of CD86, CD83, CD80 and
CD40 co-stimulatory factors compared to untreated samples, while incubation of iDCs
with CTB-GAD35 did not induce expression of CD86, CD83, CD80 and CD40 costimulatory factors. Also, our findings showed that CTB-GAD35 abrogates PMA and
Ionomycin induced iDC maturation. Further, suppression of iDC maturation by CTBGAD35 is accompanied by a dramatic decrease in the secretion of IL-12/23p40 and IL-6
pro-inflammatory cytokines while increasing the secretion of the immunosuppressive
cytokine IL-10. These findings suggest that linkage of CTB adjuvant to the dominant
T1D autoantigen GAD may play a critical role in stimulating DC priming of naïve Th0
cell development into immunosuppressive T lymphocytes. This could be important in
adjuvant stimulated vaccine responses for suppression of T1D autoimmunity.
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Introduction
TYPE 1 DIABETES MELLITUS (T1DM) is an organ-specific autoimmune
disease which results from autoreactive lymphocyte destruction of insulin-producing
pancreatic islet beta cells (Eisenbarth 1986; Tisch and McDevitt 1996). The loss of islet
β-cell function leads to insulin deficiency and elevated blood sugar levels
(hyperglycemia). Hyperglycemia increases levels of cellular oxidative stress leading to
chronic inflammation throughout the body. Therefore, diabetics have an increased and
premature risk for secondary neural and circulatory health problems, including blindness,
heart attack, and stroke (Libby, Nathan et al. 2005).
Dendritic cells (DCs), professional antigen presenting cells (APC), are implicated
in mediating islet β-cell destruction in T1D. Through antigen presentation, DCs play a
key role in the polarization and development of naïve T helper cells (Th0) into
autoreactive Th1 lymphocytes or immunosuppressive Th2 cells. This process is critical
for maintenance of immunological homeostasis (Pulendran, Smith et al. 1999; Pulendran,
Kumar et al. 2001; Itano, McSorley et al. 2003). Maturation of DCs in response to “self”
antigens such as pancreatic islet β-cell proteins induces the development of autoreactive
CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T helper (Th1) lymphocytes in addition
to initiating B cell production of autoantibodies. Subsequently, autoreactive Th1 cells
infiltrate the pancreatic islets in non-obese diabetic (NOD) mice while secreting
inflammatory cytokines such as IFN-gamma and IL-2. These cytokines are known to
stimulate macrophage and CTL secretion of oxidative compounds NO, O2, H2O2 in
addition to other inflammatory cytokines (IL-1 beta, TNF-alpha, TNF-beta) [5-7].
Consequently, these immune responses induce chronic pancreatic inflammation
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(insulitis), which results in apoptosis of the islet β-cells ultimately leading to insufficient
levels of insulin production and availability (Piccinni, Beloni et al. 1998).
In addition to induction of conventional Th1 and Th2 cells, DCs induce the
development of adaptive regulatory T cells (iTregs) for the maintenance of immunologic
tolerance (Kapsenberg 2003). Immuno-cytochemical analyses showed that M cells of the
intestinal epithelium uptake autoantigens into peripheral DCs via several routes and this
may aid in the establishment of immune tolerance (Yoon and Jun 2005). Following
activation, DCs migrate to adjacent lymph nodes. Here, they present antigen peptides on
major histocompatibility complex class II (MHCII) receptors, synthesize costimulatory
factors, and secrete cytokines. Together, these three signals guide the development of
naïve cognate T cells into antigen-specific inflammatory Th1 lymphocytes or antiinflammatory Th2 lymphocytes. Immature or peripheral DCs (iDCs), that displayed high
levels of costimulatory molecule expression and secreted cytokine IL-12, were found to
induce Th1 lymphocyte differentiation; while those that displayed low levels of
costimulatory molecule expression and secreted cytokine IL-10 induced the development
of Th2 lymphocytes (Rissoan, Soumelis et al. 1999; Liu, MacKenzie-Graham et al. 2001;
Holmgren, Adamsson et al. 2005; Li, Zhong et al. 2006).
Oral delivery of autoantigens such as insulin and glutamic acid decarboxylase
(GAD) resulted in partial suppression of diabetes symptoms in diabetic animals (Zhang,
Davidson et al. 1991; Czerkinsky, Anjuere et al. 1999). However, this form of antiinflammatory therapy requires repeated autoantigen administration over an extended
period of time. Adjuvants were considered to enhance autoantigen therapy to further
prevent T1DM onset (Weiner, Zhang et al. 1991; Zhang, Davidson et al. 1991). The

105

mucosal adjuvant, cholera enterotoxin B subunit (CTB) from Vibrio cholerae, was shown
to be highly efficient for induction of oral tolerance in T1DM when conjugated with islet
autoantigens (Sun, Holmgren et al. 1994; Sun, Rask et al. 1996; Sun, Li et al. 2000; Sun,
Xiao et al. 2000). The CTB subunit was shown to bind specifically to GM1-ganglioside,
a receptor molecule found in common on the membrane of most types of epidermal cells.
This facilitates the entry of the holotoxin into the cell (Eriksson and Holmgren 2002).
Thus, CTB is an efficient trans-mucosal carrier molecule for autoantigen induction of
peripheral tolerance (Sun, Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003). Our
laboratory has compared the protective effects of diabetes-specific autoantigens, such as
GAD and proinsulin (INS), when genetically conjugated to adjuvants such as heat labile
enterotoxin-LTB from enterotoxigenic Escherichia coli, the enterotoxin B chain from
Shigella-STB and the plant toxin ricin B subunit-RTB on diabetes onset in NOD mice.
(Carter, Yu et al. 2006).
Our laboratory has recently shown that a possible mechanism for the suppression
of T1D onset is the induction of immune tolerance through DC interaction with CTBautoantigen. The inoculation of human DCs with CTB-INS fusion protein resulted in an
enhanced suppression of DC maturation. In addition, CTB-INS stimulated DCs increased
their secretion of immunosuppressive cytokine IL-10 with a concurrent suppression of
inflammatory cytokine IL-12/23p40 (Odumosu, Payne et al. 2010). We hypothesized that
if the mechanism of immune suppression was similar that the fusion protein CTB-GAD35
could also exert an inhibitory affect on DC maturation. Thus, through analysis of CTBGAD35 fusion protein interactions with iDCs, we anticipated that we might be able to gain
a clearer understanding of the mechanisms underlying CTB-autoantigen fusion protein
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interactions with DCs to suppress the onset of T1D.

Materials and Methods
Expression and Purification of CTB-GAD35 Fusion Proteins in E. coli
A cDNA fragment encoding a 5-kDa peptide (amino acid 509-543) proximal to the
carboxyl-terminus of GAD65 –designated GAD35 was genetically linked to the carboxylterminus (309bp) of CTB to generate the fusion gene CTB-GAD35. The cholera toxin B
subunit–autoantigen fusion gene CTB-GAD35 was cloned into the (A) configuration of
the E. coli expression vector pRSET (Invitrogen™, Carlsbad, CA), under control of the
bacteriophage T7 promoter in order to achieve high levels of transgene expression. The
pRSET vector also contained an oligonucleotide encoding 6 histidines immediately
upstream of the CTB permitting isolation of the transgene product. Selective clones were
assessed by DNA sequence analysis to confirm the in-frame linkage of CTB and CTBGAD35 DNA fragments. Recombinant vectors were then introduced into E. coli producer
strain BL21 (DE3)pLysS (Invitrogen, Carlsbad, CA) by electroporation for nickel affinity
column isolation of the recombinant protein (Carter, Yu et al. 2006).
Recombinant CTB-GAD35 fusion protein expressed in E. coli was purified by
isolating the 6xHis-tagged protein from lysed cells using metal chelation
chromatography. Transformed E. coli strain BL-21, was grown in 250 ml Luria Broth
(LB) medium containing ampicillin (100mg/ml) with shaking at 37oC. While still in log
phase of growth, CTB-GAD35 protein synthesis was stimulated by addition of 90 mg
isopropyl β-D-1thiogalacto-pyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO), to
the bacterial culture. After 6 hr continued growth at 370C, the bacterial culture was
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pelleted by centrifugation in a SA-600 rotor for 10 min, at 5,000 rpm and 4oC, in a
Sorvall RC5B centrifuge. The cell pellet was resuspended in 1.0 ml/tube of 10 mM
HEPES buffer (pH 7.5), containing 100 mM imidazole. The cells were disrupted by
sonication at 3 x 10 sec bursts at 10 W, with a Sonic 60 Dismembrator (Fisher Sci.
Sunnyvale, CA). The CTB-GAD35 protein was isolated and purified from the bacterial
homogenate using a Maxwell Model 16 robotic protein purification system (Promega Inc.
TM

), according to the protein isolation protocol provided by the manufacturer (Promega

Inc., Madison, WI). In order to obtain a pure protein product, the robot employs
electromagnetically charged Magne-His Nickel-Iron alloy particles with an affinity for
the 6-HIS tag linked to the N terminus of the recombinant CTB-GAD35 fusion protein.
Imidazole was removed from the protein mixture by dialysis of the preparation against 2
x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr at 4oC. The purity of the isolated
CTB-GAD35 protein (~22kDa) was determined by electrophoretic mobility analysis in a
12% polyacrylamide gel in comparison with protein molecular weight standards (Figure
1b). The purified CTB-GAD35 protein was confirmed by immunoblot analysis using an
anti-polyhistidine primary antibody and stored at -20oC until further use.

Isolation and Culture of Monocyte-derived DC from Human Cord
Blood
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected
human umbilical cord blood. The leukocyte fraction of cord blood obtained from normal
healthy placenta donors (by LLU IRB approved protocols) was separated from red blood
cell and platelet fractions by Ficoll-paque (GE Healthcare, Uppsala, Sweden) density
gradient centrifugation for 30 min at 2,000 rpm@ 4oC, in a Beckman Coulter Allegra X-
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15R centrifuge, equipped with a SX4750 rotor. The CD14+ monocytes were obtained from
the total lymphocyte fraction by incubation with anti-CD14 PE (Phycoerythrin) (Miltenyi
Biotech, Auburn, CA) for 10 min @ 4oC followed by incubation with anti-PE magnetic
microbeads for 15 min at 4oC. The cells were separated magnetically by passing them
through the MACS column as described by the manufacturer (Miltenyi Biotech) (Devaraj,
Glaser et al. 2006; Devaraj, Dasu et al. 2008). The purity of the monocyte fraction was
determined by flow cytometry in a BD FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA).
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, in a humidified
atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ). The medium was
supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml penicillin,
100 µg/ml streptomycin, 50 ng/ml human recombinant GM-CSF, and 10 ng/ml human
recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel). The
monocyte cell culture was fed every 2 days by gentle replacement of 50% of the medium
with fresh medium. The cell cultures were kept in their original plates until harvested to
avoid induction of DC maturation caused by mechanical stress associated with replating the
cells. The percentage of monocyte-derived iDC (M-iDC) was determined directly by flow
cytometry based on expression of DC-specific cell surface markers (CD14−HLADR+CD11c+) after 6 days further incubation.

DC Maturation Assay and Phenotyping
The iDCs were stimulated by the addition of CTB (10ug/ml), GAD35 (10ug/ml), CTB-
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GAD35 fusion protein (20ug/ml) and Phorbol myristate acetate (PMA) and Ionomycin at
10ng/ml (PMA+Ionomycin) for 48 hrs at 37oC, in 5% CO2. After incubation, the
expression of DC surface markers, indicating their state of activation and maturation
(CD14, CD11c, HLA-DR), was determined by flow cytometry. The gated CD14- HLADR+ CD11c+ cell population was analyzed for the expression of CD86, CD83, CD80, and
CD40 activation markers (BD Pharmingen, San Jose, CA USA).

Flow Cytometry Analysis
For flow cytometry examination of DC surface markers, the DCs were surface stained
with antibodies conjugated to PE, Fluorescein isothiocyanate (FITC), Allophycocyanin
(APC), and Peridinin Chlorophyll Protein Complex (PerCP) (Parrish, Baez et al. 2009)
and resuspended in 1.0% of paraformaldehyde for analysis using the FACSCalibur flow
cytometer. The following antibodies were used to identify the different cell subsets: antiCD86-FITC, anti-CD83-PE, anti-CD40-FITC, anti-CD80-PE, anti-HLA-DR-PerCP antiCD14-APC anti-mouse IgG1-FITC, anti-mouse IgG1-PE, anti-mouse IgG1-HLA-DR,
anti-mouse IgG1-APC (BD Pharmingen); 7-Amino-actinomycin D (7-AAD) was used to
assess viability of the collected cells. Briefly, a pooled sample of harvested cells was
incubated with 7-AAD and prepared for flow cytometry according to the manufacturer’s
instructions (eBioscience, San Diego, CA, USA). Fluorescence intensity on all flow
histograms is shown on a log scale.

Secreted Cytokine Analysis by Cytometric Bead Array
Immature DCs were stimulated with PMA+Ionomycin and proteins for 48 hrs as
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described above. The supernatant was collected and stored at -20oC until analyzed for
concentrations of IL-6, IL-10 and IL-12/23p40 using the cytometric Bead Array (CBA)
kit (Becton Dickinson Biosciences, San Jose, CA). Fifty µl of premixed beads coated
with capture antibodies was incubated with 50µl of cytokine standards or test samples in
the dark at room temperature for 1 hr. Following the incubation, 50µl of a mixture of
Phycoerythrin-conjugated antibodies prepared against the specific cytokines was added to
each preparation, and the samples were incubated for 2 hrs in the dark at room
temperature. The beads were washed once with the wash buffer supplied with the CBA
kit and analyzed immediately in a BD FACSCalibur flow cytometer (Becton, Dickinson
Inc.). Data analysis was performed using the FCAP Array software packages supplied by
BD Biosciences. Three thousand counting events were acquired from each sample.
Cytokine calibration curves were generated using cytokine standards supplied by BD
Biosciences (Potapova, Gaudette et al. 2007; LaFrance, Kehinde et al. 2008).

Statistical Analysis
Statistical analyses of experimental treatment groups were performed using a one-way
analysis of variance method (ANOVA). Cell population percentages and fluorescence
intensity values were presented as the mean ± 95% confidence interval. A p< 0.05 was
considered statistically significant.

Results
CTB-GAD35 Fusion Protein Expression in E.coli
Recombinant GAD35 and CTB-GAD35 were identified by immunoblot with a
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monoclonal antibody made against the carboxyl terminal epitope of GAD65. The CTBGAD35 protein was identified in both monomeric (~22kDa) and multimeric form (Fig.
3.1A). In addition, identification of GAD35 and CTB-GAD35 was confirmed by
immunoblot analysis using an anti-polyhistidine antibody.
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3.1A.

3.1B.
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Figure 3.1. A. Diagram of E. coli pRSET (A) expression vector.
The cDNA fragment of cholera toxin B subunit (CTB) C-terminus was fused to the 5kDa
pancreatic islet autoantigen glutamic acid decarboxylase (GAD). The vector includes a
bacteriophage T7 promoter to generate high expression levels of inserted genes and a 6
histidine sequence tag for nickel affinity column isolation of recombinant protein. (B)
Immunoblot identification of renatured GAD35 and CTB-GAD35 subunit fusion proteins
synthesized in E. coli. Proteins identified with anti-His primary antibody.
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CTB-GAD35 Suppresses Monocyte-derived Dendritic Cell Activation and Maturation
We examined the influence of CTB, GAD35, CTB-GAD35 and lipopolysaccharide (LPS)
on immature DC maturation by measuring the surface expression of costimulatory
molecules CD86, CD83, CD80 and CD40. Immature dendritic cells (iDC) were
differentiated from monocytes and assessed for the expression of CD14-HLADR+CD11c+ surface markers indicating DC differentiation from monocytes. iDCs
(CD14-HLA-DR+CD11c+) were inoculated with CTB, GAD35 and CTB-GAD35 fusion
proteins and assessed for surface expression of CD86, CD83, CD80 and CD40 ( Fig.
3.2). Flow cytometric data obtained for CTB-GAD35 treated cells revealed that iDC
exposure to CTB-GAD35 resulted in a significantly lower expression of CD86, CD83,
CD80 and CD40 costimulatory factors as compared with CTB, GAD35, and LPS
(p<0.05). These results suggest that the physical linkage of CTB to the GAD35
autoantigen is responsible for suppression of dendritic cell activation and maturation by
CTB-GAD35.
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Figure 3.2. CTB-GAD35 suppresses activation and maturation of DCs.
Dendritic cells were stimulated for 24 hrs with CTB, GAD35, CTB-GAD35 and LPS.
Markers of DC activation and maturation were determined using flow cytometry.
Histograms depict the expression of CD86, CD83, CD80 and CD40 after stimulation.
Shaded histogram represents untreated sample (negative control).
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CTB-GAD35 Downregulates PMA and Ionomycin-induced DC
Surface Costimulatory Molecule Expression
Based on the results obtained showing that CTB-GAD35 suppresses DC
maturation, we further assessed the capacity of CTB-GAD35 to prevent activation of DCs
in the presence of PMA+Ionomycin stimulation. Separate cultures of DCs were treated
with PMA and Ionomycin alone and a combination of PMA+Ionomycin plus CTBGAD35. In preliminary experiments, 24-hr and 48-hr treatments were tested. Results
showed that the effects of CTB-GAD35 on PMA+Ionomycin DCs were more evident
during the first 24 hrs (data not shown). Therefore, in subsequent experiments, we used
the 24-hr time points. As shown in Figure 3.3, CTB-GAD35 induces a statistically
significant reduction of PMA+Ionomycin induced up- regulation of CD86, CD83 and
CD80 (p<0.05).
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Figure 3.3. CTB-GAD35 suppresses PMA+Ionomycin induced maturation of DCs.
Dendritic cells were stimulated with PMA+Ionomycin and a combination of
PMA+Ionomycin and CTB-GAD35 for 24 hrs. Maturation of DCs was determined using
flow cytometry. Histograms depict the expression of CD86, CD83, CD80 DC
costimulatory factors following fusion protein, PMA and Ionomycin stimulation.
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CTB-GAD35 Suppresses DC Pro-inflammatory Cytokine Secretion
In these experiments, we determined whether CTB-GAD35 suppression of DC
maturation (suppression of costimulatory factor surface expression) resulted in a
decreased synthesis of IL-12/23p40 and IL-6, along with an increased secretion of
immunosuppressive cytokine IL-10. The culture medium was collected from DCs
exposed to 48 hrs incubation with CTB-GAD35 fusion protein and analyzed for the
presence of secreted cytokines by cytometric bead array based flow cytometry. The
results of this experiment showed that there was a significant decrease in proinflammatory cytokines IL-12/23p40 and IL-6 with a concomitant increase in IL-10
production by DCs incubated with CTB-GAD35 compared to DCs stimulated with the
autoantigen alone (P<0.05) (Fig. 3.4). Therefore, taken together, the observed down
regulation of co-stimulatory surface marker expression, in addition to the significant
decrease in secreted IL-12/23p40 and IL-6 inflammatory cytokines and increased
secretion of the anti-inflammatory cytokine IL-10, CTB-GAD35 clearly appears to have
an important role in the suppression DC activation and maturation.
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Figure 3.4: The CTB-GAD35 fusion protein suppresses the secretion of proinflammatory
cytokines IL-12/23p40 and IL-6 while increasing synthesis of the anti-inflammatory
cytokine IL-10. Premixed plastic beads coated with capture antibodies (BD Biosciences,
San Jose, CA, USA). And a mixture of Phycoerythrin-conjugated antibodies against IL12/23p40, IL-6 and IL-10 were incubated for 2 hr with media removed from DC cultures
incubated with CTB and GAD autoantigen treatment conditions as described in the
section on materials and methods. The beads were washed and analyzed by flow
cytometry to determine the concentrations of IL-10, IL-6 and the IL-12/23p40 subunit.
The cytokine concentrations in the samples were normalized to a standard IL-10, IL-6
and IL-12/23p40 cytokine curve and concentrations were provided in pg/ml. The data
represent the Mean and SE for cytokine concentration in pg/ml (*p < 0.05) of repeated
independent CTB-GAD fusion treatment experiments in comparison with the
uninoculated cell control sample, autoantigen alone and/or PMA+ Ionomycin treatment
samples.
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Discussion
Using a CTB-insulin fusion protein, Bergerot et. al. demonstrated sustained
prevention of diabetes onset in NOD mice as late as 15 weeks after birth. Further, a
sustained protective effect against the development of insulitis was shown to be
transferable to un-inoculated NOD mice through adoptive transfer of CD4+ T cells from
CTB-INS inoculated animals (Bergerot, Ploix et al. 1997). Additional experiments in our
laboratory and by others have demonstrated that inoculation with CTB-autoantigen fusion
proteins suppresses insulitis and autoimmune diabetes in NOD mice (Bergerot, Ploix et
al. 1997; Arakawa, Yu et al. 1998; Sobel, Yankelevich et al. 1998). Specifically, our
animal immunization studies revealed that CTB-GAD35 inoculated animals showed
reduced levels of hyperglycemia and pancreatic islet inflammation as compared to
controls (Denes, Krausova et al. 2005; Denes, Yu et al. 2006). In a separate in vivo study,
our laboratory recently demonstrated that a combinatorial therapy of CTB-GAD35 + IL-10
is able to completely suppress the onset of diabetes in NOD mice (Denes, Fodor et al.
2010). However, molecular and cellular mechanisms underlying tri-component vaccine
suppression of T1D remain to be elucidated. The dominant role of DCs in the induction
of inflammation and tolerance implicates them in an early stage of the mechanism
involved in CTB-GAD35 suppression of diabetes onset.
DC synthesis of IL-12 and expression of surface costimulatory molecules are
responsible for induction of T cell morphogenesis into pro-inflammatory autoreactive
Th1 effector cells that secrete inflammatory cytokines IFN-γ and IL-2. This T cell
response is responsible to a large extent for the onset and development of insulitis and βcell death in T1D (Pulendran, Smith et al. 1999; Itano, McSorley et al. 2003; Kang and
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Kim 2006; Zorena, Mysliwska et al. 2008). Conversely, production of IL-10 by iDCs was
shown to suppress biosynthesis and secretion of pro-inflammatory cytokines and other
molecules (IL-12, TNF-α, IL-6, LTB4, NO, PGE2). Synthesis of IL-10 was also shown
to be essential for the inhibition of DC maturation by suppressing IL-12 synthesis. As a
result of increased DC IL-10 production, autoreactive Th1 cell proliferation and secretion
of downstream inflammatory cytokines IFN-γ and IL-2 is inhibited. Here we report that
the adjuvant – autoantigen fusion protein CTB-GAD35 stimulated iDCs to synthesize
significantly higher levels of IL-10 than was observed for iDCs stimulated with CTB or
PMA+Ionomycin.
Th17 cells have become very important for the treatment of autoimmune diseases
because they have been identified as significant effector cell types involved in both
human and mouse autoimmune models (Fujino, Andoh et al. 2003; Nakae, Nambu et al.
2003; Komiyama, Nakae et al. 2006). IL-17 was first detected in the serum and tissues of
patients with autoimmune diseases such as multiple sclerosis (MS), systemic lupus
erythematous (SLE) and rheumatoid arthritis (RA) (Wong, Ho et al. 2000; Tzartos, Friese
et al. 2008). In addition, IL-17 blockade was shown to prevent the development of EAE
while IL-17 knockout mice showed resistance to the development of EAE and collageninduced arthritis (CIA) (Nakae, Nambu et al. 2003; Hofstetter, Ibrahim et al. 2005).
Together, these findings suggest that the regulation of Th17 differentiation and function
may prove to be a potential treatment for autoimmune diseases. IL-6 has been found to be
an effective target for down-regulating the differentiation of Th17 cells as a treatment for
autoimmune diseases (Nishimoto, Terao et al. 2008; Yokota, Imagawa et al. 2008). This
inflammatory cytokine has evolved as a pleiotropic cytokine involved in regulating the
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balance of IL-17 producing Th17 cells and Treg cells (Bettelli, Carrier et al. 2006;
Mangan, Harrington et al. 2006). In this study, our findings show that CTB-GAD35
suppresses DC synthesis of IL-6. This result in combination with CTB-GAD35 inhibiting
DC co-stimulatory factor up-regulation may be critical elements in the elucidation of
cellular mechanisms responsible for CTB-GAD35 mediated immune suppression of T1D.
The efficacy of diabetes autoantigens as a vaccine for suppression of
autoimmunity appears to be increased when physically conjugated to an adjuvant. The
conjugation of CTB to antigens was shown to significantly enhance the immunogenicity
of linked antigens (George-Chandy, Eriksson et al. 2001; D'Ambrosio, Colucci et al.
2008) through induction of DC upregulation of CD86 and CD83 (George-Chandy,
Eriksson et al. 2001; Isomura, Yasuda et al. 2005). D’Ambrosio et al. showed that CTB
could partially prevent LPS-induced maturation of monocyte derived DCs (D'Ambrosio,
Colucci et al. 2008). Recently, we reported our that CTB conjugated to the autoantigen
proinsulin (CTB-INS) suppressed DC surface expression of CD86 and CD83
costimulatory molecules with a significant increase in the IL-10 synthesis and a
suppression of IL-12/23p40 synthesis (Odumosu, Payne et al. 2010). Similar to
D’Ambrosio’s findings, our data suggest that CTB influences DC phenotype and
function. Furthermore, CTB may possess an intrinsic capacity to modulate either
inflammation or tolerance depending on whether it is conjugated to an antigen or an
autoantigen. Further studies are necessary to resolve the question of the duality of CTB
activity as an adjuvant for inflammatory or anti-inflammatory immune responses.
In this study, we found that CTB-GAD35 suppressed iDCs capacity to mature and
become activated in vitro. Furthermore, our data show that the CTB-GAD35 fusion
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protein inhibits PMA+Ionomycin induction of DC maturation as determined by a failure
to upregulate CD86, CD83 and CD80 co-stimulatory molecules. This effect suggests that
inoculation with the fusion protein may inhibit the progression of previously established
autoimmunity e.g., in the case of T1DM, blockage of DC maturation could inhibit further
development of diabetes symptoms of insulitis and hyperglycemia, a result partially
demonstrated in earlier studies from our laboratory (Arakawa, Chong et al. 1998;
Arakawa, Yu et al. 1999). Further, our experiments indicated that CTB-GAD35 inoculated
DCs were inhibited in their ability to synthesize major pro-inflammatory cytokines IL12/23p40 and IL-6. This loss was balanced with a concomitant increase in the synthesis
of the anti-inflammatory cytokine IL-10. The results of our recent CTB-INS studies
establish a molecular basis for CTB-GAD35 suppression of diabetes onset in NOD mice
(Denes, Krausova et al. 2005; Gong, Jin et al. 2007; Gong, Long et al. 2009). In earlier
studies, we demonstrated that fusion of CTB to the autoantigen was essential for
enhancement of immune suppression, as co-delivery of CTB and the autoantigen did not
result in a significant inhibition of DC activation and maturation (Odumosu, Payne et al.
2010). Together our experimental findings suggest that linkage of CTB to the autoantigen
is key to identification of the mechanism underlying adjuvant-enhanced tolerance.
Establishment of whether CTB-GAD35 mediated immunological suppression of DCs can
halt or reverse T1D progression will provide the basis for understanding how this form of
interventional therapy can be applied to prevent, halt or reverse the onset of insulitis and
hyperglycemia in diabetes patients.
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Abstract
Linkage of the pancreatic islet proteins proinsulin (INS) and glutamic acid
decarboxylase (GAD) to the cholera toxin B chain (CTB) enhances autoantigen
suppression of type 1 diabetes (T1D). In human tissues the CTB::INS fusion protein was
shown to suppress dendritic cell (DC) biosynthesis of costimulatory factors required for
the initiation of autoreactive T cell morphogenesis. In this study, we show that
CTB::INS/GAD autoantigen inoculated immature DCs guide T cell development in the
direction of anti-inflammatory Th2 lymphocytes and regulatory T cells (Tregs). Further,
our experimental findings show that CTB-pancreatic autoantigen fusion protein
inoculated DCs suppress the proliferation of inflammatory CD4 and CD8 T lymphocytes
thought to play a major role in the initiation of diabetes onset. Inoculation of immature
DCs with CTB::INS/GAD fusion proteins significantly increased cognate T cell secretion
of immunosuppressive cytokines IL-10 and TGF-β. In contrast, fusion protein inoculated
DCs suppressed lymphocyte secretion of the pro-inflammatory cytokines IFN-γ, IL-2 and
IL-17. Taken together, our experimental data suggests that CTB-autoantigen fusion
protein inoculated immature DCs guide initial stages of naïve T cell development in the
direction of immunological tolerance while simultaneously suppressing autoreactive T
cell development. Together the experimental results provide a plausible mechanism for
initiation of CTB-autoantigen mediated immunological suppression of T1D in humans.
The absence of DC apoptosis and necrosis during the course of these studies suggests that
CTB-autoantigen fusion proteins are an effective and safe vaccination strategy for
prevention of diabetes onset in susceptible patients.
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Introduction
Type 1 Diabetes mellitus (T1D) is a chronic organ-specific autoimmune disease
that begins in childhood and persists throughout life resulting in progressive destruction
of the pancreatic insulin and glutamic acid decarboxylase-producing islet beta cells
(Eisenbarth 1986; Tisch and McDevitt 1996). The continual loss of islet β-cell function
leads to insulin deficiency and elevated blood sugar levels (hyperglycemia). The
persistence of high blood sugar levels increases cellular oxidative stress leading to
chronic inflammation in almost all organs of the body. Thus, the result is an increased
risk for a variety of secondary circulatory and neural physiological complications,
including blindness, kidney failure, heart attack, and stroke which lead to unacceptable
levels of premature mortality (Libby, Nathan et al. 2005).
Previous studies have shown that partial suppression of diabetes symptoms can be
achieved by oral delivery of small amounts of the dominant pancreatic islet autoantigens
glutamic acid decarboxylase (GAD) and insulin (Zhang, Yuen et al. 1991; Czerkinsky,
Anjuere et al. 1999). However, in diabetic animals, earlier studies showed that
suppression of insulitis and hyperglycemia could be enhanced through conjugation of
islet autoantigens to the non-toxic B subunit of Vibrio cholerae enterotoxin (CTB)
(Bergerot, Ploix et al. 1997; Arakawa, Chong et al. 1998; Arakawa, Yu et al. 1998;
Arakawa, et al. 1999). Further experiments showed that CTB is an efficient transmucosal carrier molecule for autoantigen induction of peripheral tolerance (Sun,
Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003). Experiments comparing the
efficacy of CTB to the B subunits of several related bacterial enterotoxins revealed that
most bacterial and plant enterotoxin B subunits possessed a similar level of efficacy for
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enhancement of autoantigen mediated diabetes suppression (Carter, Yu et al. 2006).
Dendritic cells (DCs) are generally thought to be the most potent of the
professional antigen presenting cells (APC) implicated in mediating islet β-cell
destruction in T1D. Through antigen presentation to cognate T cells, DCs play a key role
in the onset and regulation of adaptive immune response through the priming of naïve T
helper cells (Th0) for morphogenesis into effector T cells. In addition, a variety of proand anti-inflammatory cytokine molecules produced by DCs in response to pathogen or
toxin attack are considered important for differentiation of T cells into autoreactive Th1
lymphocytes, immunosuppressive Th2 cells or regulatory T (Tregs) cells (Banchereau
and Steinman 1998). Regulation of these processes is pivotal for maintaining
immunological homeostasis in the body (Pulendran, Smith et al. 1999; Pulendran, Kumar
et al. 2001; Itano, McSorley et al. 2003; Kapsenberg 2003). In T1D autoimmunity, the
maturation of DCs in response to uptake of “self” antigens like the islet β-cell proteins
insulin and GAD, induces the development of autoreactive CD8+ cytotoxic T
lymphocytes (CTL) and effector CD4+ T helper (Th1) lymphocytes, as well as initiating
B cell production of autoantibodies to these islet beta cell proteins. Consequently, in the
non-obese diabetic (NOD) mouse, these autoreactive immune cells migrate to the
pancreas, infiltrate the islets and secrete inflammatory cytokines such as IFN-gamma and
IL-2. These inflammation inducing cytokines are known to stimulate macrophage and
CTL secretion of oxidative compounds NO, O2, H2O2 as well as inflammatory cytokines
(IL-1 beta, TNF-alpha, TNF-beta) [5-7]. These immune responses are thought to be
responsible for induction of chronic pancreatic inflammation (insulitis), which ultimately
results in destruction of the islet β-cells and the production of insufficient levels of
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insulin to meet the growing body’s metabolic requirements for energy leading
progressively to diabetes onset (Piccinni, Beloni et al. 1998).
Recently, Our laboratory demonstrated that prevention of T1D onset may be
mediated via induction of immunological tolerance resulting from DC interactions with
CTB::proinsulin/GAD autoantigen fusion proteins (Odumosu, Payne et al. 2010).
Inoculation of human monocyte-derived DCs with CTB-INS and CTB-GAD35 fusion
proteins resulted in suppression of DC maturation. Further, our experimental results
showed that CTB-autoantigen fusion proteins modulate DC cytokine secretion profiles in
the direction of immunological tolerance while suppressing the biosynthesis of
inflammatory cytokines IL-12 that could lead to the onset of autoimmunity (Odumosu,
Payne et al. 2010). In response to these observations, the major objective of this study is
to analyze the effects of CTB-autoantigen fusion protein stimulated DCs on naïve T cell
morphogenesis and proliferation.

Methods and Materials
Expression and Purification of CTB-INS and CTB-GAD35 Fusion
Proteins in E. coli
DNA fragments encoding 35bp deoxyoligonucleotide located proximal to the
carboxyl-terminus of GAD65 –designated as GAD35 or a 258bp DNA fragment encoding
human proinsulin (INS), were genetically linked to the carboxyl-terminus (309bp) of the
cholera toxin B subunit (CTB), to generate the fusion gene CTB-GAD35 and CTB-INS
respectively. The CTB–autoantigen fusion genes were cloned into the (A) configuration
of the E. coli expression vector pRSET(A) (Invitrogen™, Carlsbad, CA), under control of
the bacteriophage T7 promoter in order to achieve high levels of transgene expression.
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The pRSET vector also contained an oligonucleotide encoding 6 histidines immediately
upstream of CTB permitting isolation of the transgene product. Selective clones were
assessed by DNA sequence analysis to confirm the in-frame linkage of CTB, CTB-INS
and CTB-GAD35 DNA fragments (Fig 4.1). Recombinant vectors were then introduced
into the E. coli producer strain BL21 (DE3)pLysS (Invitrogen, Carlsbad, CA) by
electroporation for nickel affinity column isolation of the recombinant protein (Carter, Yu
et al. 2006; Odumosu, Payne et al. 2010).
Recombinant CTB-INS and CTB-GAD35 fusion proteins expressed in E. coli
were purified by isolating the 6xHis-tagged protein from lysed cells using metal chelation
chromatography. Transformed E. coli strain BL-21, was grown in 250 ml Luria Broth
(LB) medium containing ampicillin (100mg/ml) with shaking at 37oC. While still in log
phase of growth, protein synthesis was stimulated by addition of 90 mg isopropyl β-D1thiogalacto-pyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO) to the bacterial
culture. After 6 hr continued incubation at 370C, the bacterial culture was pelleted by
centrifugation in a SA-600 rotor for 10 min, at 5,000 rpm and 4oC, in a Sorvall RC5B
centrifuge. The cell pellet was resuspended in 1.0 ml / tube of 10 mM HEPES buffer (pH
7.5), containing 100 mM imidazole. The cells were disrupted by sonication (3 x 10 sec
bursts), at 10 W, with a Sonic 60 Dismembrator (Fisher Sci. Sunnyvale, CA). The
proteins were isolated and purified from the bacterial homogenate using a Maxwell
Model 16 robotic protein purification system (Promega Inc. TM), according to the protein
isolation protocol provided by the manufacturer (Promega Inc., Madison, WI). In order to
obtain a pure protein product, the robot employs electromagnetically charged Magne-His
Nickel-Iron alloy particles with an affinity for the 6-HIS tag linked to the N terminus of
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the recombinant fusion proteins. Imidazole was removed from the protein mixture by
dialysis of the preparation against 2 x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr
at 4oC. The purity of the isolated CTB-INS (~23.4kDa) and CTB-GAD35 protein
(~22kDa) were determined by electrophoretic mobility analysis in a 12% polyacrylamide
gel in comparison with protein molecular weight standards. The purified proteins were
confirmed by immunoblot analysis and stored at -20oC until further use.

Isolation and Culture of Monocyte-derived DC from Human Cord
Blood
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected
human umbilical cord blood. The leukocyte fraction of cord blood obtained from normal
healthy placenta donors (following LLU IRB approved protocols), was separated from
red blood cell and platelet fractions by Red blood cell lysis protocol. Briefly, the cord
blood was treated with ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM
Na2EDTA) to lyse the erythrocytes. After washing the lymphocytes with Miltenyi buffer
(PBS containing 0.5% BSA and 2mM EDTA), monocytes were isolated from the blood
via MACS (Miltenyi Biotec) using PE-conjugated anti-CD14 and anti-PE microbeads
(BD biosciences, San Jose, CA). The CD14+ monocytes were obtained from the total
lymphocyte fraction by incubation with anti-CD14 PE (Phycoerythrin) (Miltenyi Biotech,
Auburn, CA) for 10 min @ 4oC followed by incubation with anti-PE antibody conjugated
to magnetic microbeads, for 15 min at 4oC. The cells were separated magnetically by
passing them through the MACS column as described by the manufacturer (Miltenyi
Biotech, Auburn, CA) (Devaraj, Glaser et al. 2006; Devaraj, Dasu et al. 2008). The
purity of the monocyte fraction was determined by flow cytometry in a BD FACSCalibur
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flow cytometer (BD Biosciences, San Jose, CA.
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA) in a
humidified atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ). The medium
was supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin, 50 ng/ml human recombinant GM-CSF, and 10 ng/ml
human recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel).
The monocyte cell culture was fed every 2 days by gentle replacement of 50% of the
medium with fresh medium. The cell cultures were kept in their original plates until
harvested to avoid induction of DC maturation caused by mechanical stress associated
with re-plating of the cells. The percentage of monocyte-derived iDCs (M-iDC) was
determined directly by flow cytometry based on expression of DC-specific cell surface
markers (CD14−HLA-DR+CD11c+) after 6 days further incubation.

DC Maturation Assay and Phenotyping
The iDCs were stimulated by the addition of CTB (10ug/ml medium), GAD35
(10ug/ml), CTB-GAD35 fusion protein (20ug/ml) or Phorbol myristate acetate (PMA) and
Ionomycin at 10ng/ml medium (PMA+Ionomycin), for 48 hrs at 37 degrees, 5% CO2.
Following the incubation period, the expression of DC surface markers (CD14, CD11c,
HLA-DR), indicating their state of activation and maturation was determined by flow
cytometry. The gated DC (CD14- HLA-DR+ CD11c+ ) cell population was analyzed for
the expression of co-stimulatory factors CD86, CD83, CD80, and CD40 DC activation
markers (BD Pharmingen, San Jose, CA USA).
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Isolation of Naïve T cells and Incubation with Vaccine Inoculated DCs
The leukocyte fraction from approximately 50 ml of human umbilical cord blood
obtained from consenting normal healthy placenta donors (following LLU approved IRB
protocols) was separated from the red blood cell and platelet fractions by a red blood cell
lysis as described above and centrifugation at (2,000 RPM), 4oC, in a Beckman Counter
Allegra X-15R centrifuge, equipped with an SX4750 rotor. The CD3+ T cells were
positively selected from the cord blood leukocyte fraction using the MACS Pan T Cell
Isolation Kit II protocol for indirect magnetic isolation of naïve T cells (Th0) from human
blood (Miltenyi Biotec. Auburn, CA). The purified Th0 lymphocytes were found to be >
99% pure, as indicated by flow cytometric analysis. The purified naïve Th0 cells were
resuspended at a concentration of 1 X 106/ml in RPMI 1640 culture medium (Mediatech
Inc. Manassas, VA, USA) supplemented with 10% FBS, 1 mM glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin. Prior to addition to the Th0 cells, the iDCs were
stimulated with CTB::INS /GAD fusion proteins as described above for 48 hrs at 370C.
After the 48 hrs incubation, DCs from each treatment sample were washed twice with
PBS and mixed with T cells at a DC:T cell ratio of 1:10, DCs (1X 104 cells) + naïve T
cells (1 X 105 cells). Each of the experimental DC-T cell cultures were incubated in
approximately 200ul of RPMI 1640 medium supplemented with 10% of FBS, 1% Lglutamine, and 1% penicillin/streptomycin (Sigma-Aldrich; complete medium)/well in a
96-well microtiter plate for 6 days at 370C without changing the medium. Early DC
mediated T cell activation was assessed after 48 hrs of DC - T cell co-culture, by
harvesting the cell mixture from several wells into a 2.0 ml culture tube by centrifugation
as already described above and staining the cells with fluorescent labeled T cell markers
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CD3, CD4, CD8, CD25, and CD69. The Treg cell populations were identified by flow
cytometry according to the following phenotype: CD4+CD25+IL7R-. The cells were
harvested from the DC:Th0 cell co-cultured samples as previously described above and
surface stained for T cell markers CD3, CD4, CD8, CD25 and CD127. Intracellular
staining for the transcriptional activator Foxp3 was also performed as described below to
allow for additional Treg characterization. The proliferation of T cells was measured by
dilution of carboxyfluorescein diacetate, succinimidyl ester dye (CFSE) after 6 days
incubation at a final concentration of 3µM CFSE and by upregulation of intracellular Ki67, a transcription factor upregulated in proliferating lymphocytes. (The CFSE dye is
incorporated into the cell membrane and becomes diluted upon successive cell divisions).

Intracellular Cytokine and KI-67 Measurement
A total of 106/ml T cells were used each intracellular cytokine assay. After 48 hrs
DC: T cell co-culture, the cells were incubated for an additional 8 hrs with 3 µM
monensin for analysis of intracellular cytokines. Intracellular staining for cytokines was
performed according to the manufacturer’s instructions (Caltag, CA). The T cells were
washed and surface stained with fluorescently labeled CD4 and CD25 antibodies, fixed,
permeabilized, and stained for detection of intracellular cytokines IFNγ, TGF-β, IL-17,
IL-2 and IL-10. After washing, the cells were resuspended in 1% paraformaldehyde and
analyzed for the presence of intracellular cytokines using the MACSQuant flow
cytometer. Intracellular analysis of Ki-67 for cell proliferation was also done as described
for intracellular cytokines.
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Flow Cytometric Analysis
For examination of DC surface markers, the cells were surface stained with
antibodies anti-CD86-FITC, anti-CD83-PE, anti-CD40-FITC, anti-CD80-PE, anti-HLADR-PerCP anti-CD14-APC anti-mouse IgG1-FITC, anti-mouse IgG1-PE, anti-mouse
IgG1-HLA-DR, and anti-mouse IgG1-APC (BD Pharmingen, San Hose, Ca); 7-Aminoactinomycin D (7-AAD) was used to assess the viability of the collected cells. To
analyze T cell populations, anti-CD4-PE, anti-CD127-PE, anti-IL-10-PE, anti-CD3PerCP, anti-CD8-APC-Cy-7, anti-IFNγ- Bio-SA-APC, anti-IL-4-Biotin-SA-APC, antiCD25-Biotin-SA-APC, anti-TGFβ-PE-Cy-7 fluorescent tagged antibodies were used.
The fluorescent tagged antibodies were obtained from eBioscience Inc, and Biolegend,
Inc., San Diego, CA, USA. The fluorescence intensity indicated on all flow histograms is
shown on a log scale. An Isotype control was run with each set of samples and was used
to define negative and positive cell populations. All samples were analyzed using a
Miltenyi MACSQuant flow cytometer (Miltenyi Biotec.).

Statistical Analysis
Statistical analyses of experimental treatment groups were performed using a one-way
analysis of variance method (ANOVA). Cell population percentages and fluorescence
intensity values were presented as the mean ± 95% confidence interval. A p value of <
0.05 was considered to be statistically significant.

144

145

Figure 4.1 Construction of the CTB-INS Fusion Gene and Isolation of the Gene Product.
(A). Plasmid map of the E. coli expression vector pRSET A (Invitrogen™, Carlsbad,
CA), carrying the CTB-INS or the CTB-GAD35 fusion gene. (B) Map of the cholera
toxin B subunit– proinsulin autoantigen gene fusion CTB-INS (567bp). (C) The cDNA
fragment of cholera toxin B subunit (CTB) was fused at the C-terminus to the 5kDa
pancreatic islet autoantigen glutamic acid decarboxylase (GAD). The expression vectors
pRSET-CTB-INS and CTB-GAD are under the control of the bacteriophage T7 promoter
containing an oligonucleotide region encoding 6 histidine amino acid residues
immediately 5’ upstream of the CTB DNA sequence. The recombinant plasmids were
introduced into the E. coli recipient strain BL21 (DE3) pLysS, for optimum fusion
protein expression and for nickel binding mediated isolation of the recombinant protein
using a Maxwell 16 TM protein isolation robot (Promega Inc, Madison, WI, USA).

146

Results
CTB-INS and CTB-GAD35 Fusion Protein Inoculated DCs Suppress T
cell Activation
We investigated the effect of CTB-autoantigen inoculated DCs on Th0 cell
morphogenesis. Allogeneic T cells (106), preactivated with anti-CD3/CD28 monoclonal
antibodies for 48hrs were cultured with CTB, INS, GAD, CTB-INS, CTB-GAD35, PMA
and Ionomycin inoculated DC for 3 days and analyzed for the expression of CD69 (the
earliest inducible cell surface glycoprotein acquired during lymphoid activation). The T
cells cultured with CTB-INS and CTB-GAD35 inoculated DCs showed a significantly
reduced capacity for expression of CD69 activation marker in contrast to Th0 cells
cultured with a single autoantigen or PMA+Ionomycin stimulated DCs (p<0.05)(Fig 4.2).
This experimental data suggests that CTB-autoantigen inoculated DCs appear to suppress
early T cell activation.
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Figure 4.2: CTB-autoantigen fusion protein inoculated DCs suppress anti-CD3/CD28 Ab
stimulated T cell expression of CD69 protein. (A) Representative flow cytometry plot
showing the presence of CD4+ and CD8+ T cell populations after gating for CD3+ T
cells. (B). FACS plots of T cells expressing CD69+ protein after gating for CD4+ (Top)
and CD8+ T cells (Bottom).
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Figure 4.2. Continued.
(C) Bar graph representing the percent of CD69+ activated CD4+ and CD8+ T cells
following incubation of naïve T cells with DCs inoculated with CTB-autoantigen fusion
proteins or autoantigen alone. The data presented represent the means and SEM for 4
individual experiments. The asterisk (*) indicates the presence of a statistically
significant reduction in T cell synthesis of CD69 T cell activation marker protein
(p<0.05) for CTB-autoantigen fusion treated samples in comparison with autoantigen
alone treated samples.

151

CTB-INS and CTB-GAD35 Fusion Protein Inoculated DCs Induce
Generation of T Cells with Reduced Proliferative Capacity
To evaluate the ability of CTB-autoantigen inoculated DCs to inhibit T cell
proliferation, CD3+ T cells were co-cultured with CTB, INS, GAD, CTB-INS, CTBGAD35 and PMA+Ionomycin following their initial activation with PMA+Ionomycin and
anti-CD3/CD28 antibodies for 48 hrs at 370C. The T cells were labeled with CFSE and
KI-67 respectively. As shown in Fig.4.3, Th0 cells co-cultured with CTB-INS and CTBGAD35 inoculated DCs consistently inhibited the proliferation of CFSE labeled Th0 cells
and the expression of transcription factor KI-67 in comparison with Th0 cells co-cultured
with INS or GAD autoantigens alone or with PMA+Ionomycin activated DCs that
demonstrated multiple divisions in the presence of CFSE (P<0.05) (Fig 4.3).
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Figure 4.3: Shows CD 3+ naïve Th0 cell stimulation following inoculation with CTBautoantigen inoculated DCs.
Naive T cells isolated from umbilical cord blood were incubated with anti-KI-67
antibodies and after 4 days additional incubation in culture medium the cells were
analyzed by flow cytometry to assess the degree of cell proliferation based on synthesis
of KI-67 protein in CD4+ T helper cells (A), or CD8+ cytotoxic T cells (B). The bars in
each graph represent the mean and SEM of three independent experiments for each T cell
treatment. Based on the synthesis of KI-67, naïve Th0 cells incubated with CTBINS/GAD autoantigen fusion protein inoculated DCs showed a significant reduction in
proliferative capacity in comparison with PMA and Ionomycin inoculated and antiCD3/CD28 Ab activated T cells. Asterisks (*) over the bars represent a significant
difference in the expression of CD69+ in Th0 cells incubated with DCs inoculated with
CTB-autoantigen fusion proteins in comparison with T cells incubated with DCs
inoculated individually with INS or GAD autoantigens (p<0.05). (C) To identify the
number of cell divisions that occur during T cell proliferation, following incubation with
CTB-autoantigen fusion protein inoculated DCs, negative control and CD3+, activated T
cell samples were labeled with CFSE dye and after 6 days incubation in culture medium,
the individual cultures were analyzed by flow cytometry for incremental reductions in
CFSE dye staining intensity signifying the presence of successive cell divisions. The
histogram represents reductions in CFSE dye fluorescence intensity commensurate with
successive cell divisions detected following proliferation of the T cells in each
experimental treatment.
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CTB-autoantigens Induce CD4+ T regulatory Cells
In the next set of experiments, we investigated the ability of CTB-autoantigen
stimulated DCs to induce suppressor CD4 + regulatory T cells (Tregs), based on the
increased recognition of their importance in mediating tolerance and protection from
autoimmune diseases (Sakaguchi, Sakaguchi et al. 1995). Therefore, DCs stimulated with
fusion proteins or activated with PMA+Ionomycin were cultured with CD3+ T cells
previously activated with anti-CD3/CD28 antibodies. After five days incubation with the
fusion proteins, the cell cultures were harvested and analyzed for the proliferation of
CD4+ CD25+ IL7- regulatory T cells (Tregs), based on the level of Ki-67 expression
(Fig 4.4). Our experimental results showed increase in expansion of Treg populations
based on Ki-67 expression in CTB-INS and CTB-GAD35 inoculated DCs, was
significantly upregulated by 4 fold and 2.5 fold in comparison with INS and GAD35
inoculated DC cultured with T cells (p<0.05). However, The expression of Foxp3 was
not found to differ among all of the Treg populations gated for the CD4+CD25+IL-7phenotype.
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Figure 4.4: CTB-autoantigen inoculated DCs induce T regulatory cell (Treg)
proliferation.
(A) Dot plot showing expansion of Tregs by staining the DC:T lymphocyte mixture with
CD4+, CD25+, IL-7R-, and intracellular Ki-67 fluorescent-labeled antibodies. The
proliferation of Tregs was measured by flow cytometric determination of the percentage
of activated Tregs expressing Ki-67. Differences in Treg population expansion were
determined by ANOVA (p<0.05). (B) The bar graph represents the percentage of Treg
cells expressing Ki-67 transcription factor as an indicator of cell division. The columns
represent the means and SEM of three independent experiments. The asterisks (*)
represent significant differences in the expression of Ki-67 (cell proliferation) in Tregs
cells for T cells incubated with CTB-autoantigen fusion protein inoculated DCs in
comparison with T cells incubated with DCs inoculated with the single autoantigens
alone (p<0.05).
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CTB-autoantigen Stimulated DCs Direct Cognate T cells to Increase
IL-10 or TGF-β Cytokine Production
To examine the ability of CTB-autoantigen stimulated DCs to modulate T cell
cytokine production, CD3+ T cells were co-cultured with CTB, INS, GAD, CTB-INS,
CTB-GAD35 or PMA+Ionomycin inoculated DC, following initial activation of the naïve
T cells with anti CD3/CD28 antibody and PMA+Ionomycin. Intracellular cytokine
production in the DC inoculated T cells was determined following incubation of the
cultures in medium containing 3 µM monensin for the last 8 hrs of the incubation period.
In comparison with INS and GAD35 inoculated DC treated T cells, both CTB-INS and
CTB-GAD35 stimulated T cells produced significantly higher amounts of
immunosuppressive IL-10 and TGF-β cytokines (p<0.05) and significantly reduced
amounts of proinflammatory IFN-γ, IL-2 and IL-17 (p<0.05). Incubation of naïve T cells
with DCs activated by CTB-INS induced significantly higher levels of IL-10
biosynthesis, while T cells incubated with DCs activated by CTB-GAD35 fusion protein
resulted in significantly increased levels of TGF-β biosynthesis (P<0.05). Taken together,
these experimental results suggest that CTB-autoantigen inoculated DCs may induce
differentiation of immunosuppressive Th2 and Treg populations with CTB-INS and
CTB-GAD35 inoculated DCs stimulating T cell biosynthesis of cytokines normally
synthesized by Tr1 and Th3 Tregs respectively. These experimental results indicate that
CTB-autoantigen inoculated DCs phenotype are likely associated with immunological
tolerance and T cell regulatory activities.
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Figure 4.5: CTB-autoantigen stimulated DCs direct cognate T cells to increase IL-10 and
TGF-β anti-inflammatory cytokine production. The CD3+ T cells isolated from umbilical
cord blood were co-cultured with CTB, INS, GAD, CTB-INS, CTB-GAD35 or
PMA+Ionomycin, following initial stimulation of the naïve T cells with
PMA+Ionomycin +antiCD3/CD28 antibodies for 48 hrs. Monensin (0.3 µM), was added
to each cell culture sample during the last 8 hrs of incubation to permit accumulation of
cytokine levels within the DC incubated T cells prior to flow cytometric measurements of
sequestered T cell cytokine levels. (A) The overlapping histograms show T cell
populations synthesizing IL-10, TGF-β, IFN-γ, IL-2 and IL-17 cytokines following T cell
incubation with DCs previously inoculated with CTB, INS, GAD, CTB-INS, CTBGAD35 or PMA+Ionomycin in comparison with the control cultures (T cells incubated
with immature DCs). The CTB-INS and CTB-GAD35 stimulated T cell samples
synthesized significantly higher amounts of immunosuppressive IL-10 and TGF-β
cytokines (p<0.05) and significantly diminished amounts of proinflammatory IFN-γ, IL-2
and IL-17 (p<0.05). (B) The graphs indicate
mean fluorescence intensity levels
representing T cell biosynthesis of IL-10, TGF-β, IFN-γ, IL-2 and IL-17 cytokines
following their incubation with DCs inoculated with the autoantigen fusion proteins
described above. Statistical significance among the T cell cultures was calculated based
on P<0.05.
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Discussion
Previous studies have demonstrated the major role played by DCs in the induction
and maintenance of immune tolerance (Steinman, Turley et al. 2000; Wakkach, Fournier
et al. 2003). The results of our previous CTB-INS animal studies have established a
molecular basis for CTB-INS and CTB-GAD35 fusion proteins in suppression of Type 1
diabetes (T1D) onset in NOD mice (Denes, Krausova et al. 2005; Gong, Jin et al. 2007;
Gong, Long et al. 2009). In these studies, we demonstrated that the fusion of CTB protein
to the autoantigen was required to achieve a dramatic enhancement of immune
suppression. Following these animal studies, our human ex vivo studies revealed that codelivery of CTB + the autoantigen did not result in a significant inhibition of DC
activation and maturation (Odumosu, Payne et al. 2010). Taken together our
experimental findings suggest that linkage of CTB to the autoantigen is key to the
identification of the mechanism underlying adjuvant-enhanced autoantigen mediated
immunological tolerance. However, cellular and molecular mechanisms underlying
multi-component vaccine suppression of T1D remain unidentified. The dominant role of
DCs in the decision required to induce inflammation or to activate immunotolerance
implicates this APC resides at the point of earliest initiation of CTB-autoantigen
mediated suppression of diabetes onset. To confirm this observation, we assessed the
interaction and outcome of CTB-autoantigen stimulated DCs on naïve T cells. Our
experimental data suggests that CTB-autoantigen inoculated DCs induce the ex vivo
differentiation of IL-10 and TGF-β producing T cells that possess limited proliferative
capacity. This experimental result is in agreement with previous experiments describing
the immunosuppressive nature of Th2 and regulatory Tr1 and Th3 cells (Levings, Gregori
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et al. 2005; Battaglia, Stabilini et al. 2006; Roncarolo, Gregori et al. 2006).
In this ex vivo study, human monocyte-derived DCs incubated with CTBautoantigen fusion proteins generate Tregs from CD3+ T cells. In comparison with Tregs
incubated directly with INS or GAD35 autoantigens alone, T cells incubated with CTBINS/GAD inoculated DCs generated more than a 2.5 fold increase in proliferation
compared to control samples and PMA+Ionomycin inoculated samples. These
experimentally identified immunosuppressive properties are in agreement with those
described for the performance and functions of Tr1 and Th3 regulatory T cells.
Traditionally, a marker for specific identification of Tregs is expression of the
forkhead box transcription factor (FOX) P3, possibly because foxp3 gene transfer was
shown to convert naïve CD4+CD25- T cells into functional regulatory T cell populations
(Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003; Khattri, Cox et al. 2003). While
FOXP3 protein biosynthesis can be used to quantify Treg populations and assess their
purity, FOXP3 is an intracellular protein that requires cell fixation and permeabilization
prior to detection. This requirement makes it impossible to use FOXP3 as a marker for
identification of live Treg cell populations for functional studies. Of particular interest
would be the identification of a cell surface marker that correlates with FOXP3 and
represents a specific marker for regulatory T cells that is independent of Treg CD25
expression. Earlier reports by Liu et al. in 2006 (Liu, Putnam et al. 2006) and Seddiki et
al (2006) showed that differential expression of CD127 (the α-chain of the IL-7 receptor)
enables separation of human CD4+CD25+CD127- Tregs based on flow cytometry. Both
studies indicated that CD127- cells were FOXP3 positive in human peripheral blood and
that CD127 was a better marker than CD25 in mice, with most CD4+Foxp3 Treg cells
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having a CD127- phenotype. In addition, the functional immunosuppressive activity of
CD127- Treg populations and its absence in the presence of the CD127+ marker protein
was also clearly demonstrated (Liu, Putnam et al. 2006). In this study, we have identified
Treg cell populations based on flow cytometric identification of the CD4+CD25+CD127phenotype, the cytokines that they synthesize and their proliferative capacity (a sign of
their expansion in response to DC activation). In confirmation of the observations of
Seddiki and Liu, the CD4+CD25+CD127- Treg populations analyzed in our study were
also found to be Foxp3+ (data not shown).
Several observations suggest that Tr1 cells are involved in CTB-INS/GAD
maintenance of DC –T cell mediated peripheral tolerance ex vivo. Certain regulatory T
cell subsets (Tr1) play an important role in modulating immune responses during the
progression of autoimmunity, based on the reduction in IL-10 producing CD4+ cells
observed in the synovial tissue and peripheral blood of rheumatoid arthritis and
autoimmune hemolytic anemia patients (Yudoh, Matsuno et al. 2000; Hall, Ward et al.
2002).
Perhaps the most significant class of novel effector cell types involved in both
human and mouse organ specific autoimmunity models are the recently identified Th17
cells that secrete the pro-inflammatory cytokine IL-17 (Fujino, Andoh et al. 2003; Nakae,
Nambu et al. 2003; Komiyama, Nakae et al. 2006). This inflammatory cytokine was first
detected in the serum and tissues of patients with autoimmune diseases such as multiple
sclerosis (MS), systemic lupus erythematous (SLE) and rheumatoid arthritis (RA) (Wong,
Ho et al. 2000; Tzartos, Friese et al. 2008). Blockade of IL-17 was shown to prevent the
development of Experimental Autoimmune Encephalitis (EAE ), while IL-17 knockout
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mice showed resistance to the development of EAE and collagen-induced arthritis (CIA)
(Nakae, Nambu et al. 2003; Hofstetter, Ibrahim et al. 2005). These experimental results
suggest that regulation of Th17 differentiation and function may prove to be a potential
therapeutic target for organ specific autoimmune diseases. Our recent experiments
identified CTB-GAD35 suppression of DC synthesis and secretion of IL-6, a pleiotropic
cytokine involved in regulating the balance of IL-17 producing Th17 cells and Treg cells
(Bettelli, Carrier et al. 2006; Mangan, Harrington et al. 2006). Further, IL-6 was found to
be an effective target for down-regulating the differentiation of Th17 cells as a
therapeutic treatment for autoimmunity (Nishimoto, Terao et al. 2008; Yokota, Imagawa
et al. 2008). In this study, our experimental findings demonstrate that CTB-INS and
CTB-GAD35 suppress T cell biosynthesis of IL-17. This experimental result in
combination with CTB-GAD35 inhibition of DC IL-6 biosynthesis may be critical
elements in the elucidation of cellular mechanisms responsible for CTB-autoantigen
mediated immune suppression of T1D autoimmunity.
In conclusion, this study supports the hypothesis that CTB-autoantigen fusion
protein modulated DCs stimulate the morphogenesis of immunosuppressive human T
cells ex vivo, largely through inhibition of DC maturation, synthesis of inflammatory
cytokines and by stimulation of DC biosynthesis of anti-inflammatory cytokines.
Although many experimental strategies have been adopted to induce or expand
immunosuppressive cells to inhibit the immune responses underlying autoimmune
pathologies, immunological tolerance can be maintained by selected adjuvant autoantigen
fusion vaccine administration through the induction of the anti-inflammatory cytokine IL10 (Arakawa, Chong et al. 1998). In a separate in vivo study, our laboratory recently
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demonstrated that a combinatorial therapy of CTB-GAD35 + IL-10 is able to completely
suppress the onset of type 1 diabetes in NOD mice (Denes, Fodor et al. 2010). Our
experimental results suggest that ex vivo inoculation of human DCs with adjuvant –
diabetes autoantigen fusion proteins favors immunological suppression of diabetes onset
and suggests that mechanisms of immunological tolerance responsible for multicomponent vaccine suppression of diabetes onset are comparable in humans and animals
and most importantly provides a readily available ex vivo experimental system closely
resembling in vivo conditions for analysis of improved therapeutic strategies for
resolution of human diabetes autoimmunity. Experiments involving CTB-INS/GAD
vaccine suppression of previously activated DCs may provide ex vivo evidence that the
progression of human T1D can be safely halted to re-establish immunological
homeostasis and thereby set the stage for pancreatic stem cell repopulation of the islets of
Langerhans with insulin secreting “beta-like” cells that may persistently alleviate T1D in
human patients.
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CHAPTER 5
CONCLUSIONS
The establishment of individual autoantigen mediated immunotolerization
strategies has provided a basis for assembly of individual therapeutic molecular
components into a multi-component vaccine for immunological suppression of Type 1
Diabetes (T1D). These multi-component vaccine strategies appear at first glance to be
safer, more effective in immune suppression and more durable than application of the
individual vaccine components alone. Early experimentation with individual molecular
therapeutic strategies was shown to provide short-term suppression of organ specific
autoimmunity (Weiner, Zhang et al. 1991; Zhang, Davidson et al. 1991). However, few
of these individual therapies were shown to demonstrate effective, safe and persistent
protection against disease onset and progression (Hutchings and Cooke 1998). When
linked to a pathogen or foreign antigen, the weak protein adjuvant cholera toxin B
subunit (CTB) was often found to stimulate antigen-specific mucosal immunity and to
strengthen immune responses against pathogen proteins. Experimental evidence
suggested that CTB stimulation of innate immunity was initiated through activation of
immature dendritic cell (iDC) signal transduction pathways that lead to DC maturation.
The stimulation of DC maturation by CTB resulted in DC synthesis and secretion of
inflammatory cytokines and chemokines such as IFN-γ, IL-2 and CTLA4 responsible for
DC migration to the spleen or peripheral lymph nodes where DC secreted inflammatory
cytokines that assisted in the guidance of cognate naïve Th0 helper cell differentiation
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into immunostimulatory effector Th1 lymphocytes and cytotoxic T cells.
However, when CTB was linked to an autoantigen such as insulin in T1D, it often
stimulated autoantigen mediated suppression of organ specific autoimmunity many fold,
achieving levels of immunological tolerance approaching that required for clinical
intervention. This exception of CTB–autoantigen fusion protein enhancement of immune
suppression to the expected paradigm of enhanced immunity emphasizes the novelty of
the CTB as an immunomodulatory molecule for development of therapeutic vaccines.
These apparent counter-intuitive attributes emphasize the extent to which the mechanisms
underlying CTB stimulation and suppression of immunity remain as yet under studied.
Combinatorial vaccines involving oral delivery of the CTB linked to pancreatic
autoantigens such as proinsulin and GAD, were shown to provide significant increases in
enhancement of autoantigen mediated suppression of Type 1 diabetes symptoms in
contrast with inoculation of prediabetic mice with glutamic acid decarboxylase (GAD) or
proinsulin alone (Arakawa, Chong et al. 1998). More recent combinatorial DNA
vaccination experiments including genes encoding CTB-GAD in combination with the
immunosuppressive cytokine IL-10 have demonstrated complete suppression of diabetes
onset in non-obese prediabetic (NOD) mouse model of T1D. Thus, it is now clear that
combinatorial vaccination strategies can completely prevent diabetes onset in genetically
susceptible mammals with no detectable undesirable effects. The experimental studies
presented here emphasize the possibilities for increased vaccine effectiveness in
suppression of diabetes onset based on the development of combinatorial vaccination
strategies.
In chapters 2 and 3 of this dissertation, the experimental data suggest that fusion
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of CTB to autoantigens appears to activate genes that stimulate DC synthesis of antiinflammatory cytokines such as IL-10 that suppresses DC maturation in combination
with inhibition of DC biosynthesis of co-stimulatory factors CD86, CD83 and CD80
required for naïve Th lymphocyte activation. Further, CTB-autoantigen fusion protein
inoculated DCs were shown to secrete reduced levels of inflammatory cytokines IL-12
and IL-6 while at the same time upregulating biosynthesis of the anti-inflammatory
cytokine IL-10. In chapter 4, the incubation of DCs with adjuvant-autoantigen fusion
proteins was found to enhance their guidance of naïve Th0 cell morphogenesis and
proliferation into anti-inflammatory Th2 lymphocytes and regulatory T cells capable of
inhibiting diabetes onset. In addition, it became clear from the cytokine analysis studies
that multi-component vaccine suppression of DC maturation lead to the suppression of
autoreactive Th1 and Th17 inflammatory lymphocyte development, suppressing their
potential for initiation of T1D insulitis and hyperglycemia. These ex vivo human immune
cell vaccination experiments establish a basis for identification of mechanisms
responsible for vaccine inhibition of human diabetes progression and the way for in vivo
analysis of multicomponent vaccine strategies for rescuing the large numbers of diabetes
patients in which the disease has already progressed to hyperglycemia,
Further, these experiments establish a basis for development of safer and more
effective treatments for supplementation or replacement of current nonspecific
immunosuppressants, anti-inflammatory steroids or interventional therapies like islet
transplantation, which can increase patient vulnerability to infection and other
complications. These experiments provide a basis for development of safer and more
effective vaccine strategies for preventing diabetes onset and progression in patients that
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can lead to restoration of immunological homeostasis and euglycemia in T1D patients.
Several studies have reported that oral administration of autoantigens may
actually exacerbate autoimmune disease (Genain, Abel et al. 1996; Bellmann, Kolb et al.
1998; Blanas and Heath 1999). Although no instances of autoimmune disease have been
reported following application of recombinant protein, experiments remain to be
performed that will determine the optimum dose and frequency of immuno-modulated
autoantigen delivery required to achieve the maximum protective efficacy.
An immediate major benefit of CTB adjuvant enhanced vaccine technology
presented in this dissertation will be delivery of mucosal subunit vaccines for protection
of populations in countries suffering health care disparities. To this end, our group has
focused on a promising approach to the production of an autoimmune disease protective
vaccine generated in edible transgenic plants (Carter, Odumosu et al. ; Chong, Roberts et
al. 1997; Arakawa, Yu et al. 1998; Arakawa, Yu et al. 1999). One of the major limitations
of this is the possibility for initiation of autoimmune disease symptoms in disease-free
individuals who accidentally consume autoantigens linked to a strong bacterial adjuvant.
Ethical issues regarding recombinant DNA mediated immunotherapy are more likely to
subside as the public becomes more adequately informed concerning the safety of
genetically modified organisms (GMO). With each successful clinical trial, confidence
in the expediency of using edible vaccines for disease prevention in the population will
increase in the scientific, corporate and private sectors.
Nonetheless, the molecular and biochemical studies presented within this doctoral
dissertation, demonstrate that CTB-INS/GAD suppression of autoimmune responses
provides a basis for development of pluripotent adult or totipotent embryonic stem cell
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repopulation of the pancreas with insulin producing beta cells for restoration of
euglycemia and return of the T1D patient to a durable state of immunological
homeostasis. The further establishment of complete immune suppression of diabetes will
help to ensure both preventive and interventional therapy for T1Din patients suffering
from this life-long chronic inflammatory autoimmune disease. This application in
combinatorial vaccination protocols may prove to be a plausible direction for effective
immune suppression of additional organ-specific autoimmune diseases such as, Graves's
disease, Hashimoto’s thyroiditis, rheumatoid arthritis, multiple sclerosis, myasthenia
gravis and uveitis.

174

REFERENCES
The DIAMOND Group: Incidence and trends of childhood Type 1 diabetes worldwide
1990-1999. Diabet Med. 23: 857-866.
Acosta-Rodriguez, E. V., G. Napolitani, et al. (2007). "Interleukins 1beta and 6 but not
transforming growth factor-beta are essential for the differentiation of interleukin 17producing human T helper cells." Nat Immunol 8(9): 942-949.
Afzali, B., G. Lombardi, et al. (2007). "The role of T helper 17 (Th17) and regulatory T
cells (Treg) in human organ transplantation and autoimmune disease." Clin Exp
Immunol 148(1): 32-46.
Agrawal S, A. A., Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B ( 2003).
"Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce
distinct Th responses via differential modulation of extracellular signal-regulated
kinase-mitogen-activated protein kinase and c-Fos.J " Immunology 5(171(10)): 49844989.
Akira, S. and H. Hemmi (2003). "Recognition of pathogen-associated molecular patterns
by TLR family." Immunol Lett 85(2): 85-95.
Akira, S. and K. Takeda (2004). "Toll-like receptor signalling." Nat Rev Immunol 4(7):
499-511.
Alyanakian, M. A., F. Grela, et al. (2006). "Transforming growth factor-beta and natural
killer T-cells are involved in the protective effect of a bacterial extract on type 1
diabetes." Diabetes 55(1): 179-185.
Anderson, M. S. and J. A. Bluestone (2005). "The NOD mouse: a model of immune
dysregulation." Annu Rev Immunol 23: 447-485.
Arakawa, T., D. K. Chong, et al. (1998). "Efficacy of a food plant-based oral cholera
toxin B subunit vaccine." Nat Biotechnol 16(3): 292-297.
Arakawa, T., J. Yu, et al. (1998). "A plant-based cholera toxin B subunit-insulin fusion
protein protects against the development of autoimmune diabetes." Nat Biotechnol
16(10): 934-938.
Arakawa, T., J. Yu, et al. (1999). "Food plant-delivered cholera toxin B subunit for
vaccination and immunotolerization." Adv Exp Med Biol 464: 161-178.
Arden, S. D., B. O. Roep, et al. (1996). "Imogen 38: a novel 38-kD islet mitochondrial
175

autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient." J
Clin Invest 97(2): 551-561.
Aspord, C. and C. Thivolet (2002). "Nasal administration of CTB-insulin induces active
tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice." Clin Exp
Immunol 130(2): 204-211.
Atkinson, M. A., M. A. Bowman, et al. (1994). "Cellular immunity to a determinant
common to glutamate decarboxylase and coxsackie virus in insulin-dependent
diabetes." J Clin Invest 94(5): 2125-2129.
Atkinson, M. A. and E. H. Leiter (1999). "The NOD mouse model of type 1 diabetes: as
good as it gets?" Nat Med 5(6): 601-604.
Atkinson, M. A. and N. K. Maclaren (1994). "The pathogenesis of insulin-dependent
diabetes mellitus." N Engl J Med 331(21): 1428-1436.
Bach, J. F. (2005). "A Toll-like trigger for autoimmune disease." Nat Med 11(2): 120121.
Baekkeskov, S., H. J. Aanstoot, et al. (1990). "Identification of the 64K autoantigen in
insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid
decarboxylase." Nature 347(6289): 151-156.
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity."
Nature 392(6673): 245-252.
Barrett, J. C., D. G. Clayton, et al. (2009). "Genome-wide association study and metaanalysis find that over 40 loci affect risk of type 1 diabetes." Nat Genet.
Battaglia, M., A. Stabilini, et al. (2006). "Induction of tolerance in type 1 diabetes via
both CD4+CD25+ T regulatory cells and T regulatory type 1 cells." Diabetes 55(6):
1571-1580.
Bauer, S., C. J. Kirschning, et al. (2001). "Human TLR9 confers responsiveness to
bacterial DNA via species-specific CpG motif recognition." Proc Natl Acad Sci U S
A 98(16): 9237-9242.
Bellmann, K., H. Kolb, et al. (1998). "Potential risk of oral insulin with adjuvant for the
prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate
disease in BB rats." Diabetologia 41(7): 844-847.
Bending, D., H. De La Pena, et al. (2009). "Highly purified Th17 cells from
BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice." J Clin
Invest.
Bergerot, I., C. Ploix, et al. (1997). "A cholera toxoid-insulin conjugate as an oral vaccine
against spontaneous autoimmune diabetes." Proc Natl Acad Sci U S A 94(9): 4610-

176

4614.
Bettelli, E., Y. Carrier, et al. (2006). "Reciprocal developmental pathways for the
generation of pathogenic effector TH17 and regulatory T cells." Nature 441(7090):
235-238.
Bettelli, E., M. Oukka, et al. (2007). "T(H)-17 cells in the circle of immunity and
autoimmunity." Nat Immunol 8(4): 345-350.
Bettelli, E., B. Sullivan, et al. (2004). "Loss of T-bet, but not STAT1, prevents the
development of experimental autoimmune encephalomyelitis." J Exp Med 200(1):
79-87.
Beutler, B., Z. Jiang, et al. (2006). "Genetic analysis of host resistance: Toll-like receptor
signaling and immunity at large." Annu Rev Immunol 24: 353-389.
Bitar, D. M. and C. C. Whitacre (1988). "Suppression of experimental autoimmune
encephalomyelitis by the oral administration of myelin basic protein." Cell Immunol
112(2): 364-370.
Blanas, E. and W. R. Heath (1999). "Oral administration of antigen can lead to the onset
of autoimmune disease." Int Rev Immunol 18(3): 217-228.
Bonifacio, E., V. Lampasona, et al. (1995). "Identification of protein tyrosine
phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related
37/40K autoantigen and a target of islet-cell antibodies." J Immunol 155(11): 54195426.
Bradshaw, E. M., K. Raddassi, et al. (2009). "Monocytes from patients with type 1
diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells." J
Immunol 183(7): 4432-4439.
Bromley, S. K., A. Iaboni, et al. (2001). "The immunological synapse and CD28-CD80
interactions." Nat Immunol 2(12): 1159-1166.
Buenafe, A. C. and D. N. Bourdette (2007). "Lipopolysaccharide pretreatment modulates
the disease course in experimental autoimmune encephalomyelitis." J Neuroimmunol
182(1-2): 32-40.
Camberg, J. L., T. L. Johnson, et al. (2007). "Synergistic stimulation of EpsE ATP
hydrolysis by EpsL and acidic phospholipids." EMBO J 26(1): 19-27.
Camberg, J. L. and M. Sandkvist (2005). "Molecular analysis of the Vibrio cholerae type
II secretion ATPase EpsE." J Bacteriol 187(1): 249-256.
Cardell, S. L. (2006). "The natural killer T lymphocyte: a player in the complex
regulation of autoimmune diabetes in non-obese diabetic mice." Clin Exp Immunol
143(2): 194-202.

177

Carnevali, C., A. Bonati, et al. (1980). "[Evaluation of the proliferative activity of
hematopoietic cells in preleukemic syndromes]." Ateneo Parmense Acta Biomed
51(3): 181-185.
Carreno, B. M. and M. Collins (2002). "The B7 family of ligands and its receptors: new
pathways for costimulation and inhibition of immune responses." Annu Rev Immunol
20: 29-53.
Carter, J. E., 3rd, O. Odumosu, et al. "Expression of a ricin toxin B subunit: insulin
fusion protein in edible plant tissues." Mol Biotechnol 44(2): 90-100.
Carter, J. E., 3rd, J. Yu, et al. (2006). "Bacterial and plant enterotoxin B subunitautoantigen fusion proteins suppress diabetes insulitis." Mol Biotechnol 32(1): 1-15.
Castano, L., E. Russo, et al. (1991). "Identification and cloning of a granule autoantigen
(carboxypeptidase-H) associated with type I diabetes." J Clin Endocrinol Metab
73(6): 1197-1201.
Caux, C., C. Massacrier, et al. (1997). "CD34+ hematopoietic progenitors from human
cord blood differentiate along two independent dendritic cell pathways in response to
GM-CSF+TNF alpha." Adv Exp Med Biol 417: 21-25.
Chaillous, L., H. Lefevre, et al. (2000). "Oral insulin administration and residual beta-cell
function in recent-onset type 1 diabetes: a multicentre randomised controlled trial.
Diabete Insuline Orale group." Lancet 356(9229): 545-549.
Chinnapen, D. J., H. Chinnapen, et al. (2007). "Rafting with cholera toxin: endocytosis
and trafficking from plasma membrane to ER." FEMS Microbiol Lett 266(2): 129137.
Chitnis, T., N. Najafian, et al. (2001). "Effect of targeted disruption of STAT4 and
STAT6 on the induction of experimental autoimmune encephalomyelitis." J Clin
Invest 108(5): 739-747.
Chong, D. K., W. Roberts, et al. (1997). "Expression of the human milk protein betacasein in transgenic potato plants." Transgenic Res 6(4): 289-296.
Ciric, B., M. El-behi, et al. (2009). "IL-23 drives pathogenic IL-17-producing CD8+ T
cells." J Immunol 182(9): 5296-5305.
Collins, M., V. Ling, et al. (2005). "The B7 family of immune-regulatory ligands."
Genome Biol 6(6): 223.
Connell, T. D., D. J. Metzger, et al. (1995). "Initial studies of the structural signal for
extracellular transport of cholera toxin and other proteins recognized by Vibrio
cholerae." Infect Immun 63(10): 4091-4098.
Czerkinsky, C., F. Anjuere, et al. (1999). "Mucosal immunity and tolerance: relevance to

178

vaccine development." Immunol Rev 170: 197-222.
Czerkinsky, C., J. B. Sun, et al. (1996). "Cholera toxin B subunit as transmucosal carrierdelivery and immunomodulating system for induction of antiinfectious and
antipathological immunity." Ann N Y Acad Sci 778: 185-193.
D'Ambrosio, A., M. Colucci, et al. (2008). "Cholera toxin B subunit promotes the
induction of regulatory T cells by preventing human dendritic cell maturation." J
Leukoc Biol 84(3): 661-668.
Davis, B. M., E. H. Lawson, et al. (2000). "Convergence of the secretory pathways for
cholera toxin and the filamentous phage, CTXphi." Science 288(5464): 333-335.
De Cosa, B., W. Moar, et al. (2001). "Overexpression of the Bt cry2Aa2 operon in
chloroplasts leads to formation of insecticidal crystals." Nat Biotechnol 19(1): 71-74.
de Saint-Vis, B., I. Fugier-Vivier, et al. (1998). "The cytokine profile expressed by
human dendritic cells is dependent on cell subtype and mode of activation." J
Immunol 160(4): 1666-1676.
De Smedt, T., E. Butz, et al. (2001). "CD8alpha(-) and CD8alpha(+) subclasses of
dendritic cells undergo phenotypic and functional maturation in vitro and in vivo." J
Leukoc Biol 69(6): 951-958.
de Waal Malefyt, R., J. Abrams, et al. (1991). "Interleukin 10(IL-10) inhibits cytokine
synthesis by human monocytes: an autoregulatory role of IL-10 produced by
monocytes." J Exp Med 174(5): 1209-1220.
Denes, B., I. Fodor, et al. (2010). "Autoantigens plus interleukin-10 suppress diabetes
autoimmunity." Diabetes Technol Ther 12(8): 649-661.
Denes, B., V. Krausova, et al. (2005). "Protection of NOD mice from type 1 diabetes
after oral inoculation with vaccinia viruses expressing adjuvanted islet autoantigens."
J Immunother 28(5): 438-448.
Denes, B., J. Yu, et al. (2006). "Suppression of hyperglycemia in NOD mice after
inoculation with recombinant vaccinia viruses." Mol Biotechnol 34(3): 317-327.
Deng, G. M., I. M. Nilsson, et al. (1999). "Intra-articularly localized bacterial DNA
containing CpG motifs induces arthritis." Nat Med 5(6): 702-705.
Devaraj, S., M. R. Dasu, et al. (2008). "Increased toll-like receptor (TLR) 2 and TLR4
expression in monocytes from patients with type 1 diabetes: further evidence of a
proinflammatory state." J Clin Endocrinol Metab 93(2): 578-583.
Devaraj, S., N. Glaser, et al. (2006). "Increased monocytic activity and biomarkers of
inflammation in patients with type 1 diabetes." Diabetes 55(3): 774-779.

179

Di Lorenzo, T. P., M. Peakman, et al. (2007). "Translational mini-review series on type 1
diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes." Clin Exp
Immunol 148(1): 1-16.
Dillon, S., A. Agrawal, et al. (2004). "A Toll-like receptor 2 ligand stimulates Th2
responses in vivo, via induction of extracellular signal-regulated kinase mitogenactivated protein kinase and c-Fos in dendritic cells." J Immunol 172(8): 4733-4743.
Drescher, K. M. and S. M. Tracy (2008). "The CVB and etiology of type 1 diabetes."
Curr Top Microbiol Immunol 323: 259-274.
Eisenbarth, G. S. (1986). "Type I diabetes mellitus. A chronic autoimmune disease." N
Engl J Med 314(21): 1360-1368.
Elliott, J. F., H. Y. Qin, et al. (1994). "Immunization with the larger isoform of mouse
glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice."
Diabetes 43(12): 1494-1499.
Elyaman, W., E. M. Bradshaw, et al. (2009). "IL-9 induces differentiation of TH17 cells
and enhances function of FoxP3+ natural regulatory T cells." Proc Natl Acad Sci U S
A 106(31): 12885-12890.
Emamaullee, J. A., J. Davis, et al. (2009). "Inhibition of Th17 cells regulates autoimmune
diabetes in NOD mice." Diabetes 58(6): 1302-1311.
Eriksson, K. and J. Holmgren (2002). "Recent advances in mucosal vaccines and
adjuvants." Curr Opin Immunol 14(5): 666-672.
Facciabene, A., L. Aurisicchio, et al. (2007). "Vectors encoding carcinoembryonic
antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific
immune responses and antitumor effects." Vaccine 26(1): 47-58.
Faustman, D., X. P. Li, et al. (1991). "Linkage of faulty major histocompatibility
complex class I to autoimmune diabetes." Science 254(5039): 1756-1761.
Faustman, D. L. and M. Davis (2009). "The primacy of CD8 T lymphocytes in type 1
diabetes and implications for therapies." J Mol Med 87(12): 1173-1178.
Fensterle, J., B. Bergmann, et al. (2008). "Cancer immunotherapy based on recombinant
Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific
antigen and cholera toxin subunit B." Cancer Gene Ther 15(2): 85-93.
Figdor, C. G., I. J. de Vries, et al. (2004). "Dendritic cell immunotherapy: mapping the
way." Nat Med 10(5): 475-480.
Fontenot, J. D., M. A. Gavin, et al. (2003). "Foxp3 programs the development and
function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4): 330-336.

180

Fujino, S., A. Andoh, et al. (2003). "Increased expression of interleukin 17 in
inflammatory bowel disease." Gut 52(1): 65-70.
Genain, C. P., K. Abel, et al. (1996). "Late complications of immune deviation therapy in
a nonhuman primate." Science 274(5295): 2054-2057.
George-Chandy, A., K. Eriksson, et al. (2001). "Cholera toxin B subunit as a carrier
molecule promotes antigen presentation and increases CD40 and CD86 expression on
antigen-presenting cells." Infect Immun 69(9): 5716-5725.
Gilkeson, G. S., P. Ruiz, et al. (1996). "Modulation of renal disease in autoimmune
NZB/NZW mice by immunization with bacterial DNA." J Exp Med 183(4): 13891397.
Gillespie, K. M., S. C. Bain, et al. (2004). "The rising incidence of childhood type 1
diabetes and reduced contribution of high-risk HLA haplotypes." Lancet 364(9446):
1699-1700.
Gogolak, P., B. Rethi, et al. (2003). "Targeting dendritic cells for priming cellular
immune responses." J Mol Recognit 16(5): 299-317.
Gong, Z., Y. Jin, et al. (2007). "Suppression of diabetes in non-obese diabetic (NOD)
mice by oral administration of a cholera toxin B subunit-insulin B chain fusion
protein vaccine produced in silkworm." Vaccine 25(8): 1444-1451.
Gong, Z., X. Long, et al. (2009). "Cloning, expression, purification and characterization
of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion
protein in Escherichia coli." Protein Expr Purif 66(2): 191-197.
Gorus, F. K., P. Goubert, et al. (1997). "IA-2-autoantibodies complement GAD65autoantibodies in new-onset IDDM patients and help predict impending diabetes in
their siblings. The Belgian Diabetes Registry." Diabetologia 40(1): 95-99.
Greenbaum, C. J., J. P. Palmer, et al. (1992). "Insulin autoantibodies measured by
radioimmunoassay methodology are more related to insulin-dependent diabetes
mellitus than those measured by enzyme-linked immunosorbent assay: results of the
Fourth International Workshop on the Standardization of Insulin Autoantibody
Measurement." J Clin Endocrinol Metab 74(5): 1040-1044.
Grimbaldeston, M. A., S. Nakae, et al. (2007). "Mast cell-derived interleukin 10 limits
skin pathology in contact dermatitis and chronic irradiation with ultraviolet B." Nat
Immunol 8(10): 1095-1104.
Grutz, G. (2005). "New insights into the molecular mechanism of interleukin-10mediated immunosuppression." J Leukoc Biol 77(1): 3-15.
Guermonprez, P., J. Valladeau, et al. (2002). "Antigen presentation and T cell stimulation
by dendritic cells." Annu Rev Immunol 20: 621-667.

181

Guidry, J. J., L. Cardenas, et al. (1997). "Role of receptor binding in toxicity,
immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin." Infect
Immun 65(12): 4943-4950.
Hackstein, H. and A. W. Thomson (2004). "Dendritic cells: emerging pharmacological
targets of immunosuppressive drugs." Nat Rev Immunol 4(1): 24-34.
Hajishengallis, G., R. I. Tapping, et al. (2005). "Toll-like receptor 2 mediates cellular
activation by the B subunits of type II heat-labile enterotoxins." Infect Immun 73(3):
1343-1349.
Hall, A. M., F. J. Ward, et al. (2002). "Interleukin-10-mediated regulatory T-cell
responses to epitopes on a human red blood cell autoantigen." Blood 100(13): 45294536.
Hamada, H., L. Garcia-Hernandez Mde, et al. (2009). "Tc17, a unique subset of CD8 T
cells that can protect against lethal influenza challenge." J Immunol 182(6): 34693481.
Han, B., P. Serra, et al. (2005). "Developmental control of CD8 T cell-avidity maturation
in autoimmune diabetes." J Clin Invest 115(7): 1879-1887.
Han, G., Y. Li, et al. (2005). "Active tolerance induction and prevention of autoimmune
diabetes by immunogene therapy using recombinant adenoassociated virus expressing
glutamic acid decarboxylase 65 peptide GAD(500-585)." J Immunol 174(8): 45164524.
Hardy, S. J., J. Holmgren, et al. (1988). "Coordinated assembly of multisubunit proteins:
oligomerization of bacterial enterotoxins in vivo and in vitro." Proc Natl Acad Sci U
S A 85(19): 7109-7113.
Harizi, H. and N. Gualde (2006). "Pivotal role of PGE2 and IL-10 in the cross-regulation
of dendritic cell-derived inflammatory mediators." Cell Mol Immunol 3(4): 271-277.
Harrington, L. E., R. D. Hatton, et al. (2005). "Interleukin 17-producing CD4+ effector T
cells develop via a lineage distinct from the T helper type 1 and 2 lineages." Nat
Immunol 6(11): 1123-1132.
Hart, D. N. (1997). "Dendritic cells: unique leukocyte populations which control the
primary immune response." Blood 90(9): 3245-3287.
Haskins, K., M. Portas, et al. (1988). "T-lymphocyte clone specific for pancreatic islet
antigen." Diabetes 37(10): 1444-1448.
Haverkos, H. W., N. Battula, et al. (2003). "Enteroviruses and type 1 diabetes mellitus."
Biomed Pharmacother 57(9): 379-385.
Hemmi, H., O. Takeuchi, et al. (2000). "A Toll-like receptor recognizes bacterial DNA."

182

Nature 408(6813): 740-745.
Herold, K. C., W. Hagopian, et al. (2002). "Anti-CD3 monoclonal antibody in new-onset
type 1 diabetes mellitus." N Engl J Med 346(22): 1692-1698.
Higgins, P. J. and H. L. Weiner (1988). "Suppression of experimental autoimmune
encephalomyelitis by oral administration of myelin basic protein and its fragments." J
Immunol 140(2): 440-445.
Hirst, T. R., J. Sanchez, et al. (1984). "Mechanism of toxin secretion by Vibrio cholerae
investigated in strains harboring plasmids that encode heat-labile enterotoxins of
Escherichia coli." Proc Natl Acad Sci U S A 81(24): 7752-7756.
Hoebe, K., Z. Jiang, et al. (2006). "TLR signaling pathways: opportunities for activation
and blockade in pursuit of therapy." Curr Pharm Des 12(32): 4123-4134.
Hofstetter, H. H., S. M. Ibrahim, et al. (2005). "Therapeutic efficacy of IL-17
neutralization in murine experimental autoimmune encephalomyelitis." Cell Immunol
237(2): 123-130.
Holmgren, J., J. Adamsson, et al. (2005). "Mucosal adjuvants and anti-infection and antiimmunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG
DNA." Immunol Lett 97(2): 181-188.
Holmgren, J., L. Lindholm, et al. (1974). "Interaction of cholera toxin and toxin
derivatives with lymphocytes. I. Binding properties and interference with lectininduced cellular stimulation." J Exp Med 139(4): 801-819.
Holmgren, J., I. Lonnroth, et al. (1975). "Interaction of cholera toxin and membrane GM1
ganglioside of small intestine." Proc Natl Acad Sci U S A 72(7): 2520-2524.
Holmgren, J., I. Lonnroth, et al. (1973). "Tissue receptor for cholera exotoxin: postulated
structure from studies with GM1 ganglioside and related glycolipids." Infect Immun
8(2): 208-214.
Hommann, M., U. Schotte, et al. (2001). "[HELLP Syndrome as an indication for liver
transplantation]." Gynakol Geburtshilfliche Rundsch 41(1): 8-11.
Hori, S., T. Nomura, et al. (2003). "Control of regulatory T cell development by the
transcription factor Foxp3." Science 299(5609): 1057-1061.
Hutchings, P. and A. Cooke (1998). "Protection from insulin dependent diabetes mellitus
afforded by insulin antigens in incomplete Freund's adjuvant depends on route of
administration." J Autoimmun 11(2): 127-130.
Inaba, K., S. Turley, et al. (2000). "The formation of immunogenic major
histocompatibility complex class II-peptide ligands in lysosomal compartments of
dendritic cells is regulated by inflammatory stimuli." J Exp Med 191(6): 927-936.

183

Inaba, K., S. Turley, et al. (1998). "Efficient presentation of phagocytosed cellular
fragments on the major histocompatibility complex class II products of dendritic
cells." J Exp Med 188(11): 2163-2173.
Isomura, I., Y. Yasuda, et al. (2005). "Recombinant cholera toxin B subunit activates
dendritic cells and enhances antitumor immunity." Microbiol Immunol 49(1): 79-87.
Itano, A. A. and M. K. Jenkins (2003). "Antigen presentation to naive CD4 T cells in the
lymph node." Nat Immunol 4(8): 733-739.
Itano, A. A., S. J. McSorley, et al. (2003). "Distinct dendritic cell populations
sequentially present antigen to CD4 T cells and stimulate different aspects of cellmediated immunity." Immunity 19(1): 47-57.
Ivanov, II, B. S. McKenzie, et al. (2006). "The orphan nuclear receptor RORgammat
directs the differentiation program of proinflammatory IL-17+ T helper cells." Cell
126(6): 1121-1133.
Iwasaki, A. and B. L. Kelsall (2000). "Localization of distinct Peyer's patch dendritic cell
subsets and their recruitment by chemokines macrophage inflammatory protein
(MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine." J Exp Med
191(8): 1381-1394.
Jaeckel, E., L. Klein, et al. (2003). "Normal incidence of diabetes in NOD mice tolerant
to glutamic acid decarboxylase." J Exp Med 197(12): 1635-1644.
Jaeckel, E., M. A. Lipes, et al. (2004). "Recessive tolerance to preproinsulin 2 reduces
but does not abolish type 1 diabetes." Nat Immunol 5(10): 1028-1035.
Jarnicki, A. G., H. Conroy, et al. (2008). "Attenuating regulatory T cell induction by TLR
agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their
efficacy as vaccine adjuvants and cancer immunotherapeutics." J Immunol 180(6):
3797-3806.
Jiao, X., R. Lo-Man, et al. (2002). "Dendritic cells are host cells for mycobacteria in vivo
that trigger innate and acquired immunity." J Immunol 168(3): 1294-1301.
Jobling, M. G. and R. K. Holmes (2002). "Mutational analysis of ganglioside GM(1)binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits
and CTB/heat-labile enterotoxin B subunit chimeras." Infect Immun 70(3): 12601271.
Jun, H. S. and J. W. Yoon (2003). "A new look at viruses in type 1 diabetes." Diabetes
Metab Res Rev 19(1): 8-31.
Kaisho, T. and S. Akira (2001). "Dendritic-cell function in Toll-like receptor- and
MyD88-knockout mice." Trends Immunol 22(2): 78-83.

184

Kaisho, T. and S. Akira (2001). "Toll-like receptors and their signaling mechanism in
innate immunity." Acta Odontol Scand 59(3): 124-130.
Kaisho, T. and S. Akira (2002). "Toll-like receptors as adjuvant receptors." Biochim
Biophys Acta 1589(1): 1-13.
Kang, B. Y. and T. S. Kim (2006). "Targeting cytokines of the interleukin-12 family in
autoimmunity." Curr Med Chem 13(10): 1149-1156.
Kanzler, H., F. J. Barrat, et al. (2007). "Therapeutic targeting of innate immunity with
Toll-like receptor agonists and antagonists." Nat Med 13(5): 552-559.
Kapsenberg, M. L. (2003). "Dendritic-cell control of pathogen-driven T-cell
polarization." Nat Rev Immunol 3(12): 984-993.
Kasimiotis, H., M. A. Myers, et al. (2000). "Sex-determining region Y-related protein
SOX13 is a diabetes autoantigen expressed in pancreatic islets." Diabetes 49(4): 555561.
Kent, S. C., Y. Chen, et al. (2005). "Expanded T cells from pancreatic lymph nodes of
type 1 diabetic subjects recognize an insulin epitope." Nature 435(7039): 224-228.
Keymeulen, B., E. Vandemeulebroucke, et al. (2005). "Insulin needs after CD3-antibody
therapy in new-onset type 1 diabetes." N Engl J Med 352(25): 2598-2608.
Khattri, R., T. Cox, et al. (2003). "An essential role for Scurfin in CD4+CD25+ T
regulatory cells." Nat Immunol 4(4): 337-342.
Kim, N., K. C. Cheng, et al. (2001). "Oral administration of collagen conjugated with
cholera toxin induces tolerance to type II collagen and suppresses chondritis in an
animal model of autoimmune ear disease." Ann Otol Rhinol Laryngol 110(7 Pt 1):
646-654.
Knip, M. and H. Siljander (2008). "Autoimmune mechanisms in type 1 diabetes."
Autoimmun Rev 7(7): 550-557.
Kobayashi, M., N. Abiru, et al. (2007). "Altered B:9-23 insulin, when administered
intranasally with cholera toxin adjuvant, suppresses the expression of insulin
autoantibodies and prevents diabetes." J Immunol 179(4): 2082-2088.
Komiyama, Y., S. Nakae, et al. (2006). "IL-17 plays an important role in the development
of experimental autoimmune encephalomyelitis." J Immunol 177(1): 566-573.
Kondo, T., H. Takata, et al. (2009). "Cutting edge: Phenotypic characterization and
differentiation of human CD8+ T cells producing IL-17." J Immunol 182(4): 17941798.
Kukko, M., T. Kimpimaki, et al. (2005). "Dynamics of diabetes-associated autoantibodies

185

in young children with human leukocyte antigen-conferred risk of type 1 diabetes
recruited from the general population." J Clin Endocrinol Metab 90(5): 2712-2717.
Kuwano, Y., C. M. Prazma, et al. (2007). "CD83 influences cell-surface MHC class II
expression on B cells and other antigen-presenting cells." Int Immunol 19(8): 977992.
LaFrance, M. W., L. E. Kehinde, et al. (2008). "Multiple cytokine analysis in human
tears: an optimized procedure for cytometric bead-based assay." Curr Eye Res 33(7):
525-544.
Lang, K. S., M. Recher, et al. (2005). "Toll-like receptor engagement converts T-cell
autoreactivity into overt autoimmune disease." Nat Med 11(2): 138-145.
Lavelle, E. C., A. Jarnicki, et al. (2004). "Effects of cholera toxin on innate and adaptive
immunity and its application as an immunomodulatory agent." J Leukoc Biol 75(5):
756-763.
Lavelle, E. C., E. McNeela, et al. (2003). "Cholera toxin promotes the induction of
regulatory T cells specific for bystander antigens by modulating dendritic cell
activation." J Immunol 171(5): 2384-2392.
Lechmann, M., S. Berchtold, et al. (2002). "CD83 on dendritic cells: more than just a
marker for maturation." Trends Immunol 23(6): 273-275.
Lechmann, M., E. Kremmer, et al. (2002). "Overexpression, purification, and
biochemical characterization of the extracellular human CD83 domain and generation
of monoclonal antibodies." Protein Expr Purif 24(3): 445-452.
Lechmann, M., E. Zinser, et al. (2002). "Role of CD83 in the immunomodulation of
dendritic cells." Int Arch Allergy Immunol 129(2): 113-118.
Lencer, W. I., C. Constable, et al. (1995). "Targeting of cholera toxin and Escherichia
coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL." J Cell
Biol 131(4): 951-962.
Levings, M. K., S. Gregori, et al. (2005). "Differentiation of Tr1 cells by immature
dendritic cells requires IL-10 but not CD25+CD4+ Tr cells." Blood 105(3): 11621169.
Levings, M. K., R. Sangregorio, et al. (2001). "IFN-alpha and IL-10 induce the
differentiation of human type 1 T regulatory cells." J Immunol 166(9): 5530-5539.
Li, F., J. Guo, et al. (1994). "Abnormal class I assembly and peptide presentation in the
nonobese diabetic mouse." Proc Natl Acad Sci U S A 91(23): 11128-11132.
Li, T., J. Zhong, et al. (2006). "Expression of chemokine-like factor 1 is upregulated
during T lymphocyte activation." Life Sci 79(6): 519-524.

186

Libby, P., D. M. Nathan, et al. (2005). "Report of the National Heart, Lung, and Blood
Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working
Group on Cardiovascular Complications of Type 1 Diabetes Mellitus." Circulation
111(25): 3489-3493.
Liu, H., A. J. MacKenzie-Graham, et al. (2001). "Mice resistant to experimental
autoimmune encephalomyelitis have increased thymic expression of myelin basic
protein and increased MBP specific T cell tolerance." J Neuroimmunol 115(1-2):
118-126.
Liu, J., H. Liao, et al. (2006). "[Regulation of the expression of interleukin-4 and
interleukin-5 by the signal pathway of PKC-NF-kappaB in T lymphocyte of allergic
rhinitis]." Lin Chuang Er Bi Yan Hou Ke Za Zhi 20(5): 197-200.
Liu, K., T. Iyoda, et al. (2002). "Immune tolerance after delivery of dying cells to
dendritic cells in situ." J Exp Med 196(8): 1091-1097.
Liu, Q. L., Y. S. Wang, et al. (2009). "Effect of insulin on functional status of cord bloodderived dendritic cells and on dendritic cell-induced CTL cytotoxicity against
pancreatic cancer cell lines." Hepatobiliary Pancreat Dis Int 8(5): 529-534.
Liu, W., A. L. Putnam, et al. (2006). "CD127 expression inversely correlates with FoxP3
and suppressive function of human CD4+ T reg cells." J Exp Med 203(7): 1701-1711.
Lodinova-Zadnikova, R., L. Prokesova, et al. (2004). "[Influence of oral colonization
with probiotic E. coli strain after birth on frequency of recurrent infections, allergy
and development of some immunologic parameters. Long-term studies]." Ceska
Gynekol 69 Suppl 1: 91-97.
Lonnroth, I. and J. Holmgren (1973). "Subunit structure of cholera toxin." J Gen
Microbiol 76(2): 417-427.
Lu, J., Q. Li, et al. (1996). "Identification of a second transmembrane protein tyrosine
phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus:
precursor of the 37-kDa tryptic fragment." Proc Natl Acad Sci U S A 93(6): 23072311.
Lucas, M. E., J. L. Deen, et al. (2005). "Effectiveness of mass oral cholera vaccination in
Beira, Mozambique." N Engl J Med 352(8): 757-767.
Lutz, M. B. and G. Schuler (2002). "Immature, semi-mature and fully mature dendritic
cells: which signals induce tolerance or immunity?" Trends Immunol 23(9): 445-449.
Mahnke, K., T. S. Johnson, et al. (2007). "Tolerogenic dendritic cells and regulatory T
cells: a two-way relationship." J Dermatol Sci 46(3): 159-167.
Maldonado-Lopez, R., C. Maliszewski, et al. (2001). "Cytokines regulate the capacity of
CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo." J

187

Immunol 167(8): 4345-4350.
Maldonado-Lopez, R. and M. Moser (2001). "Dendritic cell subsets and the regulation of
Th1/Th2 responses." Semin Immunol 13(5): 275-282.
Manel, N., D. Unutmaz, et al. (2008). "The differentiation of human T(H)-17 cells
requires transforming growth factor-beta and induction of the nuclear receptor
RORgammat." Nat Immunol 9(6): 641-649.
Mangan, P. R., L. E. Harrington, et al. (2006). "Transforming growth factor-beta induces
development of the T(H)17 lineage." Nature 441(7090): 231-234.
Marinaro, M., H. F. Staats, et al. (1995). "Mucosal adjuvant effect of cholera toxin in
mice results from induction of T helper 2 (Th2) cells and IL-4." J Immunol 155(10):
4621-4629.
Martin-Orozco, N., Y. Chung, et al. (2009). "Th17 cells promote pancreatic inflammation
but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1
cells." Eur J Immunol 39(1): 216-224.
Massol, R. H., J. E. Larsen, et al. (2004). "Cholera toxin toxicity does not require
functional Arf6- and dynamin-dependent endocytic pathways." Mol Biol Cell 15(8):
3631-3641.
Meier, J. J., A. Bhushan, et al. (2005). "Sustained beta cell apoptosis in patients with
long-standing type 1 diabetes: indirect evidence for islet regeneration?" Diabetologia
48(11): 2221-2228.
Merritt, E. A., S. Sarfaty, et al. (1995). "Surprising leads for a cholera toxin receptorbinding antagonist: crystallographic studies of CTB mutants." Structure 3(6): 561570.
Merritt, E. A., S. Sarfaty, et al. (1994). "Crystal structure of cholera toxin B-pentamer
bound to receptor GM1 pentasaccharide." Protein Sci 3(2): 166-175.
Merwe, v. d. (2002). "Formation of functions of the immunological synapse." Current
Opinions in Immunology 14: 293-298.
Millington, O. R., A. M. Mowat, et al. (2004). "Induction of bystander suppression by
feeding antigen occurs despite normal clonal expansion of the bystander T cell
population." J Immunol 173(10): 6059-6064.
Minderhoud, I. M., M. Samsom, et al. (2007). "What predicts mucosal inflammation in
Crohn's disease patients?" Inflamm Bowel Dis 13(12): 1567-1572.
Moore, K. W., P. Vieira, et al. (1990). "Homology of cytokine synthesis inhibitory factor
(IL-10) to the Epstein-Barr virus gene BCRFI." Science 248(4960): 1230-1234.

188

Nakae, S., A. Nambu, et al. (2003). "Suppression of immune induction of collageninduced arthritis in IL-17-deficient mice." J Immunol 171(11): 6173-6177.
Nayak, R. C., M. A. Omar, et al. (1985). ""Cytoplasmic" islet cell antibodies. Evidence
that the target antigen is a sialoglycoconjugate." Diabetes 34(6): 617-619.
Nishimoto, N., K. Terao, et al. (2008). "Mechanisms and pathologic significances in
increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration
of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis
and Castleman disease." Blood 112(10): 3959-3964.
O'Connor, W., Jr., M. Kamanaka, et al. (2009). "A protective function for interleukin
17A in T cell-mediated intestinal inflammation." Nat Immunol 10(6): 603-609.
O'Doherty, U., M. Peng, et al. (1994). "Human blood contains two subsets of dendritic
cells, one immunologically mature and the other immature." Immunology 82(3): 487493.
O'Neal, C. J., M. G. Jobling, et al. (2005). "Structural basis for the activation of cholera
toxin by human ARF6-GTP." Science 309(5737): 1093-1096.
Odumosu, O., K. Payne, et al. (2010). "Suppression of dendritic cell activation by
diabetes autoantigens linked to the cholera toxin B subunit." Immunobiology.
Okusawa, T., M. Fujita, et al. (2004). "Relationship between structures and biological
activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like
receptors 2 and 6." Infect Immun 72(3): 1657-1665.
Olson, J. K., J. L. Croxford, et al. (2001). "Virus-induced autoimmunity: potential role of
viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune
disease." Viral Immunol 14(3): 227-250.
Palmer, J. P., C. M. Asplin, et al. (1983). "Insulin antibodies in insulin-dependent
diabetics before insulin treatment." Science 222(4630): 1337-1339.
Parrish, Y. K., I. Baez, et al. (2009). "IL-7 Dependence in human B lymphopoiesis
increases during progression of ontogeny from cord blood to bone marrow." J
Immunol 182(7): 4255-4266.
Patterson, C. C., G. G. Dahlquist, et al. (2009). "Incidence trends for childhood type 1
diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre
prospective registration study." Lancet 373(9680): 2027-2033.
Phipps, P. A., M. R. Stanford, et al. (2003). "Prevention of mucosally induced uveitis
with a HSP60-derived peptide linked to cholera toxin B subunit." Eur J Immunol
33(1): 224-232.
Piccinni, M. P., L. Beloni, et al. (1998). "Defective production of both leukemia

189

inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained
recurrent abortions." Nat Med 4(9): 1020-1024.
Pietropaolo, M., L. Castano, et al. (1993). "Islet cell autoantigen 69 kD (ICA69).
Molecular cloning and characterization of a novel diabetes-associated autoantigen." J
Clin Invest 92(1): 359-371.
Ploix, C., I. Bergerot, et al. (1999). "Oral administration of cholera toxin B-insulin
conjugates protects NOD mice from autoimmune diabetes by inducing CD4+
regulatory T-cells." Diabetes 48(11): 2150-2156.
Porgador, A., H. F. Staats, et al. (1998). "Intranasal immunization with cytotoxic Tlymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective
augmentation of peptide-presenting dendritic cells in nasal mucosa-associated
lymphoid tissue." Infect Immun 66(12): 5876-5881.
Potapova, I. A., G. R. Gaudette, et al. (2007). "Mesenchymal stem cells support
migration, extracellular matrix invasion, proliferation, and survival of endothelial
cells in vitro." Stem Cells 25(7): 1761-1768.
Pulendran, B., P. Kumar, et al. (2001). "Lipopolysaccharides from distinct pathogens
induce different classes of immune responses in vivo." J Immunol 167(9): 5067-5076.
Pulendran, B., J. L. Smith, et al. (1999). "Distinct dendritic cell subsets differentially
regulate the class of immune response in vivo." Proc Natl Acad Sci U S A 96(3):
1036-1041.
Rachmilewitz, D., F. Karmeli, et al. (2002). "Immunostimulatory DNA ameliorates
experimental and spontaneous murine colitis." Gastroenterology 122(5): 1428-1441.
Raz, I., D. Elias, et al. (2001). "Beta-cell function in new-onset type 1 diabetes and
immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised,
double-blind, phase II trial." Lancet 358(9295): 1749-1753.
Reid, C. D. (1997). "The dendritic cell lineage in haemopoiesis." Br J Haematol 96(2):
217-223.
Reis e Sousa, C. (2001). "Dendritic cells as sensors of infection." Immunity 14(5): 495498.
Rissoan, M. C., V. Soumelis, et al. (1999). "Reciprocal control of T helper cell and
dendritic cell differentiation." Science 283(5405): 1183-1186.
Robinson, S. P., S. Patterson, et al. (1999). "Human peripheral blood contains two
distinct lineages of dendritic cells." Eur J Immunol 29(9): 2769-2778.
Roger, T., I. Miconnet, et al. (2005). "Critical role for Ets, AP-1 and GATA-like
transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression."

190

Biochem J 387(Pt 2): 355-365.
Romagnani, S. (1998). T-cell subsets (Th1, Th2) and cytokines in autoimmunity.
Autoimmune Diseases, Academin Press: 163-191.
Romagnani, S. (1998). "The Th1/Th2 paradigm and allergic disorders." Allergy 53(46
Suppl): 12-15.
Romagnani, S., M. Kapsenberg, et al. (1998). "Th1 and Th2 cells." Res Immunol 149(9):
871-873.
Roncarolo, M. G., R. Bacchetta, et al. (2001). "Type 1 T regulatory cells." Immunol Rev
182: 68-79.
Roncarolo, M. G., S. Gregori, et al. (2006). "Interleukin-10-secreting type 1 regulatory T
cells in rodents and humans." Immunol Rev 212: 28-50.
Roncarolo, M. G., M. K. Levings, et al. (2001). "Differentiation of T regulatory cells by
immature dendritic cells." J Exp Med 193(2): F5-9.
Sakaguchi, S., N. Sakaguchi, et al. (1995). "Immunologic self-tolerance maintained by
activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a
single mechanism of self-tolerance causes various autoimmune diseases." J Immunol
155(3): 1151-1164.
Sanchez, J. and J. Holmgren (2008). "Cholera toxin structure, gene regulation and
pathophysiological and immunological aspects." Cell Mol Life Sci 65(9): 1347-1360.
Sandvig, K. and B. van Deurs (2002). "Transport of protein toxins into cells: pathways
used by ricin, cholera toxin and Shiga toxin." FEBS Lett 529(1): 49-53.
Sanjeevi, C. B., A. Falorni, et al. (1996). "Glutamic acid decarboxylase (GAD) in insulindependent diabetes mellitus." Diabetes Nutrition & Metabolism 9(4): 167-182.
Sattler, J. and H. Wiegandt (1975). "Studies of the subunit structure of choleragen." Eur J
Biochem 57(1): 309-316.
Schnare, M., G. M. Barton, et al. (2001). "Toll-like receptors control activation of
adaptive immune responses." Nat Immunol 2(10): 947-950.
Segal, B. M., J. T. Chang, et al. (2000). "CpG oligonucleotides are potent adjuvants for
the activation of autoreactive encephalitogenic T cells in vivo." J Immunol 164(11):
5683-5688.
Seong, S. Y. and P. Matzinger (2004). "Hydrophobicity: an ancient damage-associated
molecular pattern that initiates innate immune responses." Nat Rev Immunol 4(6):
469-478.

191

Shinomiya, M., S. M. Fazle Akbar, et al. (1999). "Transfer of dendritic cells (DC) ex vivo
stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune
diabetes in non-obese diabetic (NOD) mice." Clin Exp Immunol 117(1): 38-43.
Shortman, K. and C. Caux (1997). "Dendritic cell development: multiple pathways to
nature's adjuvants." Stem Cells 15(6): 409-419.
Shreedhar, V. K., B. L. Kelsall, et al. (2003). "Cholera toxin induces migration of
dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's
patches." Infect Immun 71(1): 504-509.
Sica, A., A. Saccani, et al. (2000). "Autocrine production of IL-10 mediates defective IL12 production and NF-kappa B activation in tumor-associated macrophages." J
Immunol 164(2): 762-767.
Silveira, P. A. and S. T. Grey (2006). "B cells in the spotlight: innocent bystanders or
major players in the pathogenesis of type 1 diabetes." Trends Endocrinol Metab
17(4): 128-135.
Sixma, T. K., K. H. Kalk, et al. (1993). "Refined structure of Escherichia coli heat-labile
enterotoxin, a close relative of cholera toxin." J Mol Biol 230(3): 890-918.
Slavin, A. J., R. Maron, et al. (2001). "Mucosal administration of IL-10 enhances oral
tolerance in autoimmune encephalomyelitis and diabetes." Int Immunol 13(6): 825833.
Sobel, D. O., B. Yankelevich, et al. (1998). "The B-subunit of cholera toxin induces
immunoregulatory cells and prevents diabetes in the NOD mouse." Diabetes 47(2):
186-191.
Spooner, R. A., D. C. Smith, et al. (2006). "Retrograde transport pathways utilised by
viruses and protein toxins." Virol J 3: 26.
Stanford, M., T. Whittall, et al. (2004). "Oral tolerization with peptide 336-351 linked to
cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease." Clin
Exp Immunol 137(1): 201-208.
Stassen, M., S. Fondel, et al. (2004). "Human CD25+ regulatory T cells: two subsets
defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive
properties upon CD4+ T helper cells." Eur J Immunol 34(5): 1303-1311.
Stassen, M., E. Schmitt, et al. (2004). "Human CD(4+)CD(25+) regulatory T cells and
infectious tolerance." Transplantation 77(1 Suppl): S23-25.
Steinbrink, K., M. Wolfl, et al. (1997). "Induction of tolerance by IL-10-treated dendritic
cells." J Immunol 159(10): 4772-4780.
Steinman, R. M., S. Turley, et al. (2000). "The induction of tolerance by dendritic cells

192

that have captured apoptotic cells." J Exp Med 191(3): 411-416.
Stewart, C. N., Jr., H. A. t. Richards, et al. (2000). "Transgenic plants and biosafety:
science, misconceptions and public perceptions." Biotechniques 29(4): 832-836, 838843.
Sun, J. B., J. Holmgren, et al. (1994). "Cholera toxin B subunit: an efficient transmucosal
carrier-delivery system for induction of peripheral immunological tolerance." Proc
Natl Acad Sci U S A 91(23): 10795-10799.
Sun, J. B., B. L. Li, et al. (2000). "Enhanced immunological tolerance against allograft
rejection by oral administration of allogeneic antigen linked to cholera toxin B
subunit." Clin Immunol 97(2): 130-139.
Sun, J. B., C. Rask, et al. (1996). "Treatment of experimental autoimmune
encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B
subunit." Proc Natl Acad Sci U S A 93(14): 7196-7201.
Sun, J. B., B. G. Xiao, et al. (2000). "Oral administration of cholera toxin B subunit
conjugated to myelin basic protein protects against experimental autoimmune
encephalomyelitis by inducing transforming growth factor-beta-secreting cells and
suppressing chemokine expression." Int Immunol 12(10): 1449-1457.
Sutmuller, R. P., M. H. den Brok, et al. (2006). "Toll-like receptor 2 controls expansion
and function of regulatory T cells." J Clin Invest 116(2): 485-494.
Sutmuller, R. P., M. E. Morgan, et al. (2006). "Toll-like receptors on regulatory T cells:
expanding immune regulation." Trends Immunol 27(8): 387-393.
Sutton, D. W., P. K. Havstad, et al. (1992). "Synthetic cryIIIA gene from Bacillus
thuringiensis improved for high expression in plants." Transgenic Res 1(5): 228-236.
Takeda, K. and S. Akira (2001). "Regulation of innate immune responses by Toll-like
receptors." Jpn J Infect Dis 54(6): 209-219.
Takeda, K. and S. Akira (2001). "Roles of Toll-like receptors in innate immune
responses." Genes Cells 6(9): 733-742.
Takeda, K. and S. Akira (2003). "Toll receptors and pathogen resistance." Cell Microbiol
5(3): 143-153.
Takeda, K., T. Kaisho, et al. (2003). "Toll-like receptors." Annu Rev Immunol 21: 335376.
Tang, Q., J. Y. Adams, et al. (2006). "Visualizing regulatory T cell control of
autoimmune responses in nonobese diabetic mice." Nat Immunol 7(1): 83-92.
Thomas, R. and P. E. Lipsky (1994). "Human peripheral blood dendritic cell subsets.

193

Isolation and characterization of precursor and mature antigen-presenting cells." J
Immunol 153(9): 4016-4028.
Thompson, H. S. and N. A. Staines (1986). "Gastric administration of type II collagen
delays the onset and severity of collagen-induced arthritis in rats." Clin Exp Immunol
64(3): 581-586.
Tian, B., J. Hao, et al. (2009). "Upregulating CD4+CD25+FOXP3+ regulatory T cells in
pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy."
Transplantation 87(2): 198-206.
Tian, J., D. Zekzer, et al. (2006). "B cells are crucial for determinant spreading of T cell
autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice." J
Immunol 176(4): 2654-2661.
Tinker, J. K., J. L. Erbe, et al. (2003). "Cholera holotoxin assembly requires a
hydrophobic domain at the A-B5 interface: mutational analysis and development of
an in vitro assembly system." Infect Immun 71(7): 4093-4101.
Tisch, R. and H. McDevitt (1996). "Insulin-dependent diabetes mellitus." Cell 85(3):
291-297.
Todd, J. A., J. I. Bell, et al. (1987). "HLA-DQ beta gene contributes to susceptibility and
resistance to insulin-dependent diabetes mellitus." Nature 329(6140): 599-604.
Trembleau, S., T. Germann, et al. (1995). "The role of IL-12 in the induction of organspecific autoimmune diseases." Immunol Today 16(8): 383-386.
Trentham, D. E., R. A. Dynesius-Trentham, et al. (1993). "Effects of oral administration
of type II collagen on rheumatoid arthritis." Science 261(5129): 1727-1730.
Triantafilou, M., K. Miyake, et al. (2002). "Mediators of innate immune recognition of
bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell
activation." J Cell Sci 115(Pt 12): 2603-2611.
Turley, S. J., K. Inaba, et al. (2000). "Transport of peptide-MHC class II complexes in
developing dendritic cells." Science 288(5465): 522-527.
Tzartos, J. S., M. A. Friese, et al. (2008). "Interleukin-17 production in central nervous
system-infiltrating T cells and glial cells is associated with active disease in multiple
sclerosis." Am J Pathol 172(1): 146-155.
van den Akker, F., S. Sarfaty, et al. (1996). "Crystal structure of a new heat-labile
enterotoxin, LT-IIb." Structure 4(6): 665-678.
van Heyningen, S. (1976). "The subunits of cholera toxin: structure, stoichiometry, and
function." J Infect Dis 133 Suppl: 5-13.

194

van Heyningen, W. E. and C. A. King (1976). "The role of gangliosides in the action of
cholera toxin." Adv Exp Med Biol 71: 205-214.
Verge, C. F., R. Gianani, et al. (1996). "Number of autoantibodies (against insulin, GAD
or ICA512/IA2) rather than particular autoantibody specificities determines risk of
type I diabetes." J Autoimmun 9(3): 379-383.
Verge, C. F., R. Gianani, et al. (1996). "Prediction of type I diabetes in first-degree
relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies."
Diabetes 45(7): 926-933.
Vigouroux, S., E. Yvon, et al. (2004). "Antigen-induced regulatory T cells." Blood
104(1): 26-33.
Viney, J. L. (2001). "Immune fate decided by dendritic cell provocateurs." Trends
Immunol 22(1): 8-10.
Volpe, E., N. Servant, et al. (2008). "A critical function for transforming growth factorbeta, interleukin 23 and proinflammatory cytokines in driving and modulating human
T(H)-17 responses." Nat Immunol 9(6): 650-657.
Wakkach, A., N. Fournier, et al. (2003). "Characterization of dendritic cells that induce
tolerance and T regulatory 1 cell differentiation in vivo." Immunity 18(5): 605-617.
Wang, Z. J., H. Zhang, et al. (2005). "[Detection of IFN-gamma level in single CD8+ T
cell]." Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 21(1): 72-75.
Weiner, H. L. (2001). "Induction and mechanism of action of transforming growth factorbeta-secreting Th3 regulatory cells." Immunol Rev 182: 207-214.
Weiner, H. L., Z. J. Zhang, et al. (1991). "Antigen-driven peripheral immune tolerance.
Suppression of organ-specific autoimmune diseases by oral administration of
autoantigens." Ann N Y Acad Sci 636: 227-232.
Weissman, D., Y. Li, et al. (1995). "Three populations of cells with dendritic morphology
exist in peripheral blood, only one of which is infectable with human
immunodeficiency virus type 1." Proc Natl Acad Sci U S A 92(3): 826-830.
Wen, L., J. Peng, et al. (2004). "The effect of innate immunity on autoimmune diabetes
and the expression of Toll-like receptors on pancreatic islets." J Immunol 172(5):
3173-3180.
Wenzlau, J. M., K. Juhl, et al. (2007). "The cation efflux transporter ZnT8 (Slc30A8) is a
major autoantigen in human type 1 diabetes." Proc Natl Acad Sci U S A 104(43):
17040-17045.
Wingender, G., N. Garbi, et al. (2006). "Systemic application of CpG-rich DNA
suppresses adaptive T cell immunity via induction of IDO." Eur J Immunol 36(1): 12-

195

20.
Wong, C. K., C. Y. Ho, et al. (2000). "Elevation of proinflammatory cytokine (IL-18, IL17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus
erythematosus." Lupus 9(8): 589-593.
Yan, G., L. Shi, et al. (1997). "Screening of the TAP1 gene by denaturing gradient gel
electrophoresis in insulin-dependent diabetes mellitus: detection and comparison of
new polymorphisms between patients and controls." Tissue Antigens 50(6): 576-585.
Yang, L., D. E. Anderson, et al. (2008). "IL-21 and TGF-beta are required for
differentiation of human T(H)17 cells." Nature 454(7202): 350-352.
Ylipaasto, P., K. Klingel, et al. (2004). "Enterovirus infection in human pancreatic islet
cells, islet tropism in vivo and receptor involvement in cultured islet beta cells."
Diabetologia 47(2): 225-239.
Yokota, S., T. Imagawa, et al. (2008). "Efficacy and safety of tocilizumab in patients with
systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial." Lancet 371(9617): 998-1006.
Yoon, J. W. and H. S. Jun (2005). "Autoimmune destruction of pancreatic beta cells."
Am J Ther 12(6): 580-591.
Yoon, S. I., N. J. Logsdon, et al. (2006). "Conformational changes mediate interleukin-10
receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex." J Biol
Chem 281(46): 35088-35096.
Yudoh, K., H. Matsuno, et al. (2000). "Reduced expression of the regulatory CD4+ T cell
subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis."
Arthritis Rheum 43(3): 617-627.
Zhang, J., B. H. Yuen, et al. (1991). "Suppression of luteinizing hormone secretion by
atrial and brain natriuretic peptides in ovariectomized rats." Endocrinology 129(2):
801-806.
Zhang, Z. J., L. Davidson, et al. (1991). "Suppression of diabetes in nonobese diabetic
mice by oral administration of porcine insulin." Proc Natl Acad Sci U S A 88(22):
10252-10256.
Zhou, L. J., R. Schwarting, et al. (1992). "A novel cell-surface molecule expressed by
human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is
a new member of the Ig superfamily." J Immunol 149(2): 735-742.
Zhou, L. J. and T. F. Tedder (1995). "A distinct pattern of cytokine gene expression by
human CD83+ blood dendritic cells." Blood 86(9): 3295-3301.
Zhou, L. J. and T. F. Tedder (1995). "Human blood dendritic cells selectively express

196

CD83, a member of the immunoglobulin superfamily." J Immunol 154(8): 38213835.
Zhou, L. J. and T. F. Tedder (1996). "CD14+ blood monocytes can differentiate into
functionally mature CD83+ dendritic cells." Proc Natl Acad Sci U S A 93(6): 25882592.
Zhu, J. and W. E. Paul (2008). "CD4 T cells: fates, functions, and faults." Blood 112(5):
1557-1569.
Zorena, K., J. Mysliwska, et al. (2008). "Interleukin-12 and tumour necrosis factor-alpha
equilibrium is a prerequisite for clinical course free from late complications in
children with type 1 diabetes mellitus." Scand J Immunol 67(2): 204-208.

197

APPENDIX A
ISOLATION OF LEUKOCYTES FROM CORD BLOOD
Collection of umbilical cord blood from Cesarean section patient at Loma Linda
University Medical Center:
Cord blood is collected from patients who had just undergone Caesarean section
surgical procedure. 25 ml of cord blood is usually collected by Ineavely Baez in a 50ml
conical tube under specified IRB approved protocols. Stem cells CD34+ cells which
make up 1% of PBMNC are isolated by Magnetic Separation using Micro beads. The
remaining cell populations which are CD34- are frozen in Growth Media containing
RPMI 1640 supplemented with 10% FBS, 1 mM glutamine, 100 U/ml penicillin, 100
µg/ml streptomycin (D10).
Procedure
I.

Note time blood collected in notebook.

II.

Dilute CB 50/50 with Hanks (HBSS) in 50 ml tube.

III.

For each full tube of Hanks/CB mixture prepares two 50 ml tubes
containing 25 ml of Ficol.

IV.

Gently layer 25 ml of Hanks/CB mixture over Ficol being careful
not to disturb the interface between the blood and the Ficol
(holding tube at an angle may help).

V.

Spin in centrifuge at room temp, 2000 RPM; brake off, for 30
minutes.

VI.

Remove tubes from centrifuge being careful not to disturb buffy
layer of mononuclear cells that are located at the interface between
the serum (on top) and the Ficol (on bottom)

VII.

Using a pipette remove and discard serum and from top of buffy
layer leaving about 1/4 to 1/2 inch of serum on top of off buffy
layer.
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VIII.

Place pipetter at the top of serum and remove remaining serum
along with all of buffy layer and transfer to a clean 50 ml tube. Be
sure that pipetter is at surface of liquid Ficol is not aspirated from
under buffy layer. Add Hanks to fill tube to top.

IX.

Spin in centrifuge at room temp, 1500 RPM, brake on low, for 10
minutes.

X.

Aspirate off supernatant. Resuspend cells in 10 mls of PBS and
then transfer cells to pellet in next tube. Resuspend cells and
transfer to next tube, until all cells are in one 50 ml tube. Wash
remaining cells from empty tubes by repeating the process with 10
additional mls and which should be placed in 50 ml tube with cells.

XI.

Fill 50ml tube with cells to top with PBS and spin in centrifuge at
room temp, 1500 RPM, brake on low, for 10 minutes.

IF FICOLL LAYER WAS EXTREMELY BLOODY PERFORM ORTHOLYSIS
(SEE BELOW) AT THIS POINT.
XII.

Aspirate off supernatant and resuspend cells in 10 ml of PBS.
Transfer to 15 ml tube. Wash 50 ml tube with 1 ml of PBS and
transfer wash to tube with the rest of cells.

XIII.

Count by diluting 10 ul of cells in 990 (1:100) or 90 (1:10) ul of 3
% acetic acid.

XIV. Spin remainder of tube in centrifuge at room temp, 1500 RPM,
brake on low, for 5 minutes.
XV.

Aspirate supernatant off cells, and resuspend in 300 ul of Miltenyi
buffer per 108 cells.

XVI. Add 100 ul of solution A1 per 108 cells counted in step 13 above
and incubate at 4oC for 15 minutes.
XVII. Add 100 ul of Solution A2 per 108 cells and incubate an additional
15 minutes.
XVIII. Add Miltenyi buffer to 10 ml and spin down (5 minutes at 1500
RPM), aspirate off buffer.
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XIX. Resuspend in 400 ul Miltenyi buffer per 108 cells and add 100 ul of
reagent B (beads) per 108 cells and incubate at 4 oC for 15 minutes.
XX.

Add Miltenyi buffer to 10 ml, spin down and pull off supernatant.
Resuspend cells in 1 ml of Miltenyi buffer very well using 1 ml
pipet.

XXI. While beads are spinning set up magnetic apparatus: --Place
column in magnetic (2 prongs out) being careful to keep tip of
column and plunger sterile.--place pre-filter on top of column-Add .5 ml of Miltenyi buffer to prefilter and pipette up and down
until liquid goes through to column . Let drip through column to
15 ml centrifuge tube set up in Styrofoam rack.
XXII. Add cell suspension to top of column and let cells run through.
COLLECT RUN THROUGH (CD34-CELLS) IN A CLEAN
TUBE
XXIII. TO ELUTE CD34+ CELLS: Wash 3 times by adding .5 ml of
buffer to top of column and letting run through.
XXIV. Get 1.2 ml of buffer in pipetman and place in column while
holding it over 4 ml collection tube. Being careful to keep end of
plunger sterile put in top of column and plunge down.
XXV. If high purity needed plunge cells into a second column which has
been placed in magnet.

Ortholysis
Aspirate off supernatant. Lyse red blood cells by resuspending cells in 10 ml of
lysis buffer and incubating for 10 minute at 37 oC (water bath). After incubation fill tube
to top with HBSS.
Spin down cells (5 minutes at 1500 RPM), aspirate off supernatant, resuspend
cells in 10 ml of PBS and transfer to 15 ml tube. Dilute a small sample 1:10 in PBS for
counting. Continue at step 14 in above protocol.
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TIME: 5-6 hours at first, later 3-4 hours
NOTE: From one tube of cord blood can get
~1 X 108 white blood cells
1-2 X 106 CD34+ (approximately 1% of cord blood)
1 X 104 CD38- CD34+

MATERIALS:

Red Blood Cell Lysis Buffer
Dissolve the following in 800ml distilled H2O


8.3g NH4Cl



1.0g KHCO3



1.8ml of 5% EDTA

Filter sterilize through 0.2um filter
Bring volume to 1000ml with distilled H2O
Miltenyi buffer (Mini MACS buffer) --.5% BSA, 5 mM EDTA, PBS
For 250 ml:

12.5 ml 10% BSA--culture grade (or 16.7 ml of 7.5% BSA)
2.5 ml of 0.5 M EDTA
1X PBS to 250 ml

Filter-sterilize and then wrap parafilm around top of filter to seal degas for 1 hour
prior to use. Store tube at 4 oC.
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APPENDIX B
ISOLATION OF CD14+ MONOCYTES FROM CD34- CORD BLOOD

Frozen cord blood CD34-cells are thawed in thawing medium containing 25 ml of
any medium containing at least 10% serum (D10, R10, etc), 100 units of sterile heparin
(100 ul of 1000 U/ml stock) and 750 Units of DNAase (250 ul of 3000U/ml stock Sigma
#D-5025 in water) For 150,000 Unit bottle dissolve in 50 ml of sterile water and aliquot.

Procedure:
I. Thaw one 2 ml vial of frozen cells quickly in water bath.
II. Rinse vial with alcohol and dry.
III. Place cell suspension in 50 ml centrifuge tube.
IV. Add 25 ml of thawing medium drop by drop swirling after each
addition. Should take about 2-3 minutes to dilute sample.
V. Place cells at 37 oC for 1 hour.
VI. Spin down cells in centrifuge and then wash with 5 ml PBS or
Miltenyi buffer (Bechmann Counter Allegra X-15R centrifuge,
SX4750 RPM 1500 for 8 min @ 4 oC).
VII.

Aliquot 10 ul of cells for counting.

VIII.

Count cells by hemocytometer (diluting 1:2 with trypan

blue) multiply by appropriate volume:(# cells in one frame) X
(trypan blue dilution—usually 2) X (104 ) X (# of mls of
cells)
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IX. Aspirate off supernatant after washing cells transfer cells to a
FACs tube and wash again in 2 ml Miltenyi Buffer (5 minutes@
1500RPM).
X. Aspirate off supernatant.
XI. Resuspend cells in 100 ul of Miltenyi Buffer for each 50 million
cells.
XII.

Add 10 ul of CD14-PE antibody for each 100 ul of cell

suspension.
XIII.

Incubate 10 minutes in Fridge.

XIV.

Add 4ml Miltenyi Buffer to fill the tube—

XV.

Aspirate supernatant and resuspend at 5X107 cells per 80

ul of Miltenyi buffer. Add 20 ul of anti-PE microbeads (make
sure beads are mixed well—do not vortex) per 80 ul of cells.
Incubate for 15 minutes. Fill tube with Miltenyi buffer and
wash.
XVI.

Aspirate off supernatant and resuspend cells (2mls) for

separation by MACs column or other means. (SEE BELOW)
XVII.

Take a small aliquot of separated cells for FACs.

XVIII. Wash remaining cells. Aspirate off supernatant and
resuspend in medium for generating DCs as per paper.

MACS MAGNETIC SEPARATION
I.

Place column in the magnetic field of a suitable MACS Separator. For
details see the respective MACS Column data sheet.

II.

Prepare column by rinsing with the 3 ml Miltenyi buffer

III.

Apply cell suspension onto the column. 	
  

IV.

Collect unlabeled cells that pass through and wash column with the 3X
3ml Miltenyi buffer. Collect total effluent; this is the unlabeled cell
fraction. Perform washing steps by adding buffer three times. Only add
new buffer when the column reservoir is empty.
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V.

Remove column from the separator and place it on a 15 ml conical
collection tube.	
  

VI.

Pipette 5ml Miltenyi buffer onto the column. Immediately flush out the
magnetically labeled cells by firmly pushing the plunger into the
column. (CD14+ MONOCYTES)	
  

VII.

(Optional) To increase the purity of the magnetically labeled cells, the
eluted fraction can be enriched over a second MS or LS Column.
Repeat the magnetic separation procedure as described in steps 1 to 6 by
using a new column.

VIII.

Aliquot 10 ul of cells for counting (this is to determine how many cells
will be plated per well for DC cell culture.

IX.

Aliquot 100ul for FACS determination of purity (compare to sample
before magnetic separation.
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APPENDIX C
DIFFERENTIATION OF DCs FROM MONOCYTES

Adapted from Agrawal et al. JI 2007 178: 6
Medium
R10 medium
50 ng/ml rhGM-CSF
10 ng/ml IL-4

R10 M EDIUM

550 ml

FBS (tested to be good for B cell cultures)

56 ml

Penn/Strep

2.8 ml

L-glutamine

5.6 ml

2-ME (10-1 M stock) must have for B cells

560 ul

RPMI

500 ml

_________________________________________________________
~560 ml
Use of GM-CCSF
Prospec GMCSF = $50 for 2 ug
2ug is enough for 200 ml of medium
Stock: Resuspend 2 ug in 1 ml = 2 ng/ul
So add 25 ul of stock per ml of medium
Use of IL-4
Prospec IL-4 = $50 for 2 ug
2ug is enough for 200 ml of medium
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Stock: Resuspend 2 ug in 1 ml = 2 ng/ul
So add 5 ul of stock per ml of medium
Procedure:
I.

In 4 ml of Growth Media, add 100 ul of stock GM-CSF and 20ul
IL-4 of medium

II.

Spin down cells in Miltenyi buffer after counting and completely
aspirate supernatant.

III.

Plate cells at 1 X 105 cells per ml of culture medium in 24 well
plate.

IV.

Remove and replace half of medium every 2 days for 6 days.
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APPENDIX D
EXPERIMENTAL SET-UP FOR DENDRITIC CELL MATURATION AND T-CELL
FUNCTIONAL STUDIES
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Treat for 48 hours. Harvest stain an assess for DC Maturation

5.

STIMULATION OF DCS WITH FUSION PROTEINS
Conditions

Remark

1. No Stimulation
2. CTB

Negative control
Use @10ug/ml ( initial conc. is 166.6 ug/ml
Therefore use @ 60.02 ul per ml of growth media
Use @5ug/ml ( stock soln is 0.5mg/ml)
Therefore use at 10ul/ml
Use @5ug/ml initial conc. is 166.6 ug/ml
Therefore use @ 30.01 ul per ml of growth media
Use @20ug/ml ( initial conc. is 2.5ug/ml)
Therefore use @ 4 ul per ml of growth media
Use @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @ 60.02 ul per ml
of growth media
Use CTB @10ug/ml ( initial conc. is 83.3 ug/ml
Therefore use @ 30.01 ul per ml of growth media
Use @10ug/ml (stock soln is 0.5mg/ml). Therefore use at 5ul/ml

3. INS
4.GAD
5. CTB-INS
6. CTB-GAD
7. CTB + INS

8. CTB+ GAD

Use CTB @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @ 30.01 ul
per ml of growth media
Use GAD @10ug/ml initial conc. is 166.6 ug/ml. Therefore use @ 30.01 ul per
ml of growth media

9. CTB-INS + CTB-GAD

Use CTB-INS @10ug/ml (initial conc. is 2.5ug/ml). Therefore use @ 2 ul per
ml of growth media
Use CTB-GAD @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @
30.01 ul per ml of growth media

7. PMA+ Ionomycin

Positive Control
Use PMA at 10ng/mL of the cell suspension. Ionomycin use at conc. 1mg/mL.

a. Wash cells with PBS and spin down for 5 minutes
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DC-T cell Co-culture setup
a. Isolate T lymphocytes from cord blood using anti CD3-PE beads
b. Co-Culture DC-T cell (1:10 ratio) for 48 hrs
Add anti Cd3/Cd28 activation beads to T cells except last sample
NO ST

No stim DC only

T cell only

No stim DC+ T cell

CTB-DC + T cell

CTB-INS-DC + T cells

CTB-GAD-DC + T
cells

LPS-DC + T cells

PMA+Iono- DC + T
cells

CTB + INS-DC
+T cells

CTB-INS + CTB-GAD+
T cells

T cell only with no
anti Cd3/Cd28 and
PMa + Ionomycin

CTB + INS-DC + T cells

After 48 hrs, remove media and wash cells with PBS
Perform Golgi accumulation of Cytokine Assay
1. Monensin on ice
2. Remove plate from incubator after 48 hrs
3. Add (1ul/ 200ul of media) of 3 mM monensin to each well
4. Return to incubator for 6hr
5. Final Concentrations are 15mM monensin (In addition to monensin, ADD PMA
and Ionomycin to cells)
After 6 hrs
Harvest cells from each well and individually labeled FACs tube.
Wash in 2 ml PBS
Spin down cells pour off supernatant and make sure that cells are in 10ul staining
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wash.
Transfer to 96-well plates for staining
Surface Stain: CD4PB, CD127PE, CD8 E-flour antibodies: 2 ul per; APC
antibodies .5 ul per well.
Incubate 15 minutes
Wash with Staining Buffer and resuspend in 10ul staining buffer
STAIN WITH 1:50 DILUTION OF SECONDARY SA-PE CY7
•

STAIN ISOTYPE CONTROL AT THIS TIME
Incubate 15 minutes

Intracellular cytokine staining following Surface staining using CALTAG
METHOD
Note: DO NOT RESUSPEND IN 1% PARAFORMALDEHYDE AFTER
SURFACE STAINING
1. Resuspend cells in 20ul of CALTAG reagent A (fixation solution). Pipette up and
down.
2. Incubate for 15 minutes at room temperature
3. Wash cells with staining buffer (200ul, spin and flick)
4. Add 20ul of reagent B (permeabilization solution) to each well.
5. Add antibodies to each well and pipette up and down
6. Incubate for 20 minutes at room temperature.
7. Wash cells with staining buffer
8. Resuspend in 200ul 1% paraformaldehyde
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APPENDIX E
LINEAGE MAP OF LUEKOCYTE DIFFERENTIATION
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